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STEM CELLS: DEFINITION AND PROPERTIES 
 
Stem Cells (SC) are defined as unspecialized cells characterized by an 
extensive self-renewal ability, while retaining their capacity to differentiate 
into different cell types. 
The self-renewal capacity is maintained by an asymmetric cell division 
called "bivalent mitosis" a process in which stem cells can generate two 
daughter cells: 
 one similar to the starting cell, to maintain the pool of stem cells in the 
tissue; 
 another one with the ability to mature progressively towards 
phenotypically and functionally specialized cells. 
SC are able to divide even in a symmetrical way generating two stem cells 
or two differentiated cells (Cai et al., 2004). These processes depend on the 
specific stimuli of the microenvironment where SC are located. 
According to their differentiation potential, SC are divided in: 
 Totipotent Stem Cells (TSC), cells that are capable to give rise to 
embryonic and extra-embryonic tissue. The zygote, originating from the 
fusion of the male gamete and the female gamete, is a typical example 
of TSC (Seydoux and Braun, 2006). 
 Pluripotent Stem Cells reside in the internal mass of the blastocyst and 
are in an early embryonic differentiation stage in which the three 
embryonic sheets start to form: ectoderm, mesoderm and endoderm. 
These cells are able to differentiate in all tissues belonging to these three 
germinal lineages but cannot support the full development of an 
organism (Hadjantonakis and Papaioannou, 2001; Chou and Yabuuchi, 
2011). Typical pluripotent cells are Embryonic Stem Cells (ESC). 
 Multipotent Stem Cells are able to generate a limited number of somatic 
cells, restricted to a single embryo layer. Adult stem cells belong to this 
category (Flickinger, 1999). 
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 Unipotent Stem Cells can maturate into a single cell type of the 
belonging tissue and they ensure tissue repairing and maintenance. E.g. 
Unipotent luminar stem cells and spermatogonian stem/progenitor cells 
(Elias et al., 2017; Liu et al., 2016).  
 
INDUCED PLURIPOTENT STEM CELLS 
 
Induced pluripotent stem cells: an innovative technology 
Before the birth of IPSC (Induced Pluripotent Stem Cells) technology, 
primary neural cell cultures isolated from animal models and immortalized 
cell lines have been widely used to study human diseases mechanisms and 
therapeutic development; however these models showed many limitations. 
Indeed, human patologies are not always completely reflected in animal 
models because of species differences and artificially manipulated cells do 
not represent the best choice in disease modelling (Gordon et al., 2013). 
Human tissues and many primary cell types isolated from donors or patients 
could represent a more reliable model. However, the difficulty to obtain 
fresh human disease tissues represents the major limitation for the use of 
human samples. 
The pluripotency of ESC could be an excellent resource to create all cell 
types in vitro; nevertheless, the use of human ESC is severely limited in the 
clinical and preclinical fields due to ethic problems about embryo 
destruction. With the introduction of IPSC manipulation, different cell types 
were generated in vitro starting from a reprogrammed somatic cell and 
overcoming many ethical problems regarding ESC using. IPSC-derived cells 
are innovative since they can give the oppurtunity to create a patient-
specific and disease-specific model in vitro and accelerate the 
pathophysiologic understanding of different diseases. 
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Properties and characterizations of IPSC 
 
IPSC derive from reprogramming of somatic cells with retroviral 
transfection of essential pluripotency genes (usually cMyc, Octamer-
binding Transcription Factor 4 (OCT4), SRY-box 2 (SOX2) and Kruppel Like 
Factor 4 (KLF4) (Takahashi and Yamanaka, 2006)). 
To generate IPSC, different cocktail of genes and different techniques were 
used improving the efficiency of the reprogramming methods (as shown in 
table 1). Furthermore, IPSC were obtained from cells belonging to different 
species such as monkey fibroblasts (Liu et al., 2008), pig fibroblasts (Wu et 
al., 2009), marmot fibroblast (Wu et al., 2010), rat liver progenitor cells (Li 
et al., 2009), rabbit hepatocytes and rabbit stomach cells (Honda et al., 
2010). Many cells belonging to different human tissues have also been 
reprogrammed: endothelial cells of the umbilical cord vein, peripheral 
blood cells, endothelial cells, cord blood SC, adipose SC amniotic cells, 
neural SC, mesenchymal bone marrow SC, hepatocytes, astrocytes, 
keratinocytes and urine cells (Singh et al., 2015). 
 
 
Table1. IPSC reprogramming: different delivery methods for transfer and different 
combinations of transcription factors have variable efficiencies of reprogramming (Singh 




Human IPSC and human ESC are very similar in their morphology, 
proliferation rate and gene expression (including pluripotency markers and 
epigenetic status). Moreover, both IPSC and ESC can give rise to all the cell 
types belonging to ectoderm, mesoderm and endoderm. These cells are 
characterized by a high telomerase activity allowing unlimited replication 
without showing senescence phenomena (Jiang et al., 2002). The 
maintenance of self-renewal ability is also supported by the expression of 
genes encoding for transcriptional factors that guarantee pluripotency 
capacity (e.g. NANOG, OCT4 and SOX2) or for proteins implicated in 
replicative pathways such as c-MYC. Moreover, IPSC express even specific 
embryonic stage antigens such as SSEA-3 and SSEA-4 and surface markers 
such as TRA-1-60 and TRA-1-81 (Nichols et al., 1998; Carpenter et al., 2003; 
Chambers et al., 2003).  
 
In vitro maintenance 
 
IPSC are coltured in a medium contain Fibroblast Growth Factor 2 (FGF2) 
and they grow as colonies on feeder layer (usually mitotically inactivated 
fibroblasts), which provides extracellular supports (Unger et al. 2009; 
Llames et al., 2015). 
The combination of feeder layer and growth factors allows IPSC to maintain 
pluripotency and self-renewal capacity (Thomson et al., 1998; Reubinoff et 
al., 2000; Takahashi et al., 2007). However, with modern technologies IPSC 
grow even on biological or synthetic substrates in factors-rich medium such 
as FGF2 and Transforming Growth Factor 3 (TGF3) (Ludwig et al., 2006; 
Hayashi et al., 2007; Higuchi et al. 2011; Kim et al., 2009; Villa-Diaz et al., 
2010). The mainly used biological substrate derives from murine 
Engelbreth-Holm-Swarm sarcoma, such as Matrigel or Geltrex.  
These substrates recreate a microenvironment that contains elements to 
favourite the IPSC maintenance such as soluble factors (bioactive 
molecules, cytokines, growth factors and nutrients), cell-cell interaction 
and cell-biomacromolecole (or biomaterial) interaction (Dellatore et al., 
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2008). When removed from the feeder layer or the mentioned substrates 
and transferred in suspension, IPSC colonies start to differentiate by 
spontaneously forming Embryoid Bodies (EB). In vitro differentiation 
experiments demonstrated that EB are composed by a considerable variety 
of cell types morphologically distinguishable when transferred in adhesion, 
such as cardiomyocytes, showing rhythmic contraction, neuronal cells with 
long processes (Odorico et al., 2001) or retinal pigment epithelial cells with 
a dark colour (Foltz et al., 2018). 
 
Application of IPSC in neuroscience 
 
Many IPSC from patients affected by neurodegenerative, neuropsychiatric 
and neurodevelopmental diseases have been generated. These include 
patients with: 
- neurodegenerative diseases: amyotrophic lateral sclerosis (Dimos et al., 
2008), Huntington's (Liu et al., 2015), Alzheimer’s (Ooi et al., 2013) and 
Parkinson’s disease (Soldner et al., 2009); 
- neurodevelopmental diseases: Down syndrome (Brigida and Siniscalco, 
2016) or fragile-X syndrome (Vershkov and Benvenisty, 2017); 
- neuropsychiatric diseases: schizophrenia (Balan et al., 2018), autism 
(Habela et al., 2016) and depression (Licinio and Wong, 2016); 
- other diseases of nervous system: stroke (Liu, 2013), spinal cord injury 
(Teng et al., 2018) and brain tumors (Young et al., 2014). 
 
Furthermore, IPSC can differentiate in functionally and regionally 
specialized neuronal cell types. As reported (Ghaffari et al., 2018), through 
addition of different exogenous stimuli, IPSC are able to differentiate 
directly in different neuronal subtypes such as cortical glutamatergic 
neurons (Shi et al., 2012), dopaminergic neurons (Sánchez-Danés et 
al., 2012), inhibitory GABA-ergic neurons (Yang et al., 2017) and cholinergic 
neurons (Dimos et al., 2008). 
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The differentiation of IPSC in glial cells could be an additional opportunity 
to study the role of astroglial cells in several brain diseases such as 
Parkinson’s disease, Alzheimer’s disease, Down syndrome, psychiatric 
disorders, multiple sclerosis, autism and glioblastoma. GFAP and S100B 
positive astrocytes could be obtained from IPSC after 180 days of 
differentiation (Krencik et al., 2011) while oligodendrocyte precursors could 
be obtained after longer differentiation time to allow maturation and 
generation of myelin sheaths (Hu et al., 2009). More recently, IPSC-derived 
microglia, called microglia-like macrophages, were generated in vitro. 
These cells did not show a microglial morphology, but express IBA1, CD45 
and CD11b, typical microglial markers (Muffat et al., 2016).  
 
Generation of IPSC-derived Neural Stem Cells 
 
IPSC differentiation in Neural Stem Cells (NSC) is the main key to study in 
vitro physiologic and pathologic mechanisms involved in proliferation and  
differentiation processes. 
IPSC are switched from the self-renewing condition to differentiation 
conditions to allow the three embryonic germ layers induction. Under this 
condition, exogenous small molecules or growth factors are added to 
enhance the neuroephitelial differentiation and to inhibit the 
extraembryionic or meso-endodermal differentiation (Chambers et al., 
2009). These exogenous growth factors are dual SMAD inhibitors such as 
noggin, an inhibitor of BMP-SMAD1/5/8 pathway, and SB431542, an 
inhibitor of Activin/Nodal-SMAD2/3 pathway, as shown in figure 1. 
The synergistic action of dual SMAD inhibition can promote rapid neural 
commitment: 
- inhibition of Activin/Nodal-SMAD2/3 pathways decreases NANOG 
expression of IPSC and enhances ZEB2 expression, a SMAD-binding protein 
that limits the mesoderm-inducing effects.  
- inhibition of Activin/NodalSMAD2/3 and BMP-SMAD1/5/8 induces the 
expression of a COUP-TFII (NR2F2), which is one of the earliest transcription 
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factors expressed during neural commitment (Tao and Zhang, 2016; Ozair 
et al., 2015).  
Furthermore, activation of the WNT and sonic hedgehog exerts a precise 
dose-dependent effect to drive neuroephitelial differentiation in dorso-
ventral or rostro-caudal identities (Kirkeby et al., 2012).  
These cells can differentiate in neural-restricted lineages by using two 
different type of protocols, through EB formation or through adherent 
monolayer culture (Tang et al., 2017). Both methods promote the 
generation of neural tube-like rosettes positive for ZO1 and N-cadherin. 
Characterization of human IPSC-derived NSC demonstrated that these cells 
are positive for SOX2, SOX1, PAX6, NESTIN, Ki67 (nuclear protein which 
could be used as a marker for proliferative cells) and even CD133, a marker 
for multipotent stem cells (Meneghini et al., 2017; Palm et al., 2015). 
Human NSC require a serum-free, growth factor-poor medium and several 
weeks to differentiate and to mature into neurons, astrocytes and 
oligodendrocytes. These IPSC-derived cells are characterized by specific 
proteins expression such as PSA-NCAM as neuroblast marker, MAP2 and 
TUJ1 as neuronal markers, and GFAP and S100B, as glial cell markers. To 
identify neuronal subtypes γ-aminobutyric acid, vesicular glutamate 
transporter and tyrosine hydroxylase can be used to detect respectively 
GABAergic neurons, glutamatergic neurons and dopaminergic neurons. 
 
Figure 1. Schematic representation of IPSC differentiation in NSC with dual SMAD 
inhibitors: SB431542 inhibits the self-renewing capacity of IPSC by blocking of TGF3 and 
mesodermal differentiation, while Noggin inhibits trophectoderm and ectoderm 
differentiation (modified from Chambers el at., 2009). 
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ADULT STEM CELLS 
 
Adult Stem Cells (aSC) are multipotent cells organized in small niches that 
guarantee a limited differentiation capacity. aSC have two principal 
functions: a functional role that consists in long-term tissue turnover 
(guaranteed mainly by asymmetric division), and after injury, they could 
switch from a functional state to a regenerative state to maintain the 
physiological tissue homeostasis (Wabik et al., 2015). The regeneration is 
due to enhanced proliferation rate in order to increase the SC population 
that they could differentiate into several specialized cells that participate 
directly in tissue regeneration (Wabik et al., 2015). 
Typically, during aSC cell specialization, aSC generate an intermediate cell 
type, called precursor or progenitor. Progenitor cells are partially 
committed cells, but maintain their proliferative ability until they reach 
their completely differentiated state. Differentiated cells or somatic cells 
show mature phenotypes and are fully integrated into pre-existing circuits 
performing specialized functions (Clevers, 2015). Chemical modulation with 
small molecules and factors could improve the regeneration potency of aSC 
and this could be pharmacologically tagged to repair the dameged tissue 
(Qin et al., 2018). In such respect, study of aSC and their regulation 
mechanisms could be important to develop targeted therapies. 
Recently, adult Neural Stem Cells (NSC) raised interest in the scientific 
community. NSC are multipotent stem cells that can generate neurons 
(neurogenesis) and glial cells (gliogenesis). During the foetal stage, NSC are 
involved in formation of the entire brain structure, but NSC were 
demonstrated to persist also in particular regions of adult mammalian brain 
(Altman and Das, 1965). These cells were named adult NSC or adult Neural 
Progenitor Cells since they were demonstrated to have limited 
differentiation and proliferation capacity in vivo, while in vitro, in presence 
of mitogens, they show long term proliferation capacity and neuronal/glial 




Adult Neural Stem Cells 
 
In vitro analysis of NSC properties represents a very important approach to 
investigate the cellular and molecular mechanisms regulating neurogenesis 
and to find stem cell-based treatments to correct neurological 
disorders/injuries. There are different sources to obtain NSC by using 
current knowledge and technology: the direct isolation of primary cultures 
from tissues or through differentiation of pluripotent stem cells in NSC, as 
described above. For the murine model, the direct isolation of primary cells 
is the most used method. The first successful isolation of NSC was 
performed in rodents from Reynolds and Weiss in 1992 (Reynolds and 
Weiss, 1992). The isolated NSC are cultured in presence of growth factors 
and they can proliferate in suspension for long periods of time forming free-
floating clusters called neurospheres (a characheteristic that contributes to 
prove the self-renewal capacity of NSC). 
Characterization of these neurospheres revealed that cells are positive for 
two important neural stem cell markers, SOX2 and NESTIN. NESTIN is a type 
VI intermediate filament, which is expressed in NSC and in neuroblasts and 
is implicated in the radial growth of the axon. NSC in vitro can differentiate 




The majority of neurons and glial cells are generated during the foetal 
period where they maturate and perform their specific function in the 
developed brain. In past years, it was firmly believed that new neurons 
could not be generated in adult life. This dogmatic view of an ever-
immutable system has now changed as many studies demonstrated that 
new neuron generation occours in different brain regions from birth to 
adulthood (Eriksson et al., 1998). This continuous regeneration of new 
neurons in adult brain is called adult neurogenesis and is guaranteed by the 
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life-long persistence of adult NSC in neurogenic niches (Urbàn and 
Guillemot, 2015). 
The neurogenic niches are a rich network of different elements that work 
in symphony to maintain stem cells after embryogenesis and for their 
progeny production in the adult brain. The other main components of 
neurogenic niches are different cell types, factors and extracellular matrix, 
which create an appropriate microenvironment with cell-cell interactions 
that balance NSC quiescence with proliferation or differentiation (Ma et al., 
2009). 
One of the main neurogenic niches, in the adult mammalian brain, is 
documented in the subgranular layer of the dentate gyrus (DG) of the 
hippocampus (Eriksson et al., 1998, Spalding et al., 2013). Adult 
hippocampal neurogenesis is a form of neural plasticity in the adult brain 
since it is important for the consolidation of new memory and for the 
emotional behaviour formation (Jessberger et al., 2009; Deng et al., 2010; 
Sahay et al., 2011; Toda et al., 2018).  
Another well studied neurogenic niche is in the Subventricular Zone (SVZ) 
of the lateral ventricles. NSC in SVZ contribute to form new neurons, 
granule neurons or periglomerular inhibitory interneurons, which migrate 
to the olfactory bulb (Lois and Alvarez-Buylla, 1993; Doetsch et al., 1999). 
The continuous replacement of new neurons in the olfactory bulb may 
allow for adjustment of olfactory circuitry in response to odour experience 
and environmental changes (Alvarez-Buylla and Garcıá-Verdugo, 2002). 
More recent reports demonstrated that adult neurogenesis also occurs in 
other brain regions in many animal models:  
- the striatum of adult mice, monkeys and rabbits (Willaime-Morawek et al., 
2006, Bédard et al., 2006; Luzzati et al., 2006); 
- the amygdala of adult mice and monkeys (Bernier et al., 2002; Jhaveri et 
al., 2018);  
- the spinal cord of adult mice (Sabelström et al., 2014); 
- the cerebellum of adult mice (Lee et al., 2005); 
- the hypothalamus of adult mice (Li et al., 2012; Kokoeva et al., 2015);  
14 
 
Many of these NSC niches were found also in human nervous system 
(Kempermann et al., 2018). Post-mortem tissue analysis using Ki-67, a 
marker of proliferative cells, and BrdU, a synthetic nucleoside that was 
incorporated in the new synthetized DNA (Eriksson et al., 1998), identified 
neurogenesis in the human hippocampal region. Furthermore, metabolic 
biomarkers were used in humans to localize hippocampal NSC (Manganas 
et al., 2007). Striatal neurogenesis was discovered by using histological and 
a carbon-14 dating approach in human post-mortem tissue (Ernst et al., 
2014). 
 
ADULT HIPPOCAMPAL NEUROGENESIS 
 
Adult ippocampal neurogenesis (aHpNG) is characterized by complex 
processes that begin with NSC proliferation (Bonaguidi et al., 2011). 
Subsequently, neural progenitors differentiate in excitatory dentate 
granule neurons. These neurons receive information from the entorhinal 
cortex (from perforant pathway) and converge their axons, called mossy 
fibers, in the CA3 area giving excitatory input to the pyramidal cells. From 
radial glia-like precursor cells, adult neurogenesis progresses over four 
phases to generate new granule cells and this process was estimated to take 
several weeks, as shown in figure 2 (Kempermann et al., 2015) 
 Precursor cell phase: radial glial-like precursor cells expand with high 
proliferative activity and maturate in three main stages to create a pool of 
stem cells that is an important source from which progenies differentiate. 
These three progenitor stages are:  
Radial glia-like cells type 1 that are positive for GFAP, NESTIN and SOX2. 
These cells are quiescent and, under particular stimuli, are able to 
asymmetrically divide and generate a cell identical to the starting one and 
another cell with restricted neuronal lineage, called type 2 cell.  
Transient amplyfing progenitor cells type 2 express glial markers, such as 
GFAP, but they lost the typical morphology of radial cells. These cells 
express also Eomes (Tbr2), a transcription factor which appears to inhibit 
SRY-box 2 expression. This is a crucial point for the transition from stem 
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cells to more commitment cells called radial type 3 cells (Hodge et al., 
2012).  
Transient amplyfing progenitor cells type 3 start to express Doublecortin 
(DCX) and down-regulate the expression of NESTIN. They are 
characterized by reduced proliferative activity compared to that of type 1 
and type 2 cells (Kempermann et al., 2004). 
 In the early survival phase, type 3 cells enter in a quiescent state and start 
to send their axon to target the pyramidal cells in CA3 area forming 
appropriate synapses. At this stage, only a very small proportion of the 
newborn neurons survives and will be integrated into the dentate gyrus 
network (Sun et al., 2013; Kempermann et al., 2003).  
 The establishment of functional connections of newborn neurons 
characterizes the post-mitotic maturation phase where axons, dendrites, 
spines and synapsis start to develop (Kempermann et al., 2015b). 
 A late survival phase: after complete structural integration into the existing 
network, the newborn neurons become electrophysiological 
indistinguishable from their older neighbours and contribute to increase 




Figure 2. Schematic representation of adult hippocampal neurogenesis: developmental 
stages of adult hippocampal neuronal differentiation and the expression of stage specific 
markers (Kempermann et al., 2015b). 
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ROLE AND THE REGULATION OF ADULT HIPPOCAMPAL NEUROGENESIS 
 
Hippocampus is a crucial structure implicated in the formation of emotional 
behaviour, cognitive functions, learning and spatial associative memory 
(Scoville and Milner, 1957; Oomen et al., 2014). Adult hippocampal 
neurogenesis confers an extra degree of neural plasticity in the DG and is 
important for the consolidation of new cognitive functions (Toda et al., 
2018). Imparment in hippocampal neurogenesis is associated to alterated 
cognitive functions (Kempermann, 2002; Shohayeb et al., 2018). 
Shors at al. demonstrate that the administration of low dose of the DNA 
methylating agent in rats, such as methylazoxymethanol (MAM), inhibits 
hippocampal NSC to complete the cell cycle with consequent impairment 
in hippocampus-mediated learning and memory functions (Shors et al., 
2001). Moreover, recent studies demonstrated that mice, with significant 
numbers of new generated neurons, are able to learn faster in the Morris 
water maze (Merritt et al., 2015). 
 
Regulation by endougenous factors 
 
Adult hippocampal neurogenesis was demonstrated to be modulated by 
several extrinsic and intrinsic factors present in neural niche: ephrins, 
synapsins, growth factors, cell cycle regulators, neutrophines, paracrine 
signalling molecules, free radicals, transcriptional factors, neuropeptides, 
endogenous psychotropic systems and sex hormones. Furthermore, 
neurotransmitters solve an important role in the neurogenesis regulation. 
DG receives imputs from several brain regions where afferent terminals 
release different type of neurotransmitters that could modulate aHpNG 
process (Balu and Lucki, 2009; Shohayeb et al., 2018). The 
neurotransmitters involved are: 
 Catecholamines in the DG are released by noradrenergic neurons that are 
localized massively in the locus coeruleus. A study in rats demonstrated 
that depletion of norepinephrine reduces the proliferation rate of NSC and 
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the derived neurons (Kulkarni et al., 2002) while a study in mice 
demonstrated that the reduced dopamine level is linked merely to an 
aHpNG alterations (Schlachetzki et al., 2016). 
 Glutamatergic fibers originate from the entorhinal cortex and innervate 
the hippocampal DG via the perforant path. Depletion of glutamatergic-
mediated neurons by inhibition of NMDA receptos was shown to increase 
neurogenesis in the adult hippocampus rats (Gould, 1994; Cameron et al., 
1995). 
 Cholinergic neurons reside in the septum and the nucleus basalis of 
Meynert and innervate different brain regions, mainly hippocampus. In 
vivo studies demonstrated that depletion of cholinergic pathway in rats 
do not affect the hippocampal proliferative cells rate (BrdU+ cells), but on 
the contrary reduces neurogenesis (Cooper-Kuhn et al., 2004). 
 GABA levels is maintained by the activities of seven types of interneurons 
in the DG and these cells are involved in the modulation of newborn 
granule cell (Freund and Buzsaki, 1996) as well as in neurogenesis 
regulation (Sibbe and Kulik, 2017). 
 Serotonergic neurons are localized in median and dorsal raphe nuclei and 
converge to multiple forebrain structures such as hippocampus 
(Oleskevich et al., 1991). The serotoninergic neurotransmission is 
suggested to be one of the central modulator of hippocampal 
neurogenesis, neuronal maturation and synaptogenesis (Djavadian et al., 
2004; Daubert and Condron, 2010). This aspect will be deeply analysed 
below. 
 
Regulation by environmental factors 
 
Neurogenesis in the adult brain is influenced also by other extrinsic factors 
such as environmental variables. Adult hippocampal neurogenesis was 
found to correlate positively with voluntary physical activity that 
contributes to increase the survival and the number of newborn neurons 
(Van Praag et al, 1999). Environmental enrichment and running are shown 
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to positively modulate neurogenesis. Mice and rats living in enriched cages 
have a more efficient learning capacity compared to that of control rodents 
(Kempermann et al., 1997). These animals have also increased 
synaptogenesis (Hosseiny et al., 2015) and enhanced 5-HT1a receptor 
expression (Rasmuson et al., 1998). Moreover, learning and healthy diet 
consumption  have a good effect on rodent neurogenesis (Lee et al., 2002). 
The same mechanisms are potentially translatable in humans, diet and 
exercise intervention could promote aHpNG and increasing cognitive 
function (Shors et al., 2014; Hueston et al., 2017). 
Stress is another strong inhibitor of aHpNG in different mammalian species, 
including mice and humans (Mirescu and Gould, 2006). Stress reduces the 
survival of newborn neurons in the DG with consequences on behavioural 
functions such as reduction of learning and memory (Czéh et al., 2002; 
Westenbroek et al., 2004). Control mice show more neurogenesis 
compared to stressed mice: they use better spatially complex arrangements 
of food storage sites and have incresed learning and memory tasks 
compared to stressed mice (Garthe et al., 2016). 
Moreover, aHpNG decreases drastically with age in rodents and also in 
human (Kempermann, 2015a; Manganas et al., 2007; Kempermann, 2015). 
Different studies carried out in rats suggested that with aging there is a 
reduction of proliferative and migrating cells into the granule cell layer and 
originating from the SGZ (Heine et al., 2004; McDonald and Wojtowicz, 
2005).  
 
Altered neurogenesis in disease and drug modulation 
 
Interesting, aHpNG impairment is involved in different neurodegenerative 
diseases, including Alzheimer's, Parkinson's and Huntington's disease. 
Moreover, an alteration of aHpNG occurs in several neuropsychiatric and 
neurodevelopmental diseases, such as major depression, bipolar disorder, 
schizophrenia, Down syndrome, Fragile X syndrome and Rett syndrome 
(Winner and Winkler, 2015).  
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Patients suffering from depression show impairment in cognitive flexibility, 
learning and memory (Austin et al., 2001; Fossati et al., 2002). These defects 
correlate with reduced hippocampal volume (Bremner et al., 2000) and 
neurogenesis (Sahay et al., 2007). Rats, mice and humans treated with 
antidepressants show enhanced aHpNG (Schmidt and Duman, 
2007; Boldrini et al., 2009, Lee et al., 2013). 
Lithium, a typical drug to treat bipolar disorder, is able to induce neuronal 
differentiation of NSC from the adult murine hippocampus (Bianchi et al., 
2010; Guidi et al., 2017; Trazzi et al., 2014).  
Furthermore, impaired hippocampal neurogenesis correlates with 
cognitive defects in mouse models of Alzheimer's disease. Some studies 
demonstrated that donepezil, a typical AD drugs, enhances the survival of 
newborn neurons in the DG (Kotani S et al., 2008) and improves spatial 
learning and memory deficits in adult rats. 
Conversely, adult hippocampal neurogenesis is inhibited by addictive drugs 
(Xu et al., 2016) such as opiates (Bortolotto and Grilli, 2017), cocaine 
(Castilla-Ortega E et al., 2017) and alcohol (Morris et al., 2010). If these 
negative effects on hippocampal neurogenesis correlate with impairment 
of cognitive functions in addicted patients remains to be fully established. 
 
ROLE OF SEROTONINERGIC SYSTEM IN HIPPOCAMPAL NEUROGENESIS 
 
Serotonin, 5-hydroxytryptamine (5-HT), is a monoaminergic 
neurotransmitter. In the developing foetal brain, neurotransmitters like 
amino acids and monoamines, and in particular 5-HT, are expressed 
relatively early before they exert their functional role in the CNS 
maturation. In the human developing brain, the serotoninergic system is 
evident from 5th week of gestation and increase rapidly through the 10th 
week of gestation.  
In adult brain, serotonergic terminals originate from the median and dorsal 
raphe nuclei of the brainstem and innervate multiple forebrain structures 
such as striatum, spinal cord, substantia nigra, cerebellum, nucleus 
accumbens and in the hippocampal formation, hilus, molecular and 
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granular layers of the dentate gyrus. In these regions, serotoninergic 
neurons synapses connect preferentially with interneurons of the stratum 
lacunosum-molecolare of the CA1 and CA3 regions. 
5-HT plays a variety of roles in physiologic mechanisms including 
developmental, cardiovascular, gastrointestinal and endocrine functions. In 
the CNS, 5-HT is a regulatory neurotransmitter that modulates different 
brain functions like sleep, aggression, feeding, sex behaviour, 
thermoregulation and mood, depending on different target regions. In 
hippocampus, serotonin plays an important role in cognitive functions such 
as spatial learning and memory, and in stress regulation, including 
emotional behaviour and anxiety (Gould, 1999; Djavadian, 2004; Kraus et 
al., 2017).  
Serotonin binds 15 specific receptors, grouped into 7 families, with distinct 
characteristics and expression patterns. These receptors have both 
excitatory and inhibitory action and many of them can regulate 
neurotransmitter release such as dopamine, acetylcholine, GABA, 
glutamate and noradrenaline. 
Almost all these receptors are expressed in the dentate gyrus, on both 
stimulatory glutamatergic cells and inhibitory interneurons (Berumen et al., 
2012). This evidence supports the possibility that 5-HT signalling may 
influence adult hippocampal neurogenesis and functions. 
Many studies, in fact, demonstrated that administration of serotoninergic 
agonists results in increased cell proliferation and neurogenesis both in SVZ 
and in SGZ of the hippocampus. Following chronic or acute serotonin 
depletion there is a drastic decrease in the number of new generated 
neurons in the subventricular zone and dentate gyrus of rodents 
(Benninghoff et al., 2010; Ueda et al., 2005). 
The 5-HT3 receptors are the only serotonin-gated ion channels and their 
activation in hippocampus is potentially involved in proneurogenic effects 
associated with exercise-induced hippocampal neurogenesis (Kondo et al., 
2015). 




 The 5-HT1 receptors are divided in subtypes 5-HT1a, 5-HT1b, 5-HT1d, 5-
HT1e and 5-HT1f and are coupled to the Gi/o protein. Agonists for these 
receptor family decrease adenylyl cyclase activation and cAMP levels. 
Activation of 5-HT1 receptors increases cell membrane conductance for 
the potassium ions.  
 The 5-HT4, 5-HT6 and 5-HT7 receptors are associated with Gs proteins 
and their activation supports the opposite action: increased cAMP level 
and decreased potassium conductance with consequent increase in 
neuronal excitability. 
 The 5-HT2 receptors are classified in the subtypes 5-HT2a, 5-HT2b and 
5-HT2c and are associated to the Gq proteins. Activation of these 
receptors induces phospholipase C (PLC) to catalyse the hydrolysis of 
PIP2 with consequent increase of inositol triphosphate (IP3), 
diacylglycerol (DAG) and intracellular calcium levels.   
 The 5-HT5 receptors are divided in subtype 5-HT5a and 5-ht5b: as the 5-
HT1 receptors, they are coupled to Gi/o proteins and their activation 
decreases cAMP levels. 
The role of each serotonin receptor subtype is not yet fully elucidated in the 
aHpNG process. In the DG, neurons usually co-express different types of 5-
HT receptors that could have similar or opposite effects on a specific 
function. Moreover, 5-HT receptors can combine each other forming 
homodimers or heterodimers so to contribute to further complexity in the 
5-HT signalling. E.g., heterodimers of 5-HT1a with 5HT7 receptors and 5-
HT2A with mGlu2 receptors (metabotropic glutamate 2 receptors) have 
been shown to have characteristics that differ from their individual 
counterparts (Renner et al., 2012; Delille et al., 2013). Finally, the resulting 
effect of 5-HT on hippocampal neurogenesis depends also on local 
serotonin receptor concentration, on the ratio of different receptor 
subtypes in loco and on the density of 5-HT receptors in a specific cell 
population (Sahay et al., 2007; Alenina and Klempin, 2015; Dale et al., 
2016).  
Another important protein that binds 5-HT is the serotonin transporter 
(SERT or 5HTT). This transporter, localized on the presynaptic terminal 
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membrane, is able to reuptake 5-HT from the synaptic gap and to interrupt 
the action of the neurotransmitter, as shown in figure 3. 
 
Figure 3. Schematic representation of 5-HT receptors and transpoters: 5-HT, released from 
pre-synaptic neurons in the synaptic cleft, are able to bind different post-synaptic 5-HT 
receptors that activates various signal cascades. 5-HTT is able to reuptake serotonin in the 
pre-synaptic neurons interrupting neurotransmitter effect. AC= adenylate cyclase, ATP= 
adenosine triphosphate, cAMP= cyclic adenosine monophosphate, PIP2 = 
phosphatidylinositol 4,5biphosphate, IP 3 = inositol triphosphate, DAG= diacylglycerol, PC= 




Trazodone (TZD), among antidepressants, belongs to SARIs drug class, since 
it is a serotonin receptor antagonist and reuptake inhibitor. It is used to 
treat psychiatric conditions including anxiety, insomnia, obsessive and 
compulsive disorder, post-traumatic stress disorder, substance use 
disorders, feeding and eating disorders, sexual dysfunction, behavioral 
disturbances associated with cognitive dysfunction, certain pain conditions 
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and rehabilitation after acute ischemic stroke (Lance et al., 1995; Roth et 
al., 2011; Khouzam, 2017). Recently, there has been an increasing interest 
in reconsidering trazodone as an effective antidepressant and as a drug 
with additional indications (Fagiolini et al., 2013). 
Trazodone is a phenylpiperazine and a triazolopyridine derivative that is 
structurally uncorrelated to other major classes of antidepressants.  
Trazodone is an antagonist of 5-HT2a and 5-HT2c receptors and has a partial 
agonism of serotonin 5-HT1a receptors. It inhibits serotonin reuptake by 
action on serotonin transporter. Furthermore, trazodone is an antagonist 
of α1- adrenergic receptors and, with lower affinity, of α2-adrenergic 
receptors. Lastly, TZD shows minimal anticholinergic effects. For its 
characteristics, TZD can be recognized as the first ever multimodal 
antidepressant.  
TZD was demonstrated to have neuroprotective effects via the expression 
of mTOR, CREB and BDNF in neurons derived from human neural stem cells 
(Daniele et al., 2012). Electrofisiological studies in rat brain demonstrated 
that TZD is able to increase the serotoninergic neurotransmission (Ghanbari 
et al., 2010). Moreover, TZD was demonstrated to significantly improve 
cognitive performance in rat treated with the toxin 3-nitropropionic acid, 
which induces cognitive impairment, oxidative stress (glutathione) and 
mitochondrial dysfunction (Kumar et al., 2010). These studies suggest that 
TZD is involved in diffent mechanisms that are potentially correlated to the 
neurogenesis process.  
 
DOWN SYNDROME, A NEURODEVELOPMENTAL DISORDER ASSOCIATED 




Down syndrome (DS) is a neurodevelopmental disorder affecting 1 in every 
787 live born babies each year (De Graaf et al., 2017a; De Graaf et al., 
2017b; De Graaf et al., 2015). Among individuals affected by DS, in most 
cases (around 88% of DS patients), the disorder is caused by meiotic non-
disjunction of the more likely maternal chromosome 21 resulting in a 
triplication of the entire chromosome 21. In some cases (around 4%), the 
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disorder is caused by robertsonian translocation of part or entire 
chromosome 21 to the long arm of the acrocentric chromosomes 14 or 22. 
Rarely (around 1%) DS presents as a mosaic conditions where only some 
cells have an extra copy of chromosome 21. These last cases are likely due 
to a non-disjunctional event occuring during the first stages of embryo 
formation. The phenotypic effects are very similar in all three DS forms, 
except for the severity of the disease:  the mosaicism cases have a clinical 
phenotype milder than the typical full trisomy. Patients have reduced 
muscle tone that results in floppiness (hypotonia) and show typical 
craniofacial features that are geometrically well descripted (Cornejo et al., 
2017). These facial abnormalities are microgenia (abnormally small chin), 
round face, slanting eye fissures with prominent ephicanthic folds, 
Brushfield spots in the iris, a flat facial profile, a flat nasal bridge, a 
protruding tongue, a shorter neck, a smaller nose and smaller ears than 
euploid individuals. Patients with DS are predisposed to a wide range of 
medical conditions. About 40-50% of newborns with DS present cardiac 
malformations, gastrointestinal defects, immune system anomalies, thyroid 
disorders, metabolic problems and increased frequency of leukaemia 
(Whooten et al., 2018; Hasle et al., 2016). However, with advances of 
medical technologies and increased access to medical care most of these 
medical issues have become treatable and life expectancy of DS patients 
has dramatically increased from 9 years old in 1929 to an average age of 60 
years in the 2002 (Carfì et al., 2014). At present the most debilitating and 




Intellectual disabilities and mental retardation are invariably present in DS 
population, in a degree ranging from mild to severe.  DS is the commonest 
identifiable cause of mental retardation (around 15-20% of the 
intellectually disabled population). Down syndrome children show memory 
profiles that are completely different from other genetic syndromes with 
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intellectual disabilities. DS childrens are characterized, in fact, by normal 
immediate visual-spatial short memory, but poor verbal working memory 
skills that worsen in the adolescence period (Conners et al., 2011; Edgin et 
al., 2010; Vicari and Carlesimo, 2006). Furthermore, cognitive functions 
degenerate with age due to several co-morbid factors such as sleep 
disruption, depression, sensory impairments, seizures, autism and other 
medical and psychiatric conditions. In the middle-late age, DS patients 
frequently develop dementia of the Alzheimer type. The increased risk of 
dementia results from the extra copy of the gene that codes for amyloid 
precursor protein (APP) which is strongly associated with the Alzheimer’s 
disease development.   
 
Anatomical and physiological defects  
 
Mental disorders in DS patients derive from a combination of reduced 
neural development and functional alterations that appear in 4-5-months 
foetuses and drastically worsen in the last three months of gestation 
(Guihard-Costa et al., 2006). In the two to six months of gestation period, 
cortical neurons born in the proliferative ventricular zone migrate into the 
cortical plate where they assume a committed phenotype to form the 
specific layers of the cortex (Weitzdoerfer et al., 2001). Alteration in this 
period cold impact the final brain function. The late prenatal DS brain, in 
fact, shows delayed and disorganized cortical lamination with smaller and 
hypocellular hippocampal DG and hypomorphic cerebellum. Consequently, 
MRI and post-mortem studies of brain size, in children with DS between 10 
and 20 years, show an approximate 17% decrease in volume, with selective 
loss in the hippocampus, cerebellum and frontal, temporal and occipital 
lobes. In adult age, brain size and weight is about 20% smaller than euploid 
brain and there are further reductions in the proportion between frontal 
lobe and temporal lobe volumes (Beacher et al., 2010; Anderson et al., 
2013, Pinter et al., 2001). At the histological level, the cerebral cortex of 
adult brain shows a reduced number of pyramidal neurons and altered 
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granule cells distribution in the cortical layers II and IV. Ultra-structural 
studies show that trisomic neurons possess reduced dendritic 
arborisations, reduced synaptic density and length, and profound 
alterations in dendritic spine, which appear smaller and immature. 
Furthermore, there is an unbalance between the excitatory and inhibitory 
tone due to complex impairment of neurotransmitter receptor functions, 
but also of both excitatory and inhibitory neurons numbers. These defects 
have several consequences such aberrant maturation of neurons and 
defective synaptic transmission (Stagni et al., 2018). The cyto-architectonic 
alterations and their effect on the cognitive development in DS is not very 
well elucidated; however, some alterations may be associated with specific 
intellectual disabilities in DS. (Couzens et al., 2011; Tsao and Kindelberger, 
2009). Deficits in memory consolidation may be consequent to temporal 
lobe and hippocampal dysfunction as well as to cerebellum and prefrontal 
cortex alterations (Pennington et al., 2003; Lott and Dierssen, 2010). It 
seems plausible, in fact, that cognitive dysfunctions in domains such as 
attention, executive control, language learning, spatial memory and 
emotional behaviours could be correlated with cerebellar–cortical–limbic 
circuitry impairment (Lott and Dierssen, 2010; Vicari, 2006).  
 
THE MURINE MODEL OF DOWN SYNDROME 
 
Over the last several years, very promising results have been obtained with 
a mouse model of DS, the Ts65Dn model. The murine chromosome 10, 16 
and 17 show conserved synteny with human chromosome 21. The highest 
proportion of orthologues genes are on murine chromosome 16 (about 
80%) and the remaining syntenic genes are on murine chromosome 10 
(around 14% of syntenic gene) and murine chromosome 17 (around 6% of 
syntenic gene). In 1990 Davisson et al. created the first viable trisomy 
murine model, the Ts65Dn mouse, that is still the best-studied model and 
contains partial and segmental trisomy 16. The Ts65Dn mice have an extra 
chromosome composed by a region of murine chromosome 16 
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translocated onto a short segment of murine chromosome 17 and this 
correspond to trisomy of 104 genes orthologous to human chromosome 21 
genes. In particular, Ts65Dn mice carry a triplication part between Mrpl39 
and Znf295 genes that contain several studied genes like App, Sod1, Sim2 
and Mx1, important in many human pathologic conditions. However, 
Ts65Dn mice have also three copies of 19 genes of murine chromosome 17 
that are not syntenic and some their phenotypes might not be correlated 
to human DS (Gupta et al., 2016).   
 
Figure 4. Schematic representation of the long-arm of human chromosome 21 comprised 
in the mouse chromosome 16, 17 and 10: Ts65Dn mice show triplication of approximately 
104 of the 170 orthologous genes, but they include the most studied genes such as APP, 




The Ts65Dn mice show several phenotypes and behavioural alterations that 
recapitulate the human counterpart, as shown in figure 5. As reported in a 
recent review (Stagni et al., 2018), they have several anatomical, 
biochemical and molecular alterations and, very importantly, they display 
cognitive alterations as in the human disease. Ts65Dn mice have altered 
cerebral architecture and reduced brain volume. Like DS patients, the size 
of the cerebellum and hippocampal granule cells layer are reduced very 
early and further decrease with age in Ts65Dn mice. Ts65Dn hippocampus 
shows reduced granule cell number in the DG associated with reduced 
dendritic spine density/shape and decreased synaptic structures across all 
postnatal ages (Benavides-Piccione et al., 2004).  
Furthermore, the ratio between excitatory and inhibitory neurotrasmitters 
is altered in Ts65Dn mice due to increased inhibitory synapses and 
increased activity of GABAergic neurons, while the excitatory components 
are decreased (Créau, 2012). Many studies suggested that increased 
inhibitory interneurons in Ts65Dn forebrain is due to triplication of the 
genes Oligodendrocyte Transcription Factor 1 and 2 that are strongly 
involved in oligodendrogenesis and neurogenesis (Chakrabarti et al., 2010). 
The over-expression of inhibitory neruons and neurotrasmission was 
demonstrated to alter LTP and LTD in DG of trisomic mice, and these defects 
strongly correlate with learning and memory impairment (Kleschevnikov et 
al., 2004). Similarily to the human disease, in Ts65Dn mice there is also an 
unbalance between the astroglial and neuronal components, with a 
reduced number of neurons and increased number of astrocytes in multiple 
regions (Guidi et al., 2008; Stagni et al., 2018). Another similarity between 
the mouse model and the human disease is at the onset of Alzheimer's 
disease (AD). Starting from 12 months of age Ts65Dn mice show, in fact, an 
increased expression of APP protein in hippocampus and cortex and 
degeneration of basal forebrain cholinergic neurons. For this reason, 




Figure 5. Schematic representation of brain abnormalities in Ts65Dn mice:  impairment of 
NSC proliferation, reduced neuronogenesis and increased gliogenesis (A), dendritic 
atrophy and reduced density of dendritic spines (B), reduced levels of various 
neurotransmitter systems and receptor alterations (C), increased inhibition and 
impairment of long-term potentiation (D). The overall outcome is a severe impairment of 
cognitive functions, including hippocampus-dependent learning and memory (E) (from 




NSC PROLIFERATION AND NEUROGENESIS DEFECT IN DOWN SYNDROME 
 
Key deficiencies were demonstrated to occur during the NSC expansion and 
neurogenesis in the early foetal stage (Guidi et al., 2008). Stagni et al. show 
that the reduced proliferation rate and proneurogenic capacity in Ts65Dn 
mice and DS brain are likely due to common mechanisms (Stagni et al., 
2018). Through immunohistological analysis of human foetus tissues for the 
cell cycle-associated marker such as Ki-67 (expressed in S+G2+M phases) 
and phospo-histone 3 (H3, mainly expressed in M phase), the NSC 
proliferative status was investigated in DS brain. In foetus during the  first 
three months of gestation, cells expressing Ki-67 and H3 were drastically 
reduced in dentate gyrus, cortex and cerebellum in comparison with 
euploid NSC (Contestabile et al., 2007; Guidi et al., 2011). Studies in Ts65Dn 
mice confirmed the observations found in human brain. Histological 
analysis of Ts65Dn mice show that the numbers of BrdU+ cells is reduced in 
the same areas of the human brain since prenatal stage (Contestabile et al., 
2007).  
It seems that reduced NSC proliferation rate is due to elongation of cell 
cycle and precocious exit from the cell cycle. In trisomic mice, cyclins and 
cyclin dependent kinases (CDK), that regulate cell cycle, are altered: 1. cyclin 
D1 is overexpressed causing prolongation of the G1 phase; 2. cyclin-
dependent kinase inhibitor p27KIP1 is increased inducing the cells to enter in 
G0 and premature neuronal differentiation; 3. p53 and p21CIP1 (cyclin-
dependent kinase inhibitor 1) are overexpressed impairing the transition 
from G1/G0 to S phase. It has been reported that triplication of the most  
studied genes such as Dirk1A, App, Rcan1 and Olig 1/2 has an active role in 
increasing activation and overexpression of cyclin D1, P27KIP1, p53 and 
p21CIP1 (Stagni et al, 2018). 
 
In the same studies, defects in NSC proliferation were shown to result in a 
reduction of neurogenesis in the developing DS brain. Neurogenesis is 
highly compromised in favour of gliogenesis. Studies in vivo and in vitro, 
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with murine and human foetal NSC, demostrated that the newborn 
neurons significantly decrease in number, with paraller increased number 
of the astrocyte counterpart, in the hippocampus, parahippocampus gyrus 
and cerebellum (Guidi et al., 2008; Trazzi et al., 2014). This umbalance is 
due, at least in part, to triplication of genes that encode for several 
interferon receptors (such as IFNAR1, IFNAR2, IFNGR2) and IL10RB. The 
activation of interferon-receptors activates the JAK/STAT pathway, and in 
particular STAT3, that in turn activates transcription of GFAP and S100, 
whose products are typical markers of astroglial cells (Ferrando-Miguel et 
al., 2003). Moreover, increased expression of APP and its intracellular 
domain portion (AICD) can repress Shh pathway through activation of 
PTCH1 expression. Consequently, the transcription factors GLI1 and GLI2, 
mediated by Shh pathway activation, are considerably reduced. GLI2 can 
induce neurogenesis through positive regulation of Mash1 and its 
downregulation affects neuronal differentiation (Trazzi et al., 2011). 
 
TIMING OF POTENTIAL DRUG THERAPIES FOR DOWN SYNDROME 
 
In the last 20 years, since the discovery that drugs are able to modulate 
neurogenesis and potentially restore cognitive functions, a growing interest 
had turned towards novel pharmacological approaches in  DS. Experimental 
evidence further confirmed that there is the possibility to correct the DS 
NSC deficits. The target mechanisms of these studies involve different 
signalling pathways and molecules. The most important pharmacological 
approaches could be divided in 5 types, depending on targeted 
mechanisms:  
A. Restoring of the physiological neurotransmission since in the DS brain 
there is an unbalance between reduced excitatory activity and increased 
inhibitory activity (Créau, 2012), both playing an important role in cognitive 
and neurodevelopment processes. 
B. Prevention of neurodegeneration through antioxidant, neurotrophic 
molecules and free radical scavengers. Enhanced production of ROS, due to 
triplication of SOD1 gene (that plays a role in ROS scavenging) was 
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correlated with neurodegeneration and intellectual disabilities in DS 
(Perluigi and Butterfield, 2012). Treatments such as melatonin, vitamin E 
and oestrogens have shown some positive effects on learning and memory 
in Ts65Dn mice (Corrales et al., 2013; Lockrow et al., 2009; Granholm et al., 
2002). 
C. Recovery of disrupted downstream signalling pathways such as GSK3 
signalling, whose dysregulation was suggested to be implicated in the 
neural impairment in DS (Trazzi et al., 2014). Inhibition of GSK3 by lithium 
reverted DS-associated defects not only at the cellular and anatomical 
levels, but ameliorated neurogenesis and cognitive functions in Ts65Dn 
mice (Stagni et al., 2013). 
D. Correction of the protein dosage encoded by triplicated genes such as 
App and Dirk1A, which were demonstrated to be implicated in DS brain 
deficit. Several studies that blocked APP and DYRK1A downstream 
pathways using inhibitors such as DAPT (a -secretase inhibitor) and 
Epigallocatechin Gallate (EGCG, a Dirk1A kinase inhibitor) showed 
amelioration of behavioural functions in Ts65Dn mice (Netzer et al., 2010; 
Stagni et al., 2014).  
E. Increasing neurogenesis by proneurogenic molecules such as P7C3 that 
was a well-know molecule to induce hippocampal neurogenesis in Ts65Dn 
mice (Latchney et al., 2015). Moreover, certain fatty acids demonstrated to 
have proneurogenic effects in Ts65Dn mice (Stagni et al., 2017). 
More than half of these studies aimed to correct neurotransmission:  
I. Inactivation of GABAergic neurotransmission by antagonizing GABAergic 
receptors. GABA neurotransmission is increased and is strongly correlated 
to cognitive and learning deficits in Ts65Dn mice. GABA antagonists or 
GABAA 5 negative allosteric modulators were demonstrated to ameliorate 
neurogenesis, LTP and to improve cognition in trisomic mice (Kleschevnikov 
et al., 2012; Martínez-Cué et al., 2013). 
 II. Restoring the cholinergic system that is degenerated in TS65dn mice 
(starting from 4-6 months  and becoming evident at 10-12 months of age) 
and in DS individuals (Godrige et al, 1987; Chang and Gold, 2008). Reduction 
of the number of basal forebrain cholinergic neurons is correlated to 
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working memory/attention impairment. Drugs such as donezepil have been 
shown to partially restore learning and memory in Ts65Dn mice (Rueda et 
al., 2008). 
III. Restoring noradrenergic neurotransmission that is largely affected in DS 
patients and in Ts65Dn mice. This impairment strongly correlates with 
cholinergic system degeneration, inflammation and cognitive decline in 
Ts65Dn. Restoration of the noradrenergic tone, using a norepinephrine 
precursor or  adrenergic receptor agonists, caused an improvement of 
cognitive functions in Ts65Dn mice (Salehi et al., 2009). 
IV. Restoring the glutamatergic system: in DS patients and in Ts65Dn mice 
it has been demonstrated that glutamatergic neurotransmission and N-
methyl-D-aspartate (NMDA) receptor signalling are altered and this might 
potentially contribute to behavioural disabilities. Mice trated with 
memantine, a moderate-affinity antagonist of NMDA receptors, show 
increased spatial learning capacity and restored electrophysiological 
abnormalities in trisomic mice (Lockrow et al., 2011). 
V. Restoring the serotonergic system whose impairment in DS brain 
correlates to neurogenesis impairment and to declined cognitive functions 
(Whittle et al., 2007). Studies in vivo demonstrated that disruption of the 
serotoninergic tone in neonatal mice results in brain development 
dysfunctions, including generation of precursor cells, their migratory 
abilities and their differentiation in mature neurons and glial cells (Durig and 
Hornung, 2000). At the molecular level, the reason why the 5-HT pathway 
appears to be implicated in the DS may have also to do with S100β gene 
triplication since this gene product negatively regulates the outgrowth of 
serotonin terminals and reduces serotonin levels (Shapiro et al., 2010). In 
this respect, treatments that increase 5-HT availability may counteract the 
defects and even the mental retardation in DS individuals. 
VI. Restoring other pathways such as histamine neurotransmission that was 
demonstrated, when deregulated, to contribute to cognitive impairment in 
DS (Kim et al., 2001).  
Most of the studies listed above were performed in adult Ts65Dn mice and 
this is very relevant because it gives the demonstration that something 
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could be restore even in adult DS individuals.  Among the studies done in 
adult Ts65Dn mice: 58% showed recovery of cognitive defects such as 
memory and learning, 19% only a partial improvement and 28% no effects. 
Unfortunately, very few studies concerned the neurogenesis process. 
Moreover, few studies took into consideration the duration of the 
treatment effects after treatments ending. Based on these considerations, 
some of the preclinical studies have built the rationale for studing in clinical 
trials the effects of drugs such as RG1662 (a GABAA5 negative allosteric 
modulator), Memantine, donepezil and rivastagmine (acetylcholinesterase 
inhibitors), EGCG and vitamin E in adult and children affected by DS (Stagni 
et al., 2015). 
 
An important critical aspect of the summarized preclinical studies 
performed in adult mice has to do with the fact that the overall brain 
development and function depends principally on events occurring during 
the early foetal stages. Moreover, after the birth neurogenesis is 
maintained in hippocampus until adulthood, while neurogenesis in the 
cerebellum occurs and ends in the first two post-natal weeks. For this 
reason, therapies tested in adult mice could modulate hippocampal 
neurogenesis with limited changes in the neural plasticity and with a partial 
recovery of the intellectual disabilities, while it may be too late to recover 
cerebellum-associated functions, such as attention and language capacity. 
Consequently, therapies to improve neurogenesis defects should be started 
as soon as possible to allow the formation of appropriate neuronal 
connections. The two potential best time windows are likely neonatal and 
prenatal/perinatal treatments. 
The most relevant studies in neonatal mice showed increased in 
hippocampal and cerebellum neurogenesis. E.g. in vitro, newborn Ts65Dn 
mice, treated with single injection of Shh agonist at birth (such as SAG-1), 
recovered cerebellar development and hippocampal LTP when they 
reached adult age (4 month-old), but with no effect on cerebellar-mediated 
cognitive functions (Das et al., 2013; Gutierrez-Castellanos et al., 2013). In 
another study, chronic treatment of fluoxetine in trisomic mice from 
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postnatal day 3 to day 15 (P3-P15) restored hippocampal neurogenesis and 
the number of granule cells in the neonatal mice. 1 and 4 months after 
treatment cessation, Ts65Dn mice maintained restored dendritic structure, 
spine density and cellular connectivity (Stagni et al., 2015). In addition, 7, 8-
DHF, a natural small molecule, promoted neurogenesis and maturation of 
newborn neurons in neonatal Ts65Dn mice treated from P3 to P15 (Stagni 
et al., 2017). Furthermore, neonatal mice exposed to EGCG from P3-P15 
fully restored hippocampal cellularity and neurogenesis (Stagni et al., 2016). 
 
However, with the aim of fully correcting DS pathophysiology, prenatal 
stage seems to be the best treatment period and many studies 
demonstrated that drugs given to mothers had a larger impact to correct 
the whole brain functions. E.g. High concentration of choline in the diet of 
pregnant Ts65Dn mothers (beginning from embryonic day 1, or E1, to when 
pups reach P21) increased organization of cholinergic neurons in their 
progeny. When they reached 6 months-old age, mice showed increased 
cognitive functions as far as attention behaviour. The same diet, in 
combination with environmental enrichment, increased also hippocampal 
neurogenesis, spatial cognition and cholinergic neuron numbers in 
prenatally treated mice when they reached adulthood (Moon et al., 2010). 
The peptides NAPVSIPQ (that mimics the activity of the neuroprotective 
protein ADNP) and SALLRSIPA (that mimics the activity of neurotrofic factor 
ADNF) prevented neurodevelopmental delay, restored the altered subunit 
of GABA and improved learning in Ts65Dn mice treated in the prenatal 
period from E8-E12 (Vink et al., 2009). Prenatal treatment with tocoferol, 
the active form of vitamin E, increased cell density in DG and ameliorated 
learning and retention memory in Ts65Dn mice treated from E0 to 
adulthood P84 (Shichiri et al., 2011). Chronic administration of ECGC was 
able also to correct brain weight, thalamo-hypothalamic volume proportion 
and to completely restore the long-term memory (Guedj et al., 2009) in 




Fluoxetine treatment in Ts65Dn mice from E10 to P2 (10 mg/kg for 
pregnant mother and 150 ug/g body weigth for pups) was able to restore 
proliferation and cellularity in all main brain regions of prenatally treated 
mice. When these mice reached adulthood (P43), they showed increased 
numbers of NSC in the SVZ and SGZ, corrected neuronal/astroglial cells 
balance, normalized number of granule cells, restored maturation of 
dendritic spines and improved cognitive function (Guidi et al., 2014).  
 
Altogether, drug treatments in the prenatal phase showed a clear 
improvement in brain structures and functions to indicate that sooner 
treatment had more beneficial effects. However, in order to translate this 
protocol on human counterpart, it must be remembered that the human 
ontology is different from mice one. Mice development occurs mainly after 
birth, while in human nervous system maturation occurs during the 
prenatal stage and the main brain regions, except for SVZ, hippocampus 
and cerebellum, enter in a state of replicative quiescence after birth. This is 
an important critical issue to plan in the future any safe treatment in a 
human brain development phase. Since hippocampal and cerebellum 
neurogenesis in human begin from the 12th gestation week (Seress et al., 
2011; ten Donkelaar et al., 2003) and in the same week it is possible to 
perform non-invasive prenatal testing to confirm DS, the remaining 28 
weeks could potentially represent the optimal time window to treat foetus. 
Many studies are currently active with the final goal to develop new 
therapeutic drugs that have minimal side effects in mothers and unborn 
children, that are not teratogenic and that could pass through the placenta 





Alenina N, Klempin F. The role of serotonin in adult hippocampal neurogenesis. Behav Brain Res. 
2015 Jan 15;277:49-57. 
 
Allen DD, Cárdenas AM, Arriagada C, Bennett LB, García CJ, Caviedes R, Rapoport SI, Caviedes P. A 
dorsal root ganglia cell line derived from trisomy 16  fetal mice, a model for Down syndrome. 
Neuroreport. 2002 Mar 25;13(4):491-6. 
 
Altman J, Das GD. Autoradiographic and histological evidence of postnatal hippocampal 
neurogenesis in rats. J Comp Neurol. 1965 Jun;124(3):319-35.  
 
Alvarez-Buylla A, Garcia-Verdug o JM. Neurogenesis in adult subventricularzone. J Neurosci. 2002 
Feb 1;22(3):629-34.  
 
Ambrogini P, Lattanzi D, Ciuffoli S, Agostini D, Bertini L, Stocchi V, Santi S, Cuppini R. Morpho-
functional characterization of neuronal cells at different stages of maturation in granule cell layer of 
adult rat dentate gyrus. Brain Res. 2004 Aug 13;1017(1-2):21-31.  
 
Anderson JS, Nielsen JA, Ferguson MA, Burback MC, Cox ET, Dai L, Gerig G, Edgin JO, Korenberg JR. 
Abnormal brain synchrony in Down Syndrome. Neuroimage Clin. 2013 May 24;2:703-15.  
 
Austin MP, Mitchell P, Goodwin GM. Cognitive deficits in depression: possible implications for 
functional neuropathology. Br J Psychiatry. 2001 Mar;178:200-6. 
 
Balan S, Toyoshima M, Yoshikawa T. Contribution of induced pluripotent stem cell technologies to 
the understanding of cellular phenotypes in schizophrenia. Neurobiol Dis. 2018 May 3.  
 
Balu DT, Lucki I. Adult hippocampal neurogenesis: regulation, functional implications, and 
contribution to disease pathology. Neurosci Biobehav Rev. 2009  Mar;33(3):232-52.  
Bartesaghi R, Guidi S, Ciani E. Is it possible to improve neurodevelopmental abnormalities in Down 
syndrome? Rev Neurosci. 2011;22(4):419-55.  
 
Beacher F, Daly E, Simmons A, Prasher V, Morris R, Robinson C, Lovestone S, Murphy K, Murphy DG. 
Brain anatomy and ageing in non-demented adults with Down's  syndrome: an in vivo MRI study. 
Psychol Med. 2010 Apr;40(4):611-9.  
 
Bédard A, Gravel C, Parent A. Chemical characterization of newly generated neurons in the striatum 
of adult primates. Exp Brain Res. 2006 Apr;170(4):501-12.  
 
Benavides-Piccione R, Ballesteros-Yáñez I, de Lagrán MM, Elston G, Estivill X, Fillat C, Defelipe J, 
Dierssen M. On dendrites in Down syndrome and DS murine models: a spiny way to learn. Prog 
Neurobiol. 2004 Oct;74(2):111-26.  
 
Benninghoff  J, Gritti A, Rizzi M, Lamorte G, Schloesser RJ, Schmitt A, Robel S, Genius J, Moessner R, 
Riederer P, Manji HK, Grunze H, Rujescu D, Moeller HJ, Lesch KP, Vescovi AL. Serotonin depletion 
hampers survival and proliferation in neurospheres derived from adult neural stem cells. 




Bernier PJ, Bedard A, Vinet J, Levesque M, Parent A. Newly generated neurons in the amygdala and 
adjoining cortex of adult primates. Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11464-9.  
 
Berumen LC, Rodríguez A, Miledi R, García-Alcocer G. Serotonin receptors in hippocampus. 
ScientificWorldJournal. 2012;2012:823493.  
 
Bianchi P, Ciani E, Contestabile A, Guidi S, Bartesaghi R. Lithium restores neurogenesis in the 
subventricular zone of the Ts65Dn mouse, a model for Down syndrome. Brain Pathol. 2010 
Jan;20(1):106-18.  
 
Boldrini M, Underwood MD, Hen R, Rosoklija GB, Dwork AJ, John Mann J, Arango V. Antidepressants 
increase neural progenitor cells in the human hippocampus. Neuropsychopharmacology. 2009 
Oct;34(11):2376-89. 
 
Bonaguidi MA, Wheeler MA, Shapiro JS, Stadel RP, Sun GJ, Ming GL, Song H. In vivo clonal analysis 
reveals self-renewing and multipotent adult neural stem cell characteristics. Cell. 2011 Jun 
24;145(7):1142-55. . 
 
Bremner JD, Narayan M, Anderson ER, Staib LH, Miller HL, Charney DS. Hippocampal volume 
reduction in major depression. Am J Psychiatry. 2000 Jan;157(1):115-8.  
 
Brigida AL, Siniscalco D. Induced pluripotent stem cells as a cellular model for studying Down 
Syndrome. J Stem Cells Regen Med. 2016 Nov 29;12(2):54-60.  
 
Cai J, Weiss ML, Rao MS. In search of "stemness". Exp Hematol. 2004 Jul;32(7):585-98.  
 
Cameron HA, McEwen BS, Gould E. Regulation of adult neurogenesis by excitatory input and NMDA 
receptor activation in the dentate gyrus. J Neurosci. 1995 Jun;15(6):4687-92.  
 
Carfì A, Antocicco M, Brandi V, Cipriani C, Fiore F, Mascia D, Settanni S, Vetrano DL, Bernabei R, Onder 
G. Characteristics of adults with down syndrome: prevalence of age-related conditions. Front Med 
(Lausanne). 2014 Dec 3;1:51.  
 
Carpenter MK, Rosler E, Rao MS. Characterization and differentiation of human embryonic stem cells. 
Cloning Stem Cells. 2003;5(1):79-88.  
 
Castilla-Ortega E, Ladrón de Guevara-Miranda D, Serrano A, Pavón FJ, Suárez J, Rodríguez de Fonseca 
F, Santín LJ. The impact of cocaine on adult hippocampal neurogenesis: Potential neurobiological 
mechanisms and contributions to maladaptive cognition in cocaine addiction disorder. Biochem 
Pharmacol. 2017 Oct  1;141:100-117.  
 
Chakrabarti L, Best TK, Cramer NP, Carney RS, Isaac JT, Galdzicki Z, Haydar TF. Olig1 and Olig2 
triplication causes developmental brain defects in Down syndrome. Nat Neurosci. 2010 
Aug;13(8):927-34.  
 
Chambers I, Colby D, Robertson M, Nichols J, Lee S, Tweedie S, Smith A. Functional expression cloning 




Chambers SM, Christopher A. Fasano, Eirini P. Papapetrou, Mark Tomishima, Michel Sadelain, Lorenz 
Studer. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD 
signalling Nat Biotechnol. 2009 Mar; 27(3): 275–280.   
 
Chang Q, Gold PE. Age-related changes in memory and in acetylcholine functions in the hippocampus 
in the Ts65Dn mouse, a model of Down syndrome. Neurobiol Learn Mem. 2008 Feb;89(2):167-77. 
Epub 2007 Jul 20.  
 
Chou YF, Yabuuchi A. Murine embryonic stem cell derivation, in vitro pluripotency characterization, 
and in vivo teratoma formation. Curr Protoc Toxicol. 2011 Nov;Chapter 2:Unit2.22.  
 
Clevers H. STEM CELLS. What is an adult stem cell? Science. 2015 Dec 11;350(6266):1319-20.  
 
Conners FA, Moore MS, Loveall SJ, Merrill EC. Memory profiles of Down, Williams, and fragile X 
syndromes: implications for reading development. J Dev Behav Pediatr. 2011 Jun;32(5):405-17.  
 
Contestabile A, Fila T, Ceccarelli C, Bonasoni P, Bonapace L, Santini D, Bartesaghi R, Ciani E. Cell cycle 
alteration and decreased cell proliferation in  the hippocampal dentate gyrus and in the neocortical 
germinal matrix of foetuses with Down syndrome and in Ts65Dn mice. Hippocampus. 
2007;17(8):665-78.  
 
Cooper-Kuhn CM, Winkler J, Kuhn HG. Decreased neurogenesis after cholinergic forebrain lesion in 
the adult rat. J Neurosci Res. 2004 Jul 15;77(2):155-65.  
 
Cornejo JYR, Pedrini H, Machado-Lima A, Nunes FLDS. Down syndrome detection based on facial 
features using a geometric descriptor. J Med Imaging (Bellingham). 2017 Oct;4(4):044008.  
 
Corrales A, Martínez P, García S, Vidal V, García E, Flórez J, Sanchez-Barceló EJ, Martínez-Cué C, Rueda 
N. Long-term oral administration of melatonin improves  spatial learning and memory and protects 
against cholinergic degeneration in middle-aged Ts65Dn mice, a model of Down syndrome. J Pineal 
Res. 2013 Apr;54(3):346-58.  
 
Couzens D, Cuskelly M, Haynes M. Cognitive development and Down syndrome: age-related change 
on the Stanford-Binet test (fourth edition). Am J Intellect Dev Disabil. 2011 May;116(3):181-204.  
 
Créau N. Molecular and cellular alterations in Down syndrome: toward the identification of targets 
for therapeutics. Neural Plast. 2012;2012:171639.  
 
Czéh B, Welt T, Fischer AK, Erhardt A, Schmitt W, Müller MB, Toschi N, Fuchs E, Keck ME. Chronic 
psychosocial stress and concomitant repetitive transcranial magnetic stimulation: effects on stress 
hormone levels and adult hippocampal neurogenesis. Biol Psychiatry. 2002 Dec 1;52(11):1057-65.  
 
Dale E, Pehrson AL, Jeyarajah T, Li Y, Leiser SC, Smagin G, Olsen CK, Sanchez  C. Effects of serotonin 
in the hippocampus: how SSRIs and multimodal antidepressants might regulate pyramidal cell 
function. CNS Spectr. 2016 Apr;21(2):143-61.  
 
Das I, Park JM, Shin JH, Jeon SK, Lorenzi H, Linden DJ, Worley PF, Reeves RH.  Hedgehog agonist 
therapy corrects structural and cognitive deficits in a Down syndrome mouse model. Sci Transl Med. 




Daubert EA, Condron BG. Serotonin: a regulator of neuronal morphology and circuitry. Trends 
Neurosci. 2010 Sep;33(9):424-34.  
 
de Graaf G, Buckley F, Dever J, Skotko BG. Estimation of live birth and population prevalence of Down 
syndrome in nine U.S. states. Am J Med Genet A. 2017a Oct;173(10):2710-2719.  
 
de Graaf G, Buckley F, Skotko BG. Estimation of the number of people with Down syndrome in the 
United States. Genet Med 2017b;19:439–47.  
 
de Graaf G, Buckley F, Skotko BG. Estimates of the live births, natural losses, and elective terminations 
with Down syndrome in the United States. Am J Med Genet A 2015;167A:756–67.  
 
Dellatore SM, Garcia AS, Miller WM. Mimicking stem cell niches to increase stem cell expansion. Curr 
Opin Biotechnol. 2008 Oct;19(5):534-40.  
 
Delille HK, Mezler M, Marek GJ. The two faces of the pharmacological interaction of mGlu2 and 5-
HT₂A - relevance of receptor heterocomplexes and interaction through functional brain pathways. 
Neuropharmacology. 2013 Jul;70:296-305.  
 
Deng W, Aimone JB, Gage FH. New neurons and new memories: how does adult hippocampal 
neurogenesis affect learning and memory? Nat Rev Neurosci. 2010 May;11(5):339-50.  
 
Dimos JT, Rodolfa KT, Niakan KK, Weisenthal LM, Mitsumoto H, Chung W, Croft GF, Saphier G, Leibel 
R, Goland R, Wichterle H, Henderson CE, Eggan K. Induced pluripotent stem cells generated from 
patients with ALS can be differentiated into motor neurons. Science. 2008 Aug 29;321(5893):1218-
21.  
 
Djavadian RL. Serotonin and neurogenesis in the hippocampal dentate gyrus of adult mammals. Acta 
Neurobiol Exp (Wars). 2004;64(2):189-200.  
 
Doetsch F, García-Verdugo JM, Alvarez-Buylla A. Regeneration of a germinal layer in the adult 
mammalian brain. Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11619-24.  
 
Durig J, Hornung JP. Neonatal serotonin depletion affects developing and mature mouse cortical 
neurons. Neuroreport. 2000 Mar 20;11(4):833-7.  
 
Edgin JO, Pennington BF, Mervis CB. Neuropsychological components of intellectual disability: the 
contributions of immediate, working, and associative memory. J Intellect Disabil Res. 2010 
May;54(5):406-17.  
 
Elias S, Morgan MA, Bikoff EK, Robertson EJ. Long-lived unipotent Blimp1-positive luminal stem cells 
drive mammary gland organogenesis throughout adult life. Nat Commun. 2017 Nov 20;8(1):1714.  
 
Engidawork E, Lubec G. Molecular changes in fetal Down syndrome brain. J Neurochem. 2003 
Mar;84(5):895-904.  
 
Eriksson PS, Perfilieva E, Björk-Eriksson T, Alborn AM, Nordborg C, Peterson DA, Gage FH. 




Ernst A, Alkass K, Bernard S, Salehpour M, Perl S, Tisdale J, Possnert G, Druid H, Frisén J. Neurogenesis 
in the striatum of the adult human brain. Cell. 2014 Feb 27;156(5):1072-83.  
 
Fagiolini A, Comandini A, Catena Dell'Osso M, Kasper S. Rediscovering trazodone for the treatment 
of major depressive disorder. CNS Drugs. 2012 Dec;26(12):1033-49.  
 
Ferrando-Miguel R, K.S. Shim, M.S. Cheon, M. Gimona, M. Furuse, G. Lubec, Overexpression of 
interferon α/β receptor β chain in fetal Down syndrome, Brain, Neuroembryol. Aging 2 (4) (2003) 
147–155. 
 
Flickinger RA. Hierarchical differentiation of multipotent progenitor cells. Bioessays. 1999 
Apr;21(4):333-8.  
 
Foltz LP, Clegg DO. Rapid, Directed Differentiation of Retinal Pigment Epithelial Cells from Human 
Embryonic or Induced Pluripotent Stem Cells. J Vis Exp. 2017 Oct 30;(128).  
 
Fossati P, Ergis AM, Allilaire JF. [Executive functioning in unipolar depression: a review]. Encephale. 
2002 Mar-Apr;28(2):97-107.  
 
Freund TF, Buzsáki G. Interneurons of the hippocampus. Hippocampus. 1996;6(4):347-470.   
 
Garthe A, Roeder I, Kempermann G. Mice in an enriched environment learn more flexibly because of 
adult hippocampal neurogenesis. Hippocampus. 2016 Feb;26(2):261-71.  
 
Ghaffari LT, Starr A, Nelson AT, Sattler R. Representing Diversity in the Dish: Using Patient-Derived in 
Vitro Models to Recreate the Heterogeneity of Neurological Disease. Front Neurosci. 2018 Feb 
9;12:56. doi: 10.3389/fnins.2018.00056. eCollection 2018.   
 
Ghanbari R, El Mansari M, Blier P. Sustained administration of trazodone enhances serotonergic 
neurotransmission: in vivo electrophysiological study in the rat brain. J Pharmacol Exp Ther. 2010 
Oct;335(1):197-206.  
 
Gordon J, Amini S, White MK. General overview of neuronal cell culture. Methods Mol Biol. 
2013;1078:1-8.  
 
Gould E. The effects of adrenal steroids and excitatory input on neuronal birth and survival. Ann N Y 
Acad Sci. 1994 Nov 14;743:73-92; discussion 92-3.   
 
Gould E. Serotonin and hippocampal neurogenesis. Neuropsychopharmacology. 1999 Aug;21(2 
Suppl):46S-51S.  
 
Götz M, Sirko S, Beckers J, Martin Irmler Glia. Reactive astrocytes as neural stem or progenitor cells: 
In vivo lineage, In vitro potential, and Genome‐wide expression analysis 2015 Aug; 63(8): 1452–1468.  
  
Granholm AC, Sanders LA, Crnic LS. Loss of cholinergic phenotype in basal forebrain coincides with 
cognitive decline in a mouse model of Down's syndrome. Exp Neurol. 2000 Feb;161(2):647-63.  
 
Guedj F, Sébrié C, Rivals I, Ledru A, Paly E, Bizot JC, Smith D, Rubin E, Gillet B, Arbones M, Delabar JM. 





Guidi S, Stagni F, Bianchi P, Ciani E, Giacomini A, De Franceschi M, Moldrich  R, Kurniawan N, Mardon 
K, Giuliani A, Calzà L, Bartesaghi R. Prenatal pharmacotherapy rescues brain development in a Down's 
syndrome mouse model. Brain. 2014 Feb;137(Pt 2):380-401.  
 
Guidi S, Bonasoni P, Ceccarelli C, Santini D, Gualtieri F, Ciani E, Bartesaghi R. Neurogenesis 
impairment and increased cell death reduce total neuron number in the hippocampal region of 
fetuses with Down syndrome. Brain Pathol. 2008 Apr;18(2):180-97.  
 
Guidi S, Ciani E, Bonasoni P, Santini D, Bartesaghi R. Widespread proliferation impairment and 
hypocellularity in the cerebellum of fetuses with down syndrome. Brain Pathol. 2011 Jul;21(4):361-
73.  
 
Guidi S, Bianchi P, Stagni F, Giacomini A, Emili M, Trazzi S, Ciani E, Bartesaghi R. Lithium Restores Age-
related Olfactory Impairment in the Ts65Dn Mouse Model of Down Syndrome. CNS Neurol Disord 
Drug Targets. 2017;16(7):812-819.  
 
Guihard-Costa AM, Khung S, Delbecque K, Ménez F, Delezoide AL. Biometry of face and brain in 
fetuses with trisomy 21. Pediatr Res. 2006 Jan;59(1):33-8.  
 
Gupta M, Dhanasekaran AR, Gardiner KJ. Mouse models of Down syndrome: gene content and 
consequences. Mamm Genome. 2016 Dec;27(11-12):538-555. Epub 2016 Aug  18.  
 
Gutierrez-Castellanos N, Winkelman BH, Tolosa-Rodriguez L, Devenney B, Reeves  RH, De Zeeuw CI. 
Size does not always matter: Ts65Dn Down syndrome mice show cerebellum-dependent motor 
learning deficits that cannot be rescued by postnatal  SAG treatment. J Neurosci. 2013 Sep 
25;33(39):15408-13.  
 
Habela CW, Song H, Ming GL. Modeling synaptogenesis in schizophrenia and autism using human 
iPSC derived neurons. Mol Cell Neurosci. 2016 Jun;73:52-62.  
 
Hadjantonakis A, Papaioannou V. The stem cells of early embryos. Differentiation. 2001 Oct;68(4-
5):159-66.  
 
Hasle H, Friedman JM, Olsen JH, Rasmussen SA. Low risk of solid tumors in persons with Down 
syndrome. Genet Med. 2016 Nov;18(11):1151-1157. doi: 10.1038/gim.2016.23.  
 
Hayashi Y, Furue MK, Okamoto T, Ohnuma K, Myoishi Y, Fukuhara Y, Abe T, Sato JD, Hata R, Asashima 
M. Integrins regulate mouse embryonic stem cell self-renewal. Stem Cells. 2007 Dec;25(12):3005-
15.  
 
Heine VM, Maslam S, Joëls M, Lucassen PJ. Prominent decline of newborn cell proliferation, 
differentiation, and apoptosis in the aging dentate gyrus, in absence of an age-related hypothalamus-
pituitary-adrenal axis activation. Neurobiol Aging. 2004 Mar;25(3):361-75.  
 
Higuchi A, Ling QD, Ko YA, Chang Y, Umezawa A. Biomaterials for the feeder-free culture of human 
embryonic stem cells and induced pluripotent stem cells. Chem Rev. 2011 May 11;111(5):3021-35. 




Hodge RD, Nelson BR, Kahoud RJ, Yang R, Mussar KE, Reiner SL, Hevner RF. Tbr2  is essential for 
hippocampal lineage progression from neural stem cells to intermediate progenitors and neurons. J 
Neurosci. 2012 May 2;32(18):6275-87.  
 
Honda A, Hirose M, Hatori M, Matoba S, Miyoshi H, Inoue K, Ogura A. Generation of induced 
pluripotent stem cells in rabbits: potential experimental models for human regenerative medicine. J 
Biol Chem. 2010 Oct 8;285(41):31362-9. doi: 10.1074/jbc.M110.150540.  
 
Hosseiny S, Pietri M, Petit-Paitel A, Zarif H, Heurteaux C, Chabry J, Guyon A. Differential neuronal 
plasticity in mouse hippocampus associated with various periods of enriched environment during 
postnatal development. Brain Struct Funct. 2015 Nov;220(6):3435-48.  
 
Hu BY, Du ZW, Zhang SC. Differentiation of human oligodendrocytes from pluripotent stem cells. Nat 
Protoc. 2009;4(11):1614-22.  
 
Hueston CM, Cryan JF, Nolan YM. Stress and adolescent hippocampal neurogenesis: diet and exercise 
as cognitive modulators. Transl Psychiatry. 2017  Apr 4;7(4):e1081.  
 
Jessberger S, Clark RE, Broadbent NJ, Clemenson GD Jr, Consiglio A, Lie DC, Squire LR, Gage FH. 
Dentate gyrus-specific knockdown of adult neurogenesis impairs spatial and object recognition 
memory in adult rats. Learn Mem. 2009 Jan  29;16(2):147-54.  
 
Jhaveri DJ, Tedoldi A, Hunt S, Sullivan R, Watts NR, Power JM, Bartlett PF, Sah P. Evidence for newly 
generated interneurons in the basolateral amygdala of adult mice. Mol Psychiatry. 2018 
Mar;23(3):521-532. doi: 10.1038/mp.2017.134. 
 
Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, Lenvik T, 
Lund T, Blackstad M, Du J, Aldrich S, Lisberg A, Low WC, Largaespada DA, Verfaillie CM. Pluripotency 
of mesenchymal stem cells derived from adult marrow. Nature. 2002 Jul 4;418(6893):41-9.  
 
Kleschevnikov AM, Belichenko PV, Faizi M, Jacobs LF, Htun K, Shamloo M, Mobley WC. Deficits in 
cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB 
receptor antagonists. J Neurosci. 2012 Jul 4;32(27):9217-27.  
 
Kempermann G. Activity Dependency and Aging in the Regulation of Adult Neurogenesis. Cold Spring 
Harb Perspect Biol. 2015a Nov 2;7(11). pii: a018929.  
 
Kempermann G, Gast D, Kronenberg G, Yamaguchi M, Gage FH. Early determination  and long-term 
persistence of adult-generated new neurons in the hippocampus of mice. Development. 2003 
Jan;130(2):391-9.  
 
Kempermann G, Gage FH, Aigner L, Song H, Curtis MA, Thuret S, Kuhn HG, Jessberger S, Frankland 
PW, Cameron HA, Gould E, Hen R, Abrous DN, Toni N, Schinder AF, Zhao X, Lucassen PJ, Frisén J. 
Human Adult Neurogenesis: Evidence and Remaining Questions. Cell Stem Cell. 2018 Jul 5;23(1):25-
30.  
 
Kempermann G, Jessberger S, Steiner B, Kronenberg G. Milestones of neuronal development in the 




Kempermann G, Kuhn HG, Gage FH. More hippocampal neurons in adult mice living in an enriched 
environment. Nature. 1997 Apr 3;386(6624):493-5.  
 
Kempermann G, Song H, Gage FH. Neurogenesis in the Adult Hippocampus. Cold Spring Harb 
Perspect Biol. 2015b Sep 1;7(9):a018812.  
 
Khouzam HR. A review of trazodone use in psychiatric and medical conditions. Postgrad Med. 2017 
Jan;129(1):140-148.  
 
Kim D, Kim CH, Moon JI, Chung YG, Chang MY, Han BS, Ko S, Yang E, Cha KY, Lanza R, Kim KS. 
Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. 
Cell Stem Cell. 2009 Jun 5;4(6):472-6.  
 
Kim SH, Cairns N, Fountoulakisc M, Lubec G. Decreased brain histamine-releasing factor protein in 
patients with Down syndrome and Alzheimer's disease. Neurosci Lett. 2001 Mar 2;300(1):41-4.  
 
Kirkeby A, Grealish S, Wolf DA, Nelander J, Wood J, Lundblad M, Lindvall O, Parmar M. Generation of 
regionally specified neural progenitors and functional neurons from human embryonic stem cells 
under defined conditions. Cell Rep. 2012  Jun 28;1(6):703-14.  
 
Kleschevnikov AM, Belichenko PV, Villar AJ, Epstein CJ, Malenka RC, Mobley WC. Hippocampal long-
term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down 
syndrome. J Neurosci. 2004 Sep 15;24(37):8153-60.  
 
Kokoeva MV, Yin H, Flier JS. Neurogenesis in the hypothalamus of adult mice: potential role in energy 
balance. Science. 2005 Oct 28;310(5748):679-83.  
 
Kondo M, Nakamura Y, Ishida Y, Shimada S. The 5-HT3 receptor is essential for  exercise-induced 
hippocampal neurogenesis and antidepressant effects. Mol Psychiatry. 2015 Nov;20(11):1428-37.  
 
Kotani S, Yamauchi T, Teramoto T, Ogura H. Donepezil, an acetylcholinesterase  inhibitor, enhances 
adult hippocampal neurogenesis. Chem Biol Interact. 2008 Sep  25;175(1-3):227-30.  
 
Kraus C, Castrén E, Kasper S, Lanzenberger R. Serotonin and neuroplasticity -  Links between 
molecular, functional and structural pathophysiology in depression. Neurosci Biobehav Rev. 2017 
Jun;77:317-326.  
 
Krencik R, Weick JP, Liu Y, Zhang ZJ, Zhang SC. Specification of transplantable astroglial subtypes from 
human pluripotent stem cells. Nat Biotechnol. 2011 May 22;29(6):528-34. doi: 10.1038/nbt.1877.  
 
Kulkarni VA, Jha S, Vaidya VA. Depletion of norepinephrine decreases the proliferation, but does not 
influence the survival and differentiation, of granule cell progenitors in the adult rat hippocampus. 
Eur J Neurosci. 2002 Nov;16(10):2008-12.  
 
Kumar P, Kalonia H, Kumar A. Nitric oxide mechanism in the protective effect of antidepressants 
against 3-nitropropionic acid-induced cognitive deficit, glutathione and mitochondrial alterations in 
animal model of Huntington's disease. Behav Pharmacol. 2010 May;21(3):217-30.  
 
Lance R, Albo M, Costabile RA, Steers WD. Oral trazodone as empirical therapy  for erectile 




Latchney SE, Jaramillo TC, Rivera PD, Eisch AJ, Powell CM. Chronic P7C3 treatment restores 
hippocampal neurogenesis in the Ts65Dn mouse model of Down Syndrome [Corrected]. Neurosci 
Lett. 2015 Mar 30;591:86-92.  
 
Lee A, Kessler JD, Read TA, Kaiser C, Corbeil D, Huttner WB, Johnson JE, Wechsler-Reya RJ. Isolation 
of neural stem cells from the postnatal cerebellum. Nat Neurosci. 2005 Jun;8(6):723-9.  
 
Lee MM, Reif A, Schmitt AG. Major depression: a role for hippocampal neurogenesis? Curr Top Behav 
Neurosci. 2013;14:153-79. doi: 10.1007/7854_2012_226.  
 
Lee J, Seroogy KB, Mattson MP. Dietary restriction enhances neurotrophin expression and 
neurogenesis in the hippocampus of adult mice. J Neurochem. 2002 Feb;80(3):539-47.  
 
Li J, Tang Y, Cai D. IKKβ/NF-κB disrupts adult hypothalamic neural stem cells to mediate a 
neurodegenerative mechanism of dietary obesity and pre-diabetes. Nat Cell Biol. 2012 
Oct;14(10):999-1012.  
 
Li W, Wei W, Zhu S, Zhu J, Shi Y, Lin T, Hao E, Hayek A, Deng H, Ding S. Generation of rat and human 
induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors. Cell 
Stem Cell. 2009 Jan 9;4(1):16-9.  
 
Licinio J, Wong ML. Serotonergic neurons derived from induced pluripotent stem cells (iPSCs): a new 
pathway for research on the biology and pharmacology of major depression. Mol Psychiatry. 2016 
Jan;21(1):1-2.  
 
Liu H, Zhu F, Yong J, Zhang P, Hou P, Li H, Jiang W, Cai J, Liu M, Cui K, Qu X, Xiang T, Lu D, Chi X, Gao 
G, Ji W, Ding M, Deng H. Generation of induced pluripotent stem cells from adult rhesus monkey 
fibroblasts. Cell Stem Cell. 2008 Dec 4;3(6):587-90.  
 
Liu B, Filippi S, Roy A, Roberts I. Stem and progenitor cell dysfunction in human trisomies. EMBO Rep. 
2015 Jan;16(1):44-62.  
 
Liu Y, Giannopoulou EG, Wen D, Falciatori I, Elemento O, Allis CD, Rafii S, Seandel M. Epigenetic 
profiles signify cell fate plasticity in unipotent spermatogonial stem and progenitor cells. Nat 
Commun. 2016 Apr 27;7:11275.  
 
Llames S, García-Pérez E, Meana Á, Larcher F, del Río M. Feeder Layer Cell Actions and Applications. 
Tissue Eng Part B Rev. 2015 Aug;21(4):345-53.  
 
Lockrow J, Prakasam A, Huang P, Bimonte-Nelson H, Sambamurti K, Granholm AC. Cholinergic 
degeneration and memory loss delayed by vitamin E in a Down syndrome  mouse model. Exp Neurol. 
2009 Apr;216(2):278-89.  
 
Lockrow J, Boger H, Bimonte-Nelson H, Granholm AC. Effects of long-term memantine on memory 
and neuropathology in Ts65Dn mice, a model for Down syndrome. Behav Brain Res. 2011 Aug 
10;221(2):610-22.  
 
Lockrow JP, Fortress AM, Granholm AC. Age-related neurodegeneration and memory loss in down 




Lois C, Alvarez-Buylla A. Proliferating subventricular zone cells in the adult mammalian forebrain can 
differentiate into neurons and glia. Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):2074-7.  
Lott IT, Dierssen M. Cognitive deficits and associated neurological complications in individuals with 
Down's syndrome. Lancet Neurol. 2010 Jun;9(6):623-33.  
 
Ludwig TE, Bergendahl V, Levenstein ME, Yu J, Probasco MD, Thomson JA. Feeder-independent 
culture of human embryonic stem cells. Nat Methods. 2006 Aug;3(8):637-46.  
 
Luzzati F, De Marchis S, Fasolo A, Peretto P. Neurogenesis in the caudate nucleus of the adult rabbit. 
J Neurosci. 2006 Jan 11;26(2):609-21.  
 
Ma DK, Bonaguidi MA, Ming GL, Song H. Adult neural stem cells in the mammalian central nervous 
system. Cell Res. 2009 Jun;19(6):672-82.  
 
Manganas LN, Zhang X, Li Y, Hazel RD, Smith SD, Wagshul ME, Henn F, Benveniste H, Djuric PM, 
Enikolopov G, Maletic-Savatic M. Magnetic resonance spectroscopy identifies neural progenitor cells 
in the live human brain. Science. 2007 Nov 9;318(5852):980-5.  
 
Martínez-Cué C, Martínez P, Rueda N, Vidal R, García S, Vidal V, Corrales A, Montero JA, Pazos Á, 
Flórez J, Gasser R, Thomas AW, Honer M, Knoflach F, Trejo JL, Wettstein JG, Hernández MC. Reducing 
GABAA α5 receptor-mediated inhibition rescues functional and neuromorphological deficits in a 
mouse model of down syndrome. J Neurosci. 2013 Feb 27;33(9):3953-66.  
 
McDonald HY, Wojtowicz JM. Dynamics of neurogenesis in the dentate gyrus of adult rats. Neurosci 
Lett. 2005 Sep 2;385(1):70-5.  
 
Meneghini V, Cuccurazzu B, Bortolotto V, Ramazzotti V, Ubezio F, Tzschentke TM, Canonico PL, Grilli 
M. The noradrenergic component in tapentadol action counteracts μ-opioid receptor-mediated 
adverse effects on adult neurogenesis. Mol Pharmacol. 2014 May;85(5):658-70.  
 
Merritt JR, Rhodes JS. Mouse genetic differences in voluntary wheel running, adult hippocampal 
neurogenesis and learning on the multi-strain-adapted plus water maze. Behav Brain Res. 2015 
Mar 1;280:62-71.  
 
Mirescu C, Gould E. Stress and adult neurogenesis. Hippocampus. 2006;16(3):233-8. PubMed PMID: 
16411244. 
 
Moon J, Chen M, Gandhy SU, Strawderman M, Levitsky DA, Maclean KN, Strupp BJ.  Perinatal choline 
supplementation improves cognitive functioning and emotion regulation in the Ts65Dn mouse 
model of Down syndrome. Behav Neurosci. 2010 Jun;124(3):346-61.  
 
Morris SA, Eaves DW, Smith AR, Nixon K. Alcohol inhibition of neurogenesis: a  mechanism of 
hippocampal neurodegeneration in an adolescent alcohol abuse model.  Hippocampus. 2010 
May;20(5):596-607.  
 
Muffat J, Li Y, Yuan B, Mitalipova M, Omer A, Corcoran S, Bakiasi G, Tsai LH,  Aubourg P, Ransohoff 
RM, Jaenisch R. Efficient derivation of microglia-like cells from human pluripotent stem cells. Nat 




Netzer WJ, Powell C, Nong Y, Blundell J, Wong L, Duff K, Flajolet M, Greengard P. Lowering beta-
amyloid levels rescues learning and memory in a Down syndrome mouse model. PLoS One. 2010 Jun 
3;5(6):e10943.  
 
Nichols J, Zevnik B, Anastassiadis K, Niwa H, Klewe-Nebenius D, Chambers I, Schöler H, Smith A. 
Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription 
factor Oct4. Cell. 1998 Oct 30;95(3):379-91.  
 
Odorico JS, Kaufman DS, Thomson JA. Multilineage differentiation from human embryonic stem cell 
lines. Stem Cells. 2001;19(3):193-204.  
 
Oleskevich S, Descarries L, Watkins KC, Séguéla P, Daszuta A. Ultrastructural  features of the 
serotonin innervation in adult rat hippocampus: an immunocytochemical description in single and 
serial thin sections. Neuroscience.  1991;42(3):777-91.  
 
Ooi L, Sidhu K, Poljak A, Sutherland G, O'Connor MD, Sachdev P, Münch G. Induced pluripotent stem 
cells as tools for disease modelling and drug discovery  in Alzheimer's disease. J Neural Transm 
(Vienna). 2013 Jan;120(1):103-11.  
 
Oomen CA, Bekinschtein P, Kent BA, Saksida LM, Bussey TJ. Adult hippocampal neurogenesis and its 
role in cognition. Wiley Interdiscip Rev Cogn Sci. 2014 Sep;5(5):573-587.  
 
Ozair MZ, Kintner C, Brivanlou AH. Neural induction and early patterning in vertebrates. Wiley 
Interdiscip Rev Dev Biol. 2013 Jul;2(4):479-98.  
 
Pennington BF, Moon J, Edgin J, Stedron J, Nadel L. The neuropsychology of Down syndrome: 
evidence for hippocampal dysfunction. Child Dev. 2003 Jan-Feb;74(1):75-93.  
 
Perluigi M, Butterfield DA. Oxidative Stress and Down Syndrome: A Route toward Alzheimer-Like 
Dementia. Curr Gerontol Geriatr Res. 2012;2012:724904.  
 
Pinter JD, Eliez S, Schmitt JE, Capone GT, Reiss AL. Neuroanatomy of Down's syndrome: a high-
resolution MRI study. Am J Psychiatry. 2001 Oct;158(10):1659-65.  
 
Qin H, Zhao A, Fu X. Chemical modulation of cell fates: in situ regeneration.  Sci China Life Sci. 2018 
Oct;61(10):1137-1150.  
 
Rasmuson S, Olsson T, Henriksson BG, Kelly PA, Holmes MC, Seckl JR, Mohammed AH. Environmental 
enrichment selectively increases 5-HT1A receptor mRNA expression and binding in the rat 
hippocampus.  
 
Renner U, Zeug A, Woehler A, Niebert M, Dityatev A, Dityateva G, Gorinski N, Guseva D, Abdel-Galil 
D, Fröhlich M, Döring F, Wischmeyer E, Richter DW, Neher E, Ponimaskin EG. Heterodimerization of 
serotonin receptors 5-HT1A and 5-HT7 differentially regulates receptor signalling and trafficking. J 
Cell Sci. 2012 May 15;125(Pt 10):2486-99.  
 
Reubinoff BE, Pera MF, Fong CY, Trounson A, Bongso A. Embryonic stem cell lines from human 




Reynolds BA, Weiss S. Generation of neurons and astrocytes from isolated cells of the adult 
mammalian central nervous system. Science. 1992 Mar 27;255(5052):1707-10.  
 
Roth AJ, McCall WV, Liguori A. Cognitive, psychomotor and polysomnographic effects of trazodone 
in primary insomniacs. J Sleep Res. 2011 Dec;20(4):552-8. 
 
Rueda N, Llorens-Martín M, Flórez J, Valdizán E, Banerjee P, Trejo JL, Martínez-Cué C. Memantine 
normalizes several phenotypic features in the Ts65Dn mouse model of Down syndrome. J Alzheimers 
Dis. 2010;21(1):277-90.  
 
Sabelström H, Stenudd M, Frisén J. Neural stem cells in the adult spinal cord. Exp Neurol. 2014 
Oct;260:44-9.  
 
Sahay A, Hen R. Adult hippocampal neurogenesis in depression. Nat Neurosci. 2007 Sep;10(9):1110-
5.  
 
Sahay A, Scobie KN, Hill AS, O'Carroll CM, Kheirbek MA, Burghardt NS, Fenton AA, Dranovsky A, Hen 
R. Increasing adult hippocampal neurogenesis is sufficient to improve pattern separation. Nature. 
2011 Apr 28;472(7344):466-70.  
 
Salehi A, Faizi M, Colas D, Valletta J, Laguna J, Takimoto-Kimura R, Kleschevnikov A, Wagner SL, Aisen 
P, Shamloo M, Mobley WC. Restoration of norepinephrine-modulated contextual memory in a 
mouse model of Down syndrome. Sci Transl Med. 2009 Nov 18;1(7):7ra17.  
 
Sánchez-Danés A, Consiglio A, Richaud Y, Rodríguez-Pizà I, Dehay B, Edel M, Bové J, Memo M, Vila M, 
Raya A, Izpisua Belmonte JC. Efficient generation of A9 midbrain dopaminergic neurons by lentiviral 
delivery of LMX1A in human embryonic stem cells and induced pluripotent stem cells. Hum Gene 
Ther. 2012 Jan;23(1):56-69.  
 
Schlachetzki JC, Grimm T, Schlachetzki Z, Ben Abdallah NM, Ettle B, Vöhringer  P, Ferger B, Winner B, 
Nuber S, Winkler J. Dopaminergic lesioning impairs adult hippocampal neurogenesis by distinct 
modification of α-synuclein. J Neurosci Res. 2016 Jan;94(1):62-73.  
 
SCOVILLE WB, MILNER B. Loss of recent memory after bilateral hippocampal lesions. J Neurol 
Neurosurg Psychiatry. 1957 Feb;20(1):11-21.  
 
Schmidt HD, Duman RS. The role of neurotrophic factors in adult hippocampal neurogenesis, 
antidepressant treatments and animal models of depressive-like behavior. Behav Pharmacol. 2007 
Sep;18(5-6):391-418.  
 
Seress L, Abrahám H, Tornóczky T, Kosztolányi G. Cell formation in the human hippocampal formation 
from mid-gestation to the late postnatal period. Neuroscience. 2001;105(4):831-43.  
 
Seydoux G, Braun RE. Pathway to totipotency: lessons from germ cells. Cell. 2006 Dec 1;127(5):891-
904. Review.  
 
Shapiro LA, Bialowas-McGoey LA, Whitaker-Azmitia PM. Effects of S100B on Serotonergic Plasticity 
and Neuroinflammation in the Hippocampus in Down Syndrome and Alzheimer's Disease: Studies in 




Shi Y, Kirwan P, Smith J, Robinson HP, Livesey FJ. Human cerebral cortex development from 
pluripotent stem cells to functional excitatory synapses. Nat Neurosci. 2012 Feb 5;15(3):477-86, S1.  
 
Shichiri M, Yoshida Y, Ishida N, Hagihara Y, Iwahashi H, Tamai H, Niki E. α-Tocopherol suppresses lipid 
peroxidation and behavioral and cognitive impairments in the Ts65Dn mouse model of Down 
syndrome. Free Radic Biol Med. 2011 Jun 15;50(12):1801-11.  
 
Shohayeb B, Diab M, Ahmed M, Ng DCH. Factors that influence adult neurogenesis as potential 
therapy. Transl Neurodegener. 2018 Feb 21;7:4.  
 
Shors TJ, Miesegaes G, Beylin A, Zhao M, Rydel T, Gould E. Neurogenesis in the adult is involved in 
the formation of trace memories. Nature. 2001 Mar 15;410(6826):372-6.  
 
Shors TJ, Olson RL, Bates ME, Selby EA, Alderman BL. Mental and Physical (MAP) Training: a 
neurogenesis-inspired intervention that enhances health in humans. Neurobiol Learn Mem. 2014 
Nov;115:3-9.  
 
Sibbe M, Kulik A. GABAergic Regulation of Adult Hippocampal Neurogenesis. Mol  Neurobiol. 2017 
Sep;54(7):5497-5510. doi: 10.1007/s12035-016-0072-3. Epub 2016 Sep 6.  
 
Singh VK, Kalsan M, Kumar N, Saini A, Chandra R. Induced pluripotent stem cells: applications in 
regenerative medicine, disease modeling, and drug discovery. Front Cell Dev Biol. 2015 Feb 2;3:2. 
doi: 10.3389/fcell.2015.00002. eCollection 2015.  
 
Soldner F, Hockemeyer D, Beard C, Gao Q, Bell GW, Cook EG, Hargus G, Blak A, Cooper O, Mitalipova 
M, Isacson O, Jaenisch R. Parkinson's disease patient-derived induced pluripotent stem cells free of 
viral reprogramming factors. Cell. 2009 Mar 6;136(5):964-77.  
 
Spalding KL, Bergmann O, Alkass K, Bernard S, Salehpour M, Huttner HB, Boström E, Westerlund I, 
Vial C, Buchholz BA, Possnert G, Mash DC, Druid H, Frisén J. Dynamics of hippocampal neurogenesis 
in adult humans. Cell. 2013 Jun 6;153(6):1219-1227.  
 
Stagni F, Giacomini A, Emili M, Guidi S, Bartesaghi R. Neurogenesis impairment: An early 
developmental defect in Down syndrome. Free Radic Biol Med.  2018 Jan;114:15-32.  
 
Stagni F, Magistretti J, Guidi S, Ciani E, Mangano C, Calzà L, Bartesaghi R. Pharmacotherapy with 
fluoxetine restores functional connectivity from the dentate gyrus to field CA3 in the Ts65Dn mouse 
model of down syndrome. PLoS One. 2013 Apr 19;8(4):e61689.  
 
Stagni F, Giacomini A, Guidi S, Emili M, Uguagliati B, Salvalai ME, Bortolotto V, Grilli M, Rimondini R, 
Bartesaghi R. A flavonoid agonist of the TrkB receptor for BDNF improves hippocampal neurogenesis 
and hippocampus-dependent memory in the Ts65Dn mouse model of DS. Exp Neurol. 2017 
Dec;298(Pt A):79-96.  
 
Stagni F, Giacomini A, Emili M, Trazzi S, Guidi S, Sassi M, Ciani E, Rimondini R, Bartesaghi R. Short- 
and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal 





Sun GJ, Sailor KA, Mahmood QA, Chavali N, Christian KM, Song H, Ming GL. Seamless reconstruction 
of intact adult-born neurons by serial end-block imaging  reveals complex axonal guidance and 
development in the adult hippocampus. J Neurosci. 2013 Jul 10;33(28):11400-11.  
 
Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult 
fibroblast cultures by defined factors. Cell. 2006 Aug 25;126(4):663-76.  
 
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of 
pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007 Nov 30;131(5):861-
72.  
 
Tang Y, Yu P, Cheng L. Current progress in the derivation and therapeutic application of neural stem 
cells. Cell Death Dis. 2017 Oct 12;8(10):e3108. doi: 10.1038/cddis.2017.504.  
 
Tao Y, Zhang SC. Neural Subtype Specification from Human Pluripotent Stem Cells. Cell Stem Cell. 
2016 Nov 3;19(5):573-586. doi: 10.1016/j.stem.2016.10.015.  
 
ten Donkelaar HJ, Lammens M, Wesseling P, Thijssen HO, Renier WO. Development  and 
developmental disorders of the human cerebellum. J Neurol. 2003 Sep;250(9):1025-36.  
 
Teng YD, Wang L, Zeng X, Wu L, Toktas Z, Kabatas S, Zafonte RD. Updates on Human Neural Stem 
Cells: From Generation, Maintenance, and Differentiation to Applications in Spinal Cord Injury 
Research. Results Probl Cell Differ. 2018;66:233-248.  
 
Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall  VS, Jones JM. Embryonic 
stem cell lines derived from human blastocysts. Science.  1998 Nov 6;282(5391):1145-7.  
 
Toda T, Gage FH. Review: adult neurogenesis contributes to hippocampal plasticity. Cell Tissue Res. 
2018 Sep;373(3):693-709.   
 
Trazzi S, Fuchs C, De Franceschi M, Mitrugno VM, Bartesaghi R, Ciani E. APP-dependent alteration of 
GSK3β activity impairs neurogenesis in the Ts65Dn mouse model of Down syndrome. Neurobiol Dis. 
2014 Jul;67:24-36.  
 
Trazzi S, Mitrugno VM, Valli E, Fuchs C, Rizzi S, Guidi S, Perini G, Bartesaghi R, Ciani E. APP-dependent 
up-regulation of Ptch1 underlies proliferation impairment of neural precursors in Down syndrome. 
Hum Mol Genet. 2011 Apr 15;20(8):1560-73.  
 
Tsao R, Kindelberger C. Variability of cognitive development in children with  Down syndrome: 
relevance of good reasons for using the cluster procedure. Res Dev Disabil. 2009 May-Jun;30(3):426-
32.  
 
Ueda S, Sakakibara S, Yoshimoto K. Effect of long-lasting serotonin depletion on environmental 
enrichment-induced neurogenesis in adult rat hippocampus and spatial learning. Neuroscience. 
2005;135(2):395-402.  
 
Unger C, Gao S, Cohen M, Jaconi M, Bergstrom R, Holm F, Galan A, Sanchez E, rion O, Dubuisson JB, 
Giry-Laterriere M, Salmon P, Simon C, Hovatta O, Feki A. Immortalized human skin fibroblast feeder 
cells support growth and maintenance of both human embryonic and induced pluripotent stem cells. 




Urbàn N, Guillemot F. Neurogenesis in the embryonic and adult brain: same regulators, different 
roles. Front Cell Neurosci. 2015 Apr 23;9:160.  
 
van Praag H, Kempermann G, Gage FH. Running increases cell proliferation and neurogenesis in the 
adult mouse dentate gyrus. Nat Neurosci. 1999 Mar;2(3):266-70.  
 
van Praag H, Schinder AF, Christie BR, Toni N, Palmer TD, Gage FH. Functional  neurogenesis in the 
adult hippocampus. Nature. 2002 Feb 28;415(6875):1030-4.  
 
Vershkov D, Benvenisty N. Human pluripotent stem cells in modeling human disorders: the case of 
fragile X syndrome. Regen Med. 2017 Jan;12(1):53-68. doi:  10.2217/rme-2016-0100.  
 
Vicari S. Motor development and neuropsychological patterns in persons with Down syndrome. 
Behav Genet. 2006 May;36(3):355-64. Epub 2006 Feb 28..  
 
Vicari S, Carlesimo GA. Short-term memory deficits are not uniform in Down and Williams syndromes. 
Neuropsychol Rev. 2006 Jun;16(2):87-94.  
 
Villa-Diaz LG, Nandivada H, Ding J, Nogueira-de-Souza NC, Krebsbach PH, O'Shea KS, Lahann J, Smith 
GD. Synthetic polymer coatings for long-term growth of human  embryonic stem cells. Nat 
Biotechnol. 2010 Jun;28(6):581-3.  
 
Vink J, Incerti M, Toso L, Roberson R, Abebe D, Spong CY. Prenatal NAP+SAL prevents developmental 
delay in a mouse model of Down syndrome through effects on N-methyl-D-aspartic acid and gamma-
aminobutyric acid receptors. Am J Obstet Gynecol. 2009 May;200(5):524.e1-4.  
 
Wabik A, Jones PH. Switching roles: the functional plasticity of adult tissue  stem cells. EMBO J. 2015 
May 5;34(9):1164-79.  
 
Weitzdoerfer R, Dierssen M, Fountoulakis M, Lubec G. Fetal life in Down syndrome starts with normal 
neuronal density but impaired dendritic spines and synaptosomal structure. J Neural Transm Suppl. 
2001;(61):59-70.  
 
Westenbroek C, Den Boer JA, Veenhuis M, Ter Horst GJ. Chronic stress and social housing 
differentially affect neurogenesis in male and female rats. Brain Res Bull. 2004 Dec 15;64(4):303-8.  
 
Whittle N, Sartori SB, Dierssen M, Lubec G, Singewald N. Fetal Down syndrome brains exhibit 
aberrant levels of neurotransmitters critical for normal brain development. Pediatrics. 2007 
Dec;120(6):e1465-71.  
 
Whooten R, Schmitt J, Schwartz A. Endocrine manifestations of Down syndrome. Curr Opin 
Endocrinol Diabetes Obes. 2018 Feb;25(1):61-66. 
 
Willaime-Morawek S, Seaberg RM, Batista C, Labbé E, Attisano L, Gorski JA, Jones KR, Kam A, 
Morshead CM, van der Kooy D. Embryonic cortical neural stem cells migrate ventrally and persist as 
postnatal striatal stem cells. J Cell Biol. 2006 Oct 9;175(1):159-68.  
 
Winner B, Winkler J. Adult neurogenesis in neurodegenerative diseases. Cold pring Harb Perspect 




Wu Z, Chen J, Ren J, Bao L, Liao J, Cui C, Rao L, Li H, Gu Y, Dai H, Zhu H, Teng X, Cheng L, Xiao L. 
Generation of pig induced pluripotent stem cells with a  drug-inducible system. J Mol Cell Biol. 2009 
Oct;1(1):46-54.  
 
Wu Y, Zhang Y, Mishra A, Tardif SD, Hornsby PJ. Generation of induced pluripotent stem cells from 
newborn marmoset skin fibroblasts. Stem Cell Res. 2010 May;4(3):180-8.  
 
Yang N, Chanda S, Marro S, Ng YH, Janas JA, Haag D, Ang CE, Tang Y, Flores Q,  Mall M, Wapinski O, 
Li M, Ahlenius H, Rubenstein JL, Chang HY, Buylla AA, Südhof  TC, Wernig M. Generation of pure 
GABAergic neurons by transcription factor programming. Nat Methods. 2017 Jun;14(6):621-628.  
 
Young JS, Morshed RA, Kim JW, Balyasnikova IV, Ahmed AU, Lesniak MS. Advances  in stem cells, 
induced pluripotent stem cells, and engineered cells: delivery vehicles for anti-glioma therapy. Expert 







OUTLINE OF THE THESIS 
 
Neurogenesis is defined as the process of generating new neurons from 
neural stem cells (NSC). It occurs during embryogenesis to allow formation 
of the neuronal circuitries in the first stages of brain development. In recent 
years, alterations of this developmental process have been suggested to 
contribute to several neuropsychiatric disorders, including schizophrenia, 
and to neurodevelopmental disorders such as Down syndrome where brain 
abnormalities are associated with several impairments including cognitive 
defects. 
Neurogenesis persists in discrete regions of adult mammalian brain. These 
regions, called neurogenic niches, include the subgranular zone of the 
dentate gyrus and in the subventricular zone in the lateral wall of the lateral 
ventricles (Eriksson et al., 1998, Spalding et al., 2013). Also in adulthood, 
neurogenesis relies on the presence of NSC, which have persisted in 
neurogenic niches. In these locations adult NSC are largely quiescent, but 
periodically they undergo proliferation and differentiation upon activation 
by extrinsic or intrinsic signals (Urbàn and Guillemot, 2015).  
In the adult hippocampus, NSC and newborn neurons confer an extra 
degree of neural plasticity, which likely contributes to crucial brain 
functions. Although the physiological role of adult born neurons is not fully 
understood, increasing experimental evidence suggest that they are 
involved in key hippocampal-dependent functions, such as learning, 
memory and mood regulation (Kempermann, 2003; Shohayeb et al., 2018). 
In line with the idea that it is a peculiar form of neuroplasticity, adult 
neurogenesis is profoundly modulated by experiences and environmental 
conditions. Among positive modulators are environmental enrichment, 
physical exercise and learning (Van Praag et al, 1999; Lee et al., 2002). 
Negative modulators of adult hippocampal neurogenesis are aging, stress 
and social isolation (Kempermann, 2015; Czéh et al., 2002; Westenbroek et 




Deregulation of adult neurogenesis has been demonstrated in several 
neurodegenerative disorders, including Alzheimer’s and Parkinson’s 
diseases, epilepsy, stroke, chronic pain, multiple sclerosis and in 
neuropsychiatric diseases such as major depression. 
Major depression is one of the areas where adult hippocampal 
neurogenesis is extensively studied. Several preclinical studies indicate that 
chronic administration of antidepressant drugs results in enhanced 
neurogenesis in the adult rodent and human DG (Santarelli et al., 2003; 
Boldrini et al., 2009; Malberg et al., 2000), opening to the possibility that 
modulation of adult neurogenesis may contribute to the therapeutic effects 
of these drugs also in the clinical setting. More generally speaking, these 
studies once again suggest that adult hippocampal neurogenesis can be 
modulated pharmacologically and this may have therapeutic relevance in 
several undertreated disorders (Bortolotto and Grilli, 2017b; Bortolotto et 
al., 2014). 
In the last decade, the Laboratory of Neuroplasticity has contributed to the 
identification of novel molecular and pharmacological regulators of adult 
hippocampal neurogenesis of potential therapeutic relevance (Denis-
Donini et al., 2008; Meneghini et al., 2013; Valente et al, 2015; Cvjietic et 
al, 2017). Through these activities our group has been able to demonstrate, 
for the first time, that additional drugs that are already utilized in the clinical 
setting are endowed with the ability to promote hippocampal neurogenesis 
in vitro and, more importantly, in vivo in animal models. Among others, we 
have proven this novel pharmacological activity for: i) the anticonvulsants, 
anxiolytics and analgesics 2 ligands, namely pregabalin e gabapentin 
(Valente et al., 2012); ii) the analgesic drug and food supplement acetyl-L-
carnitine (Cuccurazzu et al., 2013; Chiechio et al., 2017); iii) for the MOR-
NRI drug tapentadol (Meneghini et al., Mol Pharmacology, 2014).   
These accomplishments have allowed us to propose to the scientific 
community that the proneurogenic effects of these drugs may have 
therapeutic implications. Indeed our data provide the rationale of novel 
therapeutic indications for some drugs (for example as antidepressants 
and/or cognitive enhancers for acetyl-L-carnitine and 2 ligands). On the 
other hand, they confirm the importance of increasing our current 
knowledge on drugs that are already in clinic to better understand their full 
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profile in terms of additional mechanisms of action and/or of potential side 
effects/tolerability issues (Bortolotto et al, 2014; Bortolotto and Grilli, 2017; 
Grilli; Grilli, 2017; Cuccurazzu et al., 2018).  
 
My PhD activities were all focussed in such scientific context originally 
developed in the Laboratory of Neuroplasticity that is the concept that 
neural stem cells can be regarded as potential pharmacological targets. 
 
One of my projects was aimed at a better understanding of the in vitro 
profile of the antidepressant drug trazodone and its potential effect on both 
murine and human NSC. Among many antidepressants trazodone (TZD) has 
a unique profile of interactions: it inhibits the 5-HT transporter and 
antagonizes 5-HT2a and 5-HT2c receptors. The synergistic action on 
serotonin transporter and receptors is proposed to correlate with its good 
antidepressant potency and tolerability. Surprisingly, very little it is known 
about the full pharmacological profile of TZD in vitro and no previous study 
has ever assessed its effects on NSC and its progeny.  We were able to 
provide novel and interesting information about trazodone and its mode of 
action. Moreover, we also discovered novel and distinct functions of 
serotonin receptor subtypes in the modulation of neurogenesis, at least in 
vitro. The relevance of these studies will allow to reveal the mechanisms 
underlying neurogenesis and its regulation by the serotonergic system. In 
this way, it is possible to target specific pathways to obtain a therapeutic 
effect in disease where neurogenesis is compromised. 
 
Furthermore, I gave some contribution in another laboratory project, which 
is focussed on Down syndrome. DS-associated brain abnormalities 
(atrophy, reduced neurogenesis and increased gliogenesis, aberrant 
synaptogenesis and spinogenesis, neurochemical alterations) have long 
been considered to be irreversible. However, recent experimental evidence 
suggested that early treatments of trisomic mice, in prenatal/perinatal 
stage, could restore the neurogenic defects and promote the correct 
consolidation of neural circuitry, together with an improvement of 
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cognitive functions (Bartesaghi et al., 2015; Stagni et al., 2015). The 
demonstration that neurodevelopment can be improved in DS mice 
provided proof of principle that intellectual disabilities in DS can be 
pharmacologically ameliorated. Most of the drugs which successed in 
animal models of DS are targeted on neural stem cells (Stagni et al., 2018). 
I was also involved in a project, which was aimed at identifying, among 
clinically approved drugs, novel molecules that may correct defective 
proliferation and neuronal differentiation of trisomic NSC derived from a 
murine model of Down syndrome, the Ts65Dn mice. These studies are 
relevant to develop in the future a potential therapy to treat mental 
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Several antidepressants increase adult hippocampal Neurogenesis (ahNG) 
in rodents, primates and, potentially, in humans. This effect may at least 
partially account for their therapeutic activity. The availability of 
antidepressants whose mechanism of action involves different 
neurotransmitter receptors represents an opportunity for increasing our 
knowledge on their distinctive peculiarities and for dissecting the 
contribution of receptor subtypes in ahNG modulation. The aim of this 
study was to evaluate, in vitro, the effects of the antidepressant trazodone 
(TZD) on ahNG by using primary cultures of adult hippocampal Neural 
Stem/Progenitor Cells (ahNSC) and human IPSC-derived NSC. We 
demonstrated that TZD enhances neuronal differentiation of murine as well 
as human NSC. TZD is a multimodal antidepressant, which binds with high 
affinity 5-HT2a, α1, 5-HT1a and with lower affinity 5-HT2c and 5-HTT. We 
demonstrated that TZD proneurogenic effects were mediated by 5-HT2a 
antagonism both in murine and human NSC, and by 5-HT2c antagonism in 
murine cells. Moreover NF-B p50 nuclear translocation appeared to be 
required for TZD-mediated proneurogenic effects. Interestingly, TZD had no 
proneurogenic effects in 5-HT depleted ahNSC. The TDZ bell-shaped dose 
response curve suggested additional effects. However, in our model 5-HT1a 
and α1/α2 receptors had no role on neurogenesis. Overall, our data also 
demonstrated that serotoninergic neurotransmission may exert both 
positive and negative effects on neuronal differentiation of ahNSC in vitro.  
 
 
Keywords: antidepressant, neural stem/progenitor cells, trazodone, 





Lifelong generation of new neurons takes place in the subgranular zone 
(SGZ) of the dentate gyrus (DG) from a pool of adult hippocampal Neural 
Stem/Progenitor Cells (ahNSC) (Bond et al., 2015). Newly generated 
neurons can integrate into preexisting neuronal networks and potentially 
contribute to specific functions such as hippocampal-dependent learning 
and memory, mood regulation, and stress response (Aimone et l., 2014). 
Extensive research efforts have contributed to the idea that adult 
hippocampal neurogenesis (ahNG) represents an important form of neural 
plasticity which is deregulated in several neuropsychiatric disorders, 
including major depressive disorder (MDD), and whose reduction is 
correlated with cognitive impairment and mood alterations (Kempermann 
and Kronenberng, 2003; Mirescu and Gould, 2006; Kempermann et al., 
2008; Denis-Donini et al., 2008). 
AhNG is susceptible to pharmacological modulation (Duman et al., 2001; 
Dranovsky and Hen, 2006; Zhao et al., 2008; Bortolotto et al., 2014; Xu et 
al., 2016). Several antidepressant drugs including tryciclic antidepressants 
(TCA), selective serotonin reuptake inhibitors (SSRI) and serotonin-
norepinephrine reuptake inhibitors (SNRI), counteract stress-reduced ahNG 
in preclinical models of depressive-like behaviour (Pittenger and Duman, 
2007; Eich and Petrik, 2012). Increased number of hippocampal neural 
progenitors was also reported in postmortem studies in MDD patients 
treated with antidepressants (Boldrini et al, 2009; Boldrini et al., 2012; 
Boldrine et al., 2014). Although still debated, ahNG may be required for 
some of the behavioral effects of antidepressants, at least in rodent models 
(Santarelli et al., 2003; David et al., 2009). 
Trazodone (TDZ) is a triazolopyridine derivative that in clinical studies has 
demonstrated an antidepressant activity comparable to TCA, SSRI and SNRI 
(Fagiolini et al., 2012). TZD is structurally unrelated to other antidepressant 
classes and is characterized by a unique profile (Mittur, 2011). In the past 
the drug has been classified as a serotonin receptor antagonist and 
reuptake inhibitor (SARI) able to provide simultaneous inhibition of the 
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serotonin transporter (SERT), partial agonism of serotonin 5-HT1a receptors, 
and antagonism of 5-HT2a and 5-HT2c receptors. With such a profile, the 
drug potentially avoids tolerability issues that are often associated with 5-
HT2a and 5-HT2c receptor stimulation (e.g. insomnia, anxiety and sexual 
dysfunction) (Stahl, 2009). In addition to those properties, TDZ also exerts 
antagonistic activity against α1- and α2-adrenergic receptors (AR), with 
minimal anticholinergic effects (Stahl, 2009). In such respect, by taking 
advantage of a recently introduced concept, TZD can be recognized as the 
first ever multimodal antidepressant (Stahl et al., 2013).  
In line with the accepted hypothesis that antidepressants may exert their 
therapeutic activity at least in part via positive effects on neurogenesis, 
modulation of ahNG have become part of the discovery activities of recently 
approved antidepressant drugs (Soumier et al., 2009; Guilloux et al., 2013). 
In addition, promotion of adult hippocampal neurogenesis is currently 
explored as a strategy for antidepressant drug screening (Pascual-Brazo et 
al., 2014; Cuccurazzu et al., 2013; Valente et al., 2012). Despite intense 
research efforts in this field, our current knowledge on the relative 
contribution of different receptors in the modulation of ahNG and in 
mediating the effects of antidepressant drugs is limited. Extensive literature 
data suggest a potential and complex contribution of receptors engaged by 
TZD, such as 5-HT1a, 5-HT2a/c, 1, 2, in the modulation of adult 
neurogenesis (Jha et al., 2008; Mori et al., 2014; Meneghini et al., 2014). 
How the unique pharmacological profile of TZD may affect adult 
neurogenesis is therefore of interest and could potentially increase our 




MATERIALS AND METHODS 
 
Animals. Male C57BL/6 (C57BL/6, The Jackson Laboratories, US) mice were 
housed under light- and temperature-controlled conditions in high 
efficiency particulate air (HEPA)-filtered Thoren units (Thoren Caging 
System, Hazelton, PA). Mice were kept in number of 3-4/cage with ad 
libitum access to food and water at the animal facility of Piemonte Orientale 
University. Animal care and handling were carried out according to 
protocols approved by the European Community Directive and the local 
Institutional Animal Care and Use Committees (IACUC). 
 
Drugs. All drugs concentrations were chosen based on binding affinity to 
their target receptors. The source of compounds was as follows: 5-
Hydroxytryptamine hydrochloride (5-HT) trazodone hydrochloride (TZD), 
ketanserin (+) tartrate salt, DL-P-chlorophenylalanine (PCPA), 
phenylephrine hydrochloride (Phe), and fluoxetine hydrochloride were 
purchased from Sigma-Aldrich (Milan, Italy); 4F4PP oxalate, RS102221 
hydrochloride, R-(+)-8-Hydroxy-DPAT hydrobromide (8-OH-DPAT), 
WAY161503 hydrochloride, TCB-2, NAD299 hydrochloride, idazoxan 
hydrochloride were purchased from Tocris (Bioscience, Bristol, UK).  
 
Adult murine hippocampal NSC isolation and culture. Adult murine 
hippocampal NSC isolation was performed as previously described 
(Meneghini et al., 2014). Briefly, for each culture preparation three adult 
male mice (3-4 month-old) were euthanized by cervical dislocation, and 
their hippocampi dissected. Tissue was digested by a Papain Dissociation 
System (Worthington DBA, Lakewood, NJ). Cells were plated in NUNC 
EasyFlask 25 cm2 (Thermo Scientific, Waltham, MA) and cultured in serum-
free complete proliferation medium [Neurobasal-A with B27 supplement, 2 
mM glutamine (Gibco, Life Technologies, Monza, IT), 20 ng/ml recombinant 
human Epidermal Growth Factor (rhEGF), 10 ng/ml of recombinant human 
Fibroblast Growth Factor-2 (rhFGF-2, PeproTech, Rocky Hill, NJ) and 4 μg/ml 
heparin sodium salt (Sigma-Aldrich)]. Passage 1 (P1) neurospheres were 
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dissociated for the first time after ten days in vitro (DIV). From P2, 
dissociation was performed every five days and ahNSC were replated at a 
density of 12,000 cells/cm2. NSC were used for proliferation and 
differentiation experiments from P5 to P30. Proliferating ahNSC were 
routinely tested for their undifferentiated state by expression of SOX2 (Sry-
related HMG box transcription factor) and nestin (Type VI intermediate 
filament). For irreversible inhibition of tryptophane hydroxylase (TPH), cells 
were treated with 50 μM of PCPA or vehicle for 72 hours starting from the 
second day after dissociation. At day 5, cells were dissociated and plated 
for differentation.  
 
Human iPSC-derived Neural Stem Cell culture. Human NSC derived from 
human induced pluripotent stem cells (IPSC) generated by genome 
footprint-free episomal reprogramming method were purchased from 101 
Bio (Palo Alto, CA). Cells were cultured in DMEM/F12 complete medium 
supplemented with B27 and N2 (Gibco), GlutaMax (Gibco), 20 ng/ml rhEGF, 
20 ng/ml rhFGF2, 2 μg/ml heparin and 100 U/100 μg/ml of 
Penicillin/Streptomycin. Every four days (80% confluence) hNSC were 
dissociated with StemPro Accutase (Thermo Fisher, Life Technologies) at 
37°C, 5% CO2 for 4 min. Single cells were harvested by centrifugation at 
1,000 g, counted and seeded onto GeltrexTM LDEV-Free hESC-qualified 
(Invitrogen, Life Technologies) coated dishes (3.5 cm, BD FalconTM) at a 
density of 52,000 cells/cm2. Human NSC cultures were maintained at 37°C, 
95% humidity, 5% CO2 and received daily medium changes. From P5 to P14 
cells were used for differentiation. 
 
Mouse ahNSC proliferation and differentiation. For evaluation of cell 
proliferation, dissociated NSC were seeded onto flat bottom 96-well plates 
(Falcon) at the density of 4,000 cells/well. Standard medium for basal 
conditions contained Neurobasal-A, B27, 2 mM glutamine, 10 ng/ml hbFGF, 
4 μg/ml heparin and 100 U/100 μg/ml of Penicillin/Streptomycin. Cells were 
treated with indicated drug concentration or corresponding vehicle and 
incubated in a humidified atmosphere at 37°C with 5% CO2. Complete 
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proliferation medium with EGF (20 ng/ml) was included as positive control. 
After 72 hours, proliferation rates were determined using CellTiter-Glo 
luminescent cell viability assay (Promega), according to manufacturer’s 
instructions. Values were normalized to standard medium values. For NSC 
differentiation, detailed procedure was previously described (Jha et al., 
2006). Briefly, single NSC cells were plated onto laminin-coated Lab-Tek 8-
well permanox chamber slides (Nunc) in differentiation medium containing 
Neurobasal-A, B27 and 2 mM glutamine, at a density of 43,750 cells/cm2. 
NSC were treated with indicated drug concentrations or corresponding 
vehicle for 24h. To investigate the involvement of different receptors in 
trazodone or serotonin effects, cells were treated for 30 min with selective 
agonists/antagonists, before addition of the drug. For inhibition of NF-B 
p50 nuclear translocation, NSC were treated with 10 g/ml SN-50 peptide 
(Calbiochem) for 30 min before addition of 5-HT or TZD. 
 
Human NSC differentiation and drug treatment. NSC were cultured onto 
Geltrex coated Lab-Tek 8-well permanox chamber slides (Nunc) at a density 
of 25,000 cells/cm2 in 200 μl of complete medium. Cells were allowed to 
attach for six hours, then medium was replaced by differentiation medium 
[DMEM/F12, B27 and N2 supplements, Glutamax, non-essential amino 
acids (NEAA, Sigma-Aldrich), 200 nM Ascorbic Acid (Stemcells technologies, 
FR) and 1,349 g/L of glucose (Sigma-Aldrich)] containing vehicle or drug 
treatment. Every four days medium was half changed with fresh 
differentiation medium.  
 
Immunolocalization studies in differentiated murine ahNSC and human NSC. 
After differentiation, cells were fixed with 4% paraformaldehyde/4% 
saccharose solution (Sigma) and processed for immunocytochemistry as 
detailed elsewhere (Meneghini et al., 2014). Primary antibodies were as 
follows: anti-microtubule-associated protein-2 (MAP-2; rabbit polyclonal, 
1:600; Millipore, Milan, IT), anti-nestin (Chicken monoclonal, 1:1500; 
Neuromics, DBA, IT), anti-Glial Fibrillary Acidic Protein (GFAP, mouse 
polyclonal, 1:600, Millipore), anti-chondroitin sulfate proteoglycan (NG2, 
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rabbit polyclonal, 1:500, Millipore), anti-S100 (rabbit polyclonal, 1:1000, 
Dako, DBA, IT). Secondary antibodies were as follows: Alexa Fluor 555–
conjugated goat anti-rabbit (1:1400), Alexa Fluor 488-conjugated goat anti-
chicken (1:1400), Alexa Fluor 555-conjugated goat anti-mouse (1:1,600), 
Alexa Fluor 488-conjugated goat anti-rabbit (1:1400) (all from Molecular 
Probes, Life Technologies). Nuclei were counterstained with 0.8 ng/ml 
Hoechst, diluted in PBS. In each experiment, five fields/well (corresponding 
to about 150-200 cells/well) were counted with a 60X objective by a Leica 
DMIRB inverted fluorescence microscope. Positive cells for each marker 
were counted and their percentage was calculated over total viable cells.  
 
Cytotoxicity Assay. To assess the potential cytotoxic effect of trazodone on 
ahNSC and their progeny, cells were plated for differentiation on laminin-
coated flat bottom 96-well plates (Falcon) at the density of 43,750 
cells/cm2. Cells were treated with indicated trazodone concentration or 
vehicle for 24 hours. Cytoxicity was evaluated using CellToxTM Green 
Cytotoxicity Assay (Promega) according to manufacturer’s instructions. 
Positive control for membrane damage was 0.8% Triton X-100 (Sigma) and 
four replicates for each condition were measured. Fluorescent signal was 
read by VICTOR Multilabel Plate Reader platform. The cytotoxicity results 
are expressed as Relative Fluorescent Unit (RFU). Apoptotic rate was 
determined as previously described (Meneghini et al., 2010). 
 
mRNA extraction and Polimerase Chain Reaction (unpublished data). mRNA 
was extracted from cell pellets with TRIzol™ Reagent protocol (Invitrogen). 
mRNA was converted in cDNA trough reverse transcriptase reactions by 
using ImProm-II(TM) Reverse Transcription System (Promega). cDNA was 
amplified trough Polymerase Chain Reaction (PCR) by using GoTaq(R) G2 
Flexi DNA Polymerase (Promega). The primers were chose to obtain 
transcripts for receptors 5-HT1a, 5-HT2a, 5-HT2c, 1 adrenergic and 2 
adrenergic, and the serotonin transporters (SERT), as shown in table 1. 
Finally, PCR products were then resolved by electrophoresis in a 1.2% 




Primers for murine genes 
Receptors 1a (for) 5'-GGACAAGTCAGACTCAGAGCAAGTGACG-3' 
Receptors 1a (rev) 5'-TATAGCCCAGGGCATGCTTGGAAGAC-3' 
Receptors 1b (for) 5'-TTTCATGAGGACACCCTCAGCAGTACC-3' 
Receptors 1b (rev) 5'-CTGCCGCTGTCATCCAGAGAGTCC-3' 
Receptors 2a (for) 5’-CAAGATCAACGACCAGAAGT-3’  
Receptors 2a (rev) 5’-GTGCGACGCTTGGCGATCT-3’ 
Receptors 2b (for) 5’-GCAGAGGTCTCGGAGCTAA-3’ 
Receptors 2b (rev) 5’-GCCTCTCCGACAGAAGATA-3’ 
Receptors 5-HT1a (for) 5′-ATCTCGCTCACTTGGCTCAT-3' 
Receptors 5-HT1a (rev) 5′- CCACTACCTGGCTGACCATT -3′ 
Receptors 5-HT2a (for) 5′- ATAGCCGCTTCAACTCCAGA -3′ 
Receptors 5-HT2a (rev) 5′- ACGGCCATGATATTGGTGAT-3′ 
Receptors 5-HT2c (for) 5′- TGATTGGACTGAGGGACGAAAGCA -3′ 
Receptors 5-HT2c (rev) 5′- TTCCCACAAAGCACCGACAGGATA -3′ 
SERT (for) 5'-TCGCCCAGGACAACATCACCTGGAC-3' 
SERT (rev) 5'-TATGTGATGAAAAGGAGGCTGG-3' 
Primers for human genes 
Receptors 5-HT1a (for) 5‘- GGCGGCAACACTACTGGTAT-3‘ 
Receptors 5-HT1a (rev) 5‘- AGCCAAGTGAGCGAGATGAG-3‘ 
Receptors 5-HT2a (for) 5'-ACTCGCCGATGATAACTTTGTCCT-3' 
Receptors 5-HT2a (rev) 5‘- TGACGGCCATGATGTTTGTGAT-3 
SERT (for) 5'-TCGCCCAGGACAACATCACCTGGAC-3' 
SERT (rev) 5'-TATGTGATGAAAAGGAGGCTGG-3' 
Table1. List of primers annealing the endogenous promoters of serotonin transporter gene 
and serotoninergic/adrenergic receptor genes. 
 
LC-ESI-MS analysis. LC-ESI-MS analyses were carried out using a Thermo 
Finnigan LCQ Deca XP Plus system equipped with a quaternary pump, a 
Surveyor AS autosampler and a vacuum degasser (Thermo Finnigan, San 
Josè, CA). The liquid chromatography was performed on a Phenomenex 
Luna HILIC column (150 x 2 mm, 3 µm) with a Phenomenex Luna HILIC 
security guard column (4 mm x 2 mm), at 25 °C, at 200 μl/min flow rate, 
under isocratic elution. The mobile phase was composed by a 90:10 ratio of 
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acetonitrile and water (both with 0.2% v/v of formic acid). The injection 
volume was 5 μl and the run time was 20 min. The MS detection of 
serotonin was performed in positive ionization mode. Quantitation was 
carried out using single reaction monitoring (SRM) mode to monitor the 
transition m/z 177 > 160 (C.I.D. 22 eV). The principle instrument parameters 
were set as follows: ion spray voltage, 5.2 kV; source current, 80 μA; 
capillary temperature, 350°C. 
 
Sample preparation for LC-ESI-MS analysis. Vehicle- or PCPA-treated ahNSC 
were differentiated in presence of vehicle, trazodone or fluoxetine. 
Differentiation media were collected after 24 hours and centrifuged for 10 
min at 16,000 g. 140 µl of acetonitrile with 0.2% of formic acid were added 
to 60 µl of collected media. Proteins were precipitated by centrifugation for 
10 min at 11,300 g. An aliquot of 180 µl of supernatant was evaporated to 
dryness in a rotational vacuum concentrator (for about 4h at 40 °C). The 
sample was reconstituted in 80 µl of water/acetonitrile with 0.2% of formic 
acid (3:7 vol/vol), before the injection. For quantification of serotonin in 
differentiation medium, a calibration curve was prepared in blank matrix 
(differentiation medium treated with acetonitrile with 0.2% of formic acid, 
3:7 vol/vol) in the appropriate range. 
 
Statistical analysis. All experiments were run in triplicates using different cell 
preparations and repeated at least three times. Data were expressed as 
mean ± S.D. and analyzed by one-way analysis of variance (ANOVA), 
followed by Tuckey’s post-hoc test or by Student’s t test. Statistical 
significance level was set for p values < 0.05
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RESULTS AND DISCUSSION 
 
Serotonin promotes neuronal differentiation of murine ahNSC. 
For our studies, we used a well characterized in vitro model of murine 
ahNSC. In this experimental setting when ahNSC from the adult mouse 
hippocampus are grown in presence of growth factors they are 
phenotypically characterized by expression of nestin and SRY-related HMG-
box gene 2 (SOX2), bonafide markers of undifferentiated neural 
progenitors, and by absence of markers of mature and immature neurons 
such as MAP-2, Tuj-1, and Doublecortin (Valente et al., 2012). Upon 
removal of growth factors and exposure to a serum-free defined medium, 
ahNSC stop dividing and differentiate onto laminin-coated chamber slides. 
By double immunolabeling for markers of neurons (MAP-2) and 
undifferentiated ahNSC (nestin), the appearance of new neurons that are 
MAP-2+ and nestin− and newly generated neuroblasts (cells positive for 
both MAP-2 and nestin) can be evaluated and quantified as previously 
described (Cuccurazzu et al., 2013). Under these experimental conditions, 
within 24 h, ahNSC give rise to about 2% and 30% of neurons and 
neuroblasts, respectively (Figure 1a,b). We initially exposed ahNSC to 
increasing concentrations of the endogenous neurotransmitter 5-HT 
(0.0001-100 µM). As depicted in Figure 1, 5-HT is able to significantly 
increase the percentage of newly generated neurons and neuroblasts 
compared to vehicle-treated cells (p < 0.001, ANOVA, Figure 1a,b). 
Altogether these data confirm that in our in vitro model ahNSC 
differentiation is positively modulated by 5-HT levels, in line with previous 




Fig. 1. 5-HT promotes neuronal differentiation of murine ahNSC in vitro. Adult hippocampal 
NSC were treated with 5-HT (0.0001-100 µM) or vehicle, for 24h. Effects on the percentage 
of MAP-2+/nestin- (a) and MAP-2+/nestin+ (b) cells generated from ahNSC were evaluated. 
Data are expressed as mean ± S.D. ** p < 0.01, *** p < 0.001 vs vehicle-treated cells (One-


































Murine ahNSC and human IPSC-derived NSC express serotoninergic and 
adrenergic receptors (unpublished data). 
In order to characterize further murine and human NSC, we analysed the 
mRNA expression of different serotoninergic and adrenergic receptors. The 
transcript-based analysis of the two cell types demonstrated that murine 
ahNSC were characterized by distinct receptors expression such as 5-HT1a, 
5-HT2a and 5-HT2c, and serotonin transporter (SERT). In parallel, we found 
that murine cells express even transcripts of 1 and 2 adrenergic 
receptors (as shown in figure 2a). On the other hand, human IPSC-derived 
NSC express 5-HT1a, 5-HT2a receptors and SERT. By this approach, we were 
able to define a unique expression signature of our model of murine and 
human NPC and it will be important to analyse the involvement of single 
receptors in the pro-neurogenic effect mediated by TZD (figura 2b). 
 
Figure 2. PCR analysis of 5-HT and adrenergic receptor subtypes in murine ahNSC and human 
IPSC-derived NSC. (a) Murine ahNSC express transcripts of receptors 5-HT1a, 5-HT2a, 5-
HT2c, 1, 2 and SERT. (b) Human IPSC-derived NSC express transcripts of receptors 5-
HT1a, 5-HT2a and SERT. As positive controls, murine hippocampal tissue (HP), HEK293 or 
SH-SY5Y were used. 
 
Murine ahNSC Human IPSC-derived NSC 
a b 
hNSC      HEK293 ahNSC       HP 
ahNSC       HP ahNSC       HP 
ahNSC        HP 
hNSC        SH-SY5Y 
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TZD promotes neuronal but not glial differentiation of ahNSC in vitro. 
Subsequently, ahNSC were differentiated in presence of a wide range of 
TZD concentrations (0.0003-1 M) for 24 h. Such concentration range was 
chosen with the purpose of studying the potential involvement of all 
receptor subtypes bound, with high and low affinity, by TZD (Stahl, 2009). 
Compared to vehicle-treated cells, a significant increase in the percentage 
of MAP-2+ (and nestin-) cells was observed in presence of 0.01-0.3M TZD 
(0.1 M TZD: p < 0.001 vs vehicle, ANOVA, Figure 3a), suggesting that the 
drug is able to promote neuronal differentiation of murine ahNSC in a 
concentration-dependent manner. Interestingly, at the highest 
concentration (1 M) TZD was ineffective, suggesting that at that 
concentration the drug may activate mechanisms and/or receptors that 
potentially counteract those promoting neurogenesis at lower 
concentrations. Similar effects were obtained by the drug on the population 
of MAP-2+/nestin+ neuroblasts (data not shown). We also tested the effects 
of maximally effective concentrations of TZD (100 nM) and 5-HT (1M), in 
comparison with vehicle, as a function of time exposure (2-12-24-48 h). In 
presence of vehicle, the number of neurons (and neuroblasts, data not 
shown) progressively increased with time. When we analyzed the number 
of newly generated MAP-2+/nestin- neurons, in comparison with vehicle, 5-
HT promoted a significant increase at 12 and 24 h but not at 48 h (12 h: p < 
0.05, 24h: p < 0.001, ANOVA, Figure 3b). Compared with 5-HT, TZD 
proneurogenic effects appeared slightly delayed but longer lasting and 
more pronounced, with a significantly higher number of neurons generated 
at 24 and 48 h (% of MAP-2+/nestin- cells: 24h, 5-HT 6.1 ± 0.7, TZD 8.9 ± 0.4, 
p < 0.01 vs 5-HT-treated cells; 48h, 5-HT 9.1 ± 0.7, TZD 14.3 ± 1.3, p < 0.001 
vs 5-HT treated cells, ANOVA, Figure 3b).  
In absence of growth factors, ahNSC can also differentiate toward non-
neuronal lineages. Interestingly, 24 h exposure of ahNSC to TZD (0.0003-1 
M) affected neither the percentage of newly generated GFAP+ astrocytes 
(Figure 3c) nor the percentage of NG2+ oligodendrocyte precursors (Figure 
3d). In order to investigate whether TZD may affect survival of ahNSC and 
their progeny, we also analyzed apoptotic and necrotic rate in our cell 
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culture. As shown in Figure 3e, the percentage of apoptotic cells was not 
significantly different in TZD- versus vehicle-treated conditions. Similarly, no 
difference was observed in the number of necrotic cells, as established by 
disrupted membrane integrity in vehicle- vs TZD-treated ahNSC cultures 
(Figure 3f). Some antidepressants are also positive modulators of NSC 
proliferation (Boldrini et al., 2012). We tested the effect of TZD on the 
proliferation rate of ahNSC, using Epidermal Growth Factor (EGF) as a 
positive control. At all tested concentrations, 72 h-exposure to TZD had no 
effect on ahNSC proliferation rate (Figure3g). Overall, these data suggested 
that: i) TZD effects on ahNSC neuronal differentiation do not occur at the 
expense of NSC differentiation toward glial lineages; ii) the effect of TZD is 
merely differentiative in nature, since neither neuroprotective nor 





































Fig. 3.  Effects of TZD on murine ahNSC differentiation survival and proliferation. Adult 
hippocampal NSC were treated with TZD, at the indicated concentrations, or vehicle, for 24h. 
(a) TZD effects on the percentage of MAP-2+/nestin- cells generated from ahNSC. (b) Time 
course analysis of the proneurogenic effects of TZD and 5-HT. The percentage of MAP-2+ 
cells generated in presence of TZD (100 nM) and 5-HT (1 µM) was assessed after 2-12-24-
48 h of treatment. Data are expressed as mean ± S.D. * p < 0.05, *** p < 0.001 vs vehicle-
treated cells; ## p < 0.01, ### p < 0.001 vs 5-HT-treated cells (One-way ANOVA, Tukey’s 
post-hoc). (c,d) Evaluation of TZD effect on the percentage of newly generated GFAP+ 
astrocytes (c) and NG2+ oligodendrocyte precursors (d). (e) Assessment of TZD effect on 
the apoptotic rate of ahNSC and their progeny. Data are expressed as the percentage of 
apototic cells over the total number of cells. (f) Evaluation of TZD cytotoxic effect. 0.8 % 
Triton X-100 was used as positive control (TX100). (g) Evaluation of TZD effect on ahNSC 
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proliferation. 20 ng/ml EGF was used as positive control. Data are expressed as mean ± 
S.D. *** p < 0.001 vs vehicle-treated cells (One-way ANOVA, Tukey’s post-hoc). 
 
 
The proneurogenic effects of TZD are mediated by 5-HT2a antagonism. 
We investigated the receptor subtypes involved in the proneurogenic effect 
of TZD. TZD binds with high affinity to 5-HT2a, α1, 5-HT1a and with lower 
affinity to 5-HT2c, 2 and 5-HTT (Mittur, 2011; Stahl, 2009). We first 
evaluated the involvement of 5-HT2a receptors in TZD-mediated effect. 
When tested in ahNSC cultures, 10 nM TCB-2, a selective 5-HT2a agonist [Ki 
(5-HT2a): 0.73 nM], produced a rightward shift in TZD concentration-response 
curve, while the compound was inactive per se (Figure 4a). These data 
suggested that the proneurogenic effects elicited by TZD are mediated by 
its antagonistic activity at 5-HT2a receptors. To further support the 
contribution of 5-HT2a receptors in TZD proneurogenic effects, 1-30 nM 
4F4PP, a 5-HT2a selective antagonist, [Ki (5-HT2a): 4 nM] and 0.3-100 nM 
ketanserin [a 5-HT2a/c antagonist, Ki (5-HT2a): 3.6 nM, Ki (5-HT2c): 200 nM], were 
both capable of promoting neuronal differentiation of ahNSC, in a 
concentration-dependent manner (ANOVA; Figure 4b,c). Interestingly, as 
shown for TZD, also for these drugs we observed an inverted U-shaped 
response curve.  
At first sight the finding that antagonism at 5-HT2a receptors may promote 
neurogenesis may be surprising, given the vast plethora of data supporting 
the view of 5-HT as an endogenous positive modulator of adult 
hippocampal neurogenesis (Brezun and Daszuta, 1999; Banasr et al., 2003, 
Brezun et al., 2000), in line with its proneurogenic effect in our 
experimental model. However, literature data on a role of 5-HT specific 
receptor subtypes in the regulation of neurogenesis also support the idea 
of distinct and even opposite effects on neurogenesis (Klempin et al., 2010). 
In particular, in vivo data suggested oppositional effects of serotonin 
receptors 5-HT1a and 5-HT2 in the regulation of adult hippocampal 
neurogenesis (Klempin et al., 2010). Unfortunately, in several reports these 
data appear contradictory, in part probably due to limited selectivity of 
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utilized agonists and antagonists. Klempin et al. (Klempin et al., 2010), by 
using cinanserin as a non-selective 5-HT2 antagonist in vivo, demonstrated 
that it acutely produces an increase in cell proliferation in hippocampus. 
When the same authors tested the non-selective 5-HT2 agonist -methyl-
5-HT, a net decrease in the number of BrdU+ cells was found. Phenotypic 
analysis for 5-HT2 agonist treatment revealed a net decrease in type 
1/2a/2b cells after acute treatment and a significantly reduced number of 
newborn neurons after 7 days of treatment. Surprisingly, the same authors 
showed that in vitro blockade of 5-HT2 receptors by cinanserin in NSC 
cultures produced a significant reduction in the number of III-tubulin 
positive cells, which represent newly generated neuroblasts (Klempin et al., 
2010). Even more confusing, a similar result was obtained upon incubation 
with the non selective agonist -methyl-5-HT. Kemplin’s data are in 
contrast with those obtained by Banasr et al. (2004) who showed that the 
non selective 5-HT2a/c antagonist ketanserin produced a decrease in the 
number of BrdU-labeled cells whereas the 5-HT2a/c agonist DOI did not 
change cell proliferation. Similarly, Jha et al. (2008) demonstrated an 
enhanced adult hippocampal progenitor proliferation as a result of a 
sustained blockade of the 5-HT2a/c receptors by ketanserin treatment in 
mice. In our experimental setting we could confirm that TZD, but also a 
selective 5-HT2a antagonist, promote neuronal differentiation of ahNSC and 
that TZD proneurogenic effects are counteracted in presence of a selective 
5-HT2a agonist. Based on these findings, herein we suggest that 5-HT2a 
antagonism may have a significant role in neuronal differentiation of ahNSC, 
at least in vitro, and that TZD may act, at least in part, via this mechanism 
to promote neurogenesis. Recently, another novel pharmacological activity 
was described for TZD in a model of human neuronal cells, namely its 
neuroprotective effects against inflammatory insults (Daniele et al., 2015). 
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Interestingly, also this TZD-mediated effect involved antagonism at 5-HT2a 
receptors, since it was counteracted by (R)-DOI (Daniele et al., 2015).   
Fig. 4. TZD proneurogenic activity in murine ahNSC is mediated by 5-HT2a antagonism. (a) 
Effects of the selective 5-HT2a agonist TCB-2 (10 nM) on TZD-mediated increase of newly 
generated MAP-2+ cells. (b) Effects of 4F4PP (0.3-100 nM), selective 5-HT2a antagonist and 
(c) ketanserin (0.1-300 nM), a non-selective 5-HT2 antagonist, on ahNSC differentiation 
toward the neuronal lineage. Data are expressed as mean ± S.D. * p < 0.05, ** p < 0.01, 
*** p < 0.001 vs vehicle-treated cells. # p < 0.05 vs 30 nM TZD-treated cells. §§ p < 0.01 vs 




5-HT2a-mediated proneurogenic effects of TZD in human iPSC-derived NSC. 
Very little is known about the effects elicited in vitro by antidepressant 
drugs in human NSC. We tested the proneurogenic activity of 5-HT on NSCs 
generated from a human iPSC line. Human iPSC-derived NSC were 
differentiated in absence of growth factors and in presence of vehicle or 5-
HT (0.0001-100 M) for 28 days. A significant increase in the percentage of 
MAP-2+ cells was observed at all tested 5-HT concentrations (ANOVA, 
Figure 5a). In the same experimental setting we evaluated the effect of TZD. 
As shown in figure 5b, similarly to 5-HT, TZD significantly increased the 
percentage of newly generated MAP-2+ cells (0.1 µM TZD: p < 0.01, ANOVA, 
Figure 5b-d). As demonstrated in murine cells, TZD produced no significant 
effect on human NSC differentiation toward the astroglial lineage, as 
measured by GFAP (Figure 5e) and S100B immunostaining (Figure 5f). 
Based on the results obtained on murine ahNSC, we then tested the effect 
of TZD (1-10 nM) in presence of the selective 5-HT2a receptor agonist TCB-
2 (10 nM). TCB-2 completely counteracted the effect of TZD (Figure 5g), 
suggesting that, as in murine ahNSC, also in human NSC TZD promotes 
neuronal differentiation via 5-HT2a antagonism. To further confirm this 
hypothesis, the selective 5-HT2a antagonist 4F4PP (3-30 nM) significantly 
increased the percentage of MAP-2+ cells generated in vitro, when 




Fig. 5. Neuronal differentiation of human iPSC-derived NSC is increased in presence of 5-HT 
and of TZD: drug activity is mediated by 5-HT2a antagonism. (a) Effect of 28 day-long 5-HT 
treatment (0.0001-100 µM) on the percentage of MAP-2+ cells generated from human 
NSC, compared to vehicle. (b) Effect of 28 day-long TZD treatment (0.001-1 M) on the 
percentage of MAP-2+ cells generated from human NSC, compared to vehicle. (c-d) 
Representative confocal microscopy images for MAP-2 immunolabelling (green) of human 
NSC in presence of vehicle (c) and TZD 100 nM (d). Nuclei are counterstained with Hoechst 
(blue). Magnification= X40, Scale bar: 20 µM. Effect of TZD treatment on the differentiation 
of human NSC toward astroglial lineages (e-f), as indicated by the percentages of GFAP (e) 
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and S100B (f) immunopositive cells.  (g) Effect of the selective 5-HT2a agonist TCB-2 (10 
nM) on TZD-mediated effects. (h) Evaluation of the percentage of in vitro generated MAP-
2+ cells in presence of the selective 5-HT2a antagonist 4F4PP (0.3-30 nM). Data are 
expressed as mean ± S.D. * p < 0.05, ** p < 0.01, *** p < 0.001 vs vehicle-treated cells 
(One-way ANOVA, Tukey post hoc). 
 
 
Evaluation of the involvement of other receptor subtypes in TZD-mediated 
proneurogenic effects: a potential role for 5-HT2c receptors. 
In light of the multimodal mechanism of action of TZD we further expanded 
our investigation. TZD indeed binds with high affinity also α1 and 5-HT1a 
receptors (Stahl, 2009). Previous data in our laboratory suggested that 1 
antagonists like doxazosin could promote in vitro neuronal differentiation 
of murine ahNSC (Meneghini et al., 2014). However, when the 1 agonist 
phenylephrine hydrocloride (30-100 nM) was tested in presence of TZD, it 
did not counteract its proneurogenic effects in ahNSC cultures (Figure 6a). 
Although with low affinity, TZD also exerts antagonistic activity at α2 
receptors (Stahl, 2009). Blockade of this receptor subtype has been 
demonstrated to accelerate the proneurogenic effects of chronic 
antidepressant treatment (Yanpallewar et al., 2010). Based on these 
observations and on a previous report of a noradrenergic tone in our 
cellular model (Meneghini et al., 2014) we then tested idazoxan (0.001-1 
M), an 2 antagonist [Ki(α2a): 10 nM; Ki(α2b): 100 nM]. In our experimental 
setting idazoxan was devoid of proneurogenic effects on ahNSC (Figure 6b). 
Altogether these data strongly suggested the lack of involvement of both 
1 and 2 receptors in TZD proneurogenic activity in vitro.  
A vast array of information suggested that 5-HT1a may be the predominant 
receptor for antidepressant activity and, more recently, also for serotonin-
mediated regulation of hippocampal neurogenesis in vivo (Gardier et al., 
1996; Cryan and Leonard, 2000; Thomas and Hagan, 2004). Although our 
cellular model expressed 5-HT1a receptor mRNA, when murine ahNSC were 
exposed to the 5-HT1a agonist 8-OH-DPAT [Ki (5-HT1a): 1.78 nM; 0.1-10 nM] 
we did not observe any proneurogenic effect (Figure 6c), suggesting that 5-
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HT1a receptors may not be involved in neuronal differentiation elicited by 
TZD and even by 5-HT. To further corroborate this finding, the selective 5-
HT1a antagonist NAD299 [Ki (5-HT1a): 0.6 nM; 30 nM] had no effect on the 
proneurogenic response elicited by 100 nM TZD (Figure 6d). NAD299 alone 
had no effect on ahNSC neuronal differentiation (Figure 6d). Of note, also 
human NSC expressed 5-HT1a mRNA but, as in murine ahNSC, we could not 
observe any effect of NAD299 on TZD-mediated effects on these cells (data 
not shown). The lack of involvement of 5-HT1a receptors in TZD-mediated 
neuronal differentiation of both murine and human NSC is in agreement 
with previously published data suggesting that 5-HT1a receptor subtype is 
not involved in modulation of ahNSC differentiation but rather in their 
proliferation. In line with our results, two 5-HT1a agonists, 8-OH-DPAT and 
ipsapirone, failed to regulate neuronal differentiation of NSC in vitro 
(Klempin et al., 2010). Conversely, in vivo blockade of 5-HT1a receptors 
significantly reduced the number of proliferating ahNSC in rat dentate gyrus 
(Radley and Jacobs, 2002). Moreover, after serotonin depletion by para-
chlorophenylalanine (PCPA), an irreversible inhibitor of the synthetizing 
enzyme TPH2, treatment with 8-OH-DPAT could rescue the number of 
proliferative ahNSC BrdU+ in the dentate gyrus (Banasr et al., 2003). 
Similarly, in vitro, PCPA treatment and a 5-HT1aR antagonist hampered 
proliferation, but not differentiation of ahNPSC (Benninghoff et al., 2010). 
Again, NSC proliferation was restored after treatment with 5-HT or a 5-HT1a 
receptor agonist (Benninghoff et al., 2010). Interestingly, in a different 
model of human neuronal cells where TZD elicited neuroprotective effects 
against inflammatory insults, the antidepressant drug activated ERK 
phosphorylation and BDNF gene transcription, and this effect appeared to 
be mediated by activation of 5-HT1a receptors (Daniele et al., 2015). 
TZD binds, although with low affinity, also 5-HT2c receptors. When tested in 
murine ahNSC cultures, the selective 5-HT2c agonist WAY161503 [Ki (5-HT2c): 
4 nM] produced a rightward shift in TZD concentration- response curve 
(Figure 6e). WAY was inactive per se (Figure 6e). These data suggested that 
the proneurogenic effects elicited by TZD are also mediated by its 
antagonistic activity at 5-HT2c receptors. To confirm our observation we 
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differentiated murine ahNSC in presence of 0.3-300 nM RS102221, a 5-HT2c 
selective antagonist [Ki (5-HT2c): 10 nM]. RS102221 significantly increased the 
percentage of MAP-2+ cells (10 nM RS102221: p < 0.001, ANOVA, Figure 6f). 
These in vitro results are in line with the observation that the 
antidepressant drug agomelatine can promote hippocampal neurogenesis 
both via melatonergic agonistic activity and 5-HT2c antagonism in rodents 
(Soumier et al., 2009). Altogether these data suggest: i) the lack of 
involvement of 5-HT1a and 1/2 receptors in TZD proneurogenic activity in 
vitro; ii) a possible involvement of 5-HT2c antagonism in TZD effect, at least 
in murine cells. Indeed, we failed to demonstrate 5-HT2c mRNA expression 









Fig. 6. 5-HT2c, but not 5-HT1a and α1/2 adrenergic receptors, contribute to the 
proneurogenic effects of TZD in murine ahNSC. (a) Effect of the α1 agonist phenylephrine 
hydrochloride (Phe) on TZD proneurogenic effects. (b) Effect of the α2 antagonist idazoxan 
(0.001-1 M) on neuronal differentiation of ahNSC. (c) Effect of the 5-HT1a agonist 8-OH-
DPAT (0.1-10 nM) on neuronal differentiation of ahNSC. (d) Evaluation of the effect of 
pretreatment of ahNSC with the selective 5-HT1a antagonist, NAD299 (30 nM), on TZD-
mediated proneurogenic effects. (e) Effect of the selective 5-HT2c agonist WAY161503 (10 
nM) on TZD-mediated increase of newly generated MAP-2+ cells. (f) Evaluation of the 
percentage of newly generated neurons in presence of the 5-HT2c antagonist RS102221 
(0.3-300 nM). Data are expressed as mean ± S.D. ** p < 0.01, *** p < 0.001 vs vehicle-
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treated cells, ## p < 0.01 vs 30 nM TZD-treated cells. §§§ p < 0.001 vs 100 nM TZD-treated 
cells (One-way ANOVA, Tukey’s post-hoc). 
 
The in vitro proneurogenic effects of TZD require 5-HT synthesis by murine 
ahNSC.  
The fact that TZD exerted its effects via 5-HT2a/c antagonism supported the 
idea of an endogenous serotoninergic tone in our in vitro model and also 
raised the question of serotonin source both under basal conditions and in 
response to TZD. We measured, by LC-ESI-MS, extracellular 5-HT 
concentration in our murine cultures. Values were, on average, 0.86 ± 0.19 
ng/ml (Figure 7a), corresponding to 4.9 ± 1.1 nM. Interestingly, murine and 
human ahNSC not only express several 5-HT receptors, but also 5-HTT 
(Klempin et al., 2010; Benninghoff et al., 2010). TZD is a low affinity 5-HTT 
blocker (Stahl, 2009) and this drug activity can result in an increased 
availability of extracellular 5-HT. Interestingly, a slight, although not 
statistically significant, increase in 5-HT extracellular concentration was 
observed in presence of a proneurogenic concentration of 100 nM TZD 
compared to vehicle (TZD: 1.25 ± 0.20 ng/ml; vehicle: 0.86 ± 0.19 ng/ml, p 
= 0.07, Figure 7a).  Under the same experimental conditions the SSRI 
antidepressant fluoxetine (0.003-3 µM) promotes neuronal differentiation 
of murine ahNSC in a concentration-dependent manner (p < 0.001, ANOVA, 
Figure 7b). The proneurogenic effect of fluoxetine correlated with a 
significant increase in 5-HT extracellular concentration, compared with 
vehicle-treated conditions (1 µM FLX: 1.76 ± 0.1 ng/ml, p < 0.01 vs vehicle, 
t test), suggesting that our cellular model indeed does express functional 5-
HTT (Figure 7a). Undifferentiated ahNSC also express both isoforms of 
tryptophane-hydroxylase, TPH1 and TPH2 (Benninghoff et al., 2010). We 
performed a three-day treatment of proliferating ahNSC with 50 M PCPA 
so to irreversibly inhibit TPH and deplete ahNSC of endogenous serotonin 
(Benninghoff et al., 2010). As expected, extracellular 5-HT levels became 
undetectable by LC-ESI-MS in culture medium of PCPA- compared to 
vehicle-treated cells. Although literature data report that PCPA treatment 
significantly decreases proliferation of ahNSC both in vitro and in vivo 
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(Benninghoff et al., 2010; Jha et al., 2006), in our hands blockade of 5-HT 
synthesis caused a small but not statistically significant reduction (about -
23 %) in the number of recovered PCPA-treated NSC compared to vehicle-
treated cells, suggesting a more limited effect of 5-HT depletion on ahNSC 
proliferation. Similarly, PCPA treatment did not affect the survival of ahNSC 
(% dead cells/total cells: 12.9 ± 2.5 and 16.2 ± 2.9 in vehicle- and PCPA-
treated cells, respectively, p > 0.05, t test). After PCPA/vehicle treatment 
ahNSC were washed and plated, at the same cellular density, under 
conditions promoting neuronal differentiation either in presence of TZD 
(30-300 nM) or the corresponding vehicle. The percentage of newly 
generated MAP-2+ cells was then determined in vehicle- and PCPA-treated 
cells. Under basal conditions we observed a statistically significant 
reduction in the percentage of MAP-2+ cells in PCPA-treated cells compared 
to vehicle-treated cells (Figure 7c; - 59.1 %, p < 0.01, t test). This effect 
cannot be ascribed to a reduction in cell viability since we did not observe 
significant differences in the apoptotic/necrotic rate of ahNSC and their 
progeny under the same experimental conditions (data not shown). Even 
more interestingly, 30-300 nM TZD promoted neuronal differentiation in 
vehicle-treated, but not in PCPA-treated ahNSC (Figure 7c). As a control, 
exogenously added 5-HT (1 M) promoted neurogenesis in both vehicle- 
and PCPA-treated ahNSC (p < 0.001 vs vehicle, ANOVA Figure 7c), 
suggesting that PCPA-treated cells were not affected in their ability to 
respond to proneurogenic signals. Of note, although not significantly 
different, the percent of increase of MAP-2+ cells over basal differentiating 
conditions was higher in PCPA-treated compared to vehicle-treated ahNSC 
(+260.9 ± 83.9 and +127.2 ± 32.3 % in PCPA- and vehicle-treated cells, 
respectively, p = 0.062, t test; Figure 7c). Altogether, these data strongly 
support the finding that the effects of TZD on neuronal differentiation of 
ahNSC are mediated by drug antagonism at 5-HT2 receptors, in presence of 
a serotoninergic tone which, in our experimental setting, is not significantly 





Fig. 7. TZD proneurogenic activity requires synthesis of endogenous 5-HT by murine ahNSC. 
(a) LC-ESI-MS analysis of extracellular 5-HT content in our in vitro model under basal 
conditions and after treatment with 1 µM fluoxetine (FLX) and 100 nM TZD. (b) Effect of 
fluoxetine (0.0003-3 µM) on the percentage of MAP-2+ cells generated from ahNSC. Data 
are expressed as mean ± S.D. *** p < 0.001 vs vehicle-treted cells. (One-way ANOVA, 
Tukey’s post-hoc). (c) Effect of irreversible inhibition of tryptophan hydroxylase by para-
chlorophenylalanine (PCPA, 50 M, 3 day-treatment of proliferating ahNSC) on the 
proneurogenic activity by TZD. Evaluation of exogenous 5-HT (1 M) treatment on 
neuronal differentiation of both PCPA-treated and vehicle-treated ahNSC. Data are 
expressed as mean ± S.D. *** p < 0.001 vs basal condition in vehicle-treated cells; §§§ p < 
0.001 vs basal condition in PCPA-treated cells (One-way ANOVA, Tukey’s post-hoc), ## p < 
0.01 vs basal condition in vehicle-treated cells (Student’s t test).  
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Nuclear translocation of NF-κB p50 is required for the proneurogenic effects 
elicited by TZD .  
Based on the current results our working hypothesis is that 5-HT exerts 
proneurogenic and antineurogenic effects by interacting with different 
serotonergic receptor subtypes. While the 5-HT receptors responsible for 
the serotonin proneurogenic effect in the present model remain to be 
clarified, we investigated which downstream signaling pathways could play 
a role in the TZD effect mediated by 5-HT2a and 5-HT2c receptors subtypes. 
Previous data from our laboratory established the relevance of NF-B 
proteins, and in particular of the p50 subunit, in the in vitro and in vivo 
proneurogenic effect of several drugs (Cuccurazzu et l., 2013; Valente et al., 
2012) as well as of neural mediators (Meneghini et al., 2010; Meneghini et 
al., 2013; Cvijetic et al., 2017). Based on these data we tested the 
involvement of NF-κB p50 in TZD-mediated proneurogenic effects on 
ahNSC. Interestingly, co-treatment of ahNSC with SN50 (10 μg/ml), an 
inhibitor of NF-κB p50 nuclear translocation, completely counteracted the 
proneurogenic effects of 1-10-100 nM TZD (Figure 8a).  
However, unlike TZD, in same experimental setting the enhancement of the 
proneurogenic effect obtained by adding external 5-HT did not require NF-
B p50 nuclear translocation (Figure 8b). These results would need 
additional studies to further characterize the signaling pathways that 
operate downstream the different 5-HT receptor subtypes and their 





Fig. 8. NF-κB p50 nuclear translocation is required for TZD, but not for 5-HT proneurogeic 
effect. (a) Effect of TZD after inhibition of NF-κB p50 nuclear translocation. Data are 
expressed as mean ± S.D. *** p < 0.001 vs vehicle treated cells. (b) 5-HT proneurogenic 
activity in presence of NF-κB p50 nuclear translocation inhibition. Data are expressed as 





This in vitro study suggests, for the first time, a new pharmacological activity 
of TZD, namely its ability to promote neuronal differentiation of murine and 
human NSC. An extensive pharmacological characterization of receptors 
involved in TZD proneurogenic activity in murine cells revealed that 5-HT2a/c 
antagonism is mainly responsible for that effect. Interestingly, also in IPSC-
derived human NSC the antidepressant drug promotes neuronal 
differentiation via blockade of 5-HT2a receptors. This piece of information is 
quite important since most in vitro studies evaluating the activity of 
clinically relevant drugs on neurogenesis have been performed in rodent 
cells. Moreover in our hands, unlike the SSRI fluoxetine, the proneurogenic 
effects of TZD did not appear to correlate with an increase in 5-HT 
extracellular concentration, as a result of 5-HTT blockade. Finally, our data 
add further complexity to the role played by serotoninergic 
neurotransmission in the regulation of adult hippocampal neurogenesis. 
Previous in vivo data suggested oppositional effects of serotonin receptors 
5-HT1a and 5-HT2 in the regulation of adult hippocampal neurogenesis 
(Klempin et al., 2010). Although obtained in vitro, our data also support the 
concept that serotonin, acting on different receptor subtypes, may 
promote but also counteract, via 5-HT2 receptors, neuronal differentiation 
of adult NSC. Despite the widespread view of 5-HT as an endogenous 
positive modulator of hippocampal neurogenesis it is not surprising that 
homeostasis within this process may be reached also by oppositive effects 
via different receptor subtypes. In our experimental setting we could not 
demonstrate that 5-HT1a receptors may play a role in the positive 
modulation of ahNG neither in murine and human cells, so at this stage we 
cannot point to the receptor subtype which mediates the in vitro 
proneurogenic effects of 5-HT in these cells. Based on literature reports, 5-
HT4 is known to promote neurogenesis both in vitro and in vivo (Lucas et al., 
2007; Samuels et al., 2016), but mRNA for that receptor subtype was not 
expressed in our cellular model (data not shown). The other receptor 
subtype which has been proposed to play a role in neurogenesis is the 
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ionotropic 5-HT3, although conflicting results have been obtained since 
both activation and blockade of that receptor have been proposed to 
promote neuronal differentiation of ahNSC (Kondo et al., 2015; Bétry et al., 
2015).  Again, mRNA for this receptor subtype was not detected in our 
model (data not shown). 
Interestingly, at least in murine cells, in our experimental setting the time 
course of TZD pro-neurogenic effects was also different compared to that 
of 5-HT, again pointing to differences in the overall effects on neurogenesis 
on molecules that act via distinct receptor subtypes. The different time 
course profile of TZD and 5-HT could be also potentially explained by 
changes in receptor subtype expression by ahNSC and their progeny over 
time in vitro. Such changes could even be triggered differently by TZD or 5-
HT during in vitro cell maturation stages. For these reasons, future studies 
will need to further explore the differential contribution of distinct 5-HT 
receptors on NSC, their progeny and their overall impact on adult 
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Down syndrome (DS), a genetic condition due to triplication of 
chromosome 21, is characterized by reduced proliferation of Neural 
Stem/Progenitor Cells (NSC) starting from early life stages. This defect is 
worsened by a reduction of neurogenesis (accompanied by an increase in 
astrogliogenesis) and dendritic spine atrophy. Since this triad of defects 
underlies intellectual disability, it seems important to establish whether it 
is possible to pharmacologically correct these alterations. In this study, we 
exploited the Ts65Dn mouse model of DS in order to obtain an answer to 
this question. In the framework of an in vitro drug-screening campaign of 
FDA/EMA-approved drugs, we found that the immunosuppressant 
cyclosporine A (CSA) restored proliferation, acquisition of a neuronal 
phenotype, and maturation of NSC from the subventricular zone (SVZ) of 
the lateral ventricle of Ts65Dn mice. Based on these findings, we treated 
Ts65Dn mice with CSA in the postnatal period P3-P15. We found that 
treatment fully restored NSC proliferation in the SVZ and in the subgranular 
zone of the hippocampal dentate gyrus, and total number of hippocampal 
granule cells. Moreover, CSA enhanced development of dendritic spines on 
the dendritic arbor of the granule cells whose density even surpassed that 
of euploid mice. In hippocampal homogenates from Ts65Dn mice, we found 
that CSA normalized the excessive levels of p21, a key determinant of 
proliferation impairment. Results show that neonatal treatment with CSA 
restores the whole triad of defects of the trisomic brain. In DS CSA 
treatment may pose caveats because it is an immunosuppressant that may 
cause adverse effects. However, CSA analogues that mimic its effect 
without eliciting immunosuppression may represent practicable tools for 
ameliorating brain development in individuals with DS.  
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Intellectual disability is one of the most serious problems in Down 
syndrome (DS), a genetic condition caused by triplication of chromosome 
21. The impairment of brain function, which is already detectable in infants 
with DS, is attributable to severe impairment of key neurodevelopmental 
processes. In particular, evidence in fetuses/infants with DS and in DS 
mouse models shows that trisomic neural precursor cells have a reduced 
proliferation rate and exhibit an altered differentiation program that causes 
a reduction in the number of cells that differentiate into neurons and an 
increase in the number of cells that differentiate into astrocytes (Dierssen, 
2012, Stagni et al., 2018). Neuronal maturation is also altered in DS, which 
leads to neurons with a reduced dendritic arborization and a reduced 
density of dendritic spines. The unavoidable outcome of these defects is the 
impairment of overall brain wiring, explaining the alteration within a 
constellation of cognitive domains that characterizes DS. 
Intense efforts are currently underway in order to establish whether it is 
possible to pharmacologically ameliorate intellectual disability in DS. In this 
connection, there are two possible and not mutually exclusive approaches. 
One possibility is to use drugs that specifically target cellular pathways that 
are altered in the DS brain and that are known to regulate one or more of 
the neurodevelopmental processes mentioned above. This approach 
requires preliminary knowledge regarding the molecular alterations of the 
DS brain, the choice of the molecular pathway to be targeted, and the 
choice of the drug that putatively acts on this pathway. A second possibility 
is the repositioning of drugs/compounds that were designed and approved 
for other pathologies. Various studies show that drugs designed for quite 
different purposes may actually exert some benefits in various brain 
disorders. Thus, this strategy is not simply based on an a priori assumption. 
This approach requires i) the development of a reproducible and sensitive 
phenotypic assay, based on relevant defective properties of trisomic neural 
stem/progenitor cells (NSC); ii) a subsequent in vitro screening of libraries 
of clinically approved drugs in the search for those that may revert that 
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phenotype. In principle, cell-based screening combined with strategies of 
drug repurposing offers the opportunity to significantly reduce risks and 
costs associated with developing new therapeutics and, more importantly, 
may dramatically reduce time for human translation. By following this 
strategy, we aim to identify clinically approved drugs that are able to restore 
proliferative and differentiative defects of NSC derived from the Ts65Dn 
mouse, a widely-used model of DS. After in vitro identification of effective 
molecules, our final goal is to test their effects in vivo in the Ts65Dn mouse. 
Herein we show the identification of the immunosuppressant and clinically 
relevant cyclosporine A (CSA) as a drug that can not only restore the 
proliferation rate of NSC and their differentiation into neurons in vitro, but 
that is also effective in vivo in the Ts65Dn mouse. According to recent work, 
a dose of 15 mg/kg/day of CSA increases the pool of actively dividing cells 
in the dentate gyrus of wild type mice and also favors the generation of new 
granule neurons (Chow and Morshead, 2016). Herein we show that Ts65Dn 
neonatal treatment with 15 mg/kg/day of CSA for a short period of time (13 
days) restores proliferation of NSC in the two major brain neurogenic niches 
(the subventricular zone and the subgranular zone of the hippocampal 
dentate gyrus) and reinstates hippocampal development, in terms of 
granule cell number and spinogenesis. This provides evidence that CSA 






MATERIALS AND METHODS 
 
Animals. Ts65Dn mice were generated by mating B6EiC3Sn a/A-
Ts(17^16)65Dn females with C57BL/6JEiJ x C3H/HeSnJ (B6EiC3Sn) F1 hybrid 
males. This parental generation was provided by Jackson Laboratories (Bar 
Harbor, ME, USA). To maintain the original genetic background, the mice 
used were of the first generation of this breeding. Animals were genotyped 
as previously described (Reinholdt et al., 2011). The day of birth was 
designated postnatal day zero (P0). The animals’ health and comfort were 
controlled by the veterinary service. The animals had access to water and 
food ad libitum and lived in a room with a 12:12 h light/dark cycle. 
Experiments were performed in accordance with the European 
Communities Council Directive of 24 November 1986 (86/609/EEC) for the 
use of experimental animals and were approved by Italian Ministry of Public 
Health. In this study, all efforts were made to minimize animal suffering and 
to keep the number of animals used to a minimum. 
 
IN VITRO EXPERIMENTS 
 
Isolation and Culture of neonatal SVZ NSC. Cells were isolated from the 
subventricular zone (SVZ) of the lateral ventricle of newborn (age 1-2 days) 
euploid and Ts65Dn mice, as previously described (Stagni et al., 2017). 
Briefly, brains were removed, the SVZ region was isolated and collected in 
ice-cold PIPES buffer pH 7.4. After centrifugation, tissue was digested for 10 
min at 37°C using Trypsin/EDTA 0.25% (Life Technologies) aided by gentle 
mechanical dissociation. Cell suspensions from individual mice were pooled 
and plated onto 25 cm2 cell-culture flask (Thermo Fisher Scientific) and 
cultured as floating neurospheres in medium containing basic fibroblast 
growth factor (bFGF, 10 ng/ml; Peprotech) and epidermal growth factor 
(EGF, 20 ng/ml; Peprotech) using an established protocol (Meneghini et al., 
2014). Primary (Passage 1, P1) neurospheres were dissociated using 
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Stempro Accutase (Life Technologies) after 7 days in vitro (DIV); thereafter 
neurospheres were passaged every 5 DIV. For further in vitro studies, cells 
from P3 to P12 were used.  
 
Phenotypic drug screening. For the drug screening, two different 
commercial libraries (Prestwick chemical library®, Prestwick Chemical, and 
Screen-Well® FDA Approved Drug Library V2, Enzo Life Sciences), containing 
a total of 1,887 FDA/EMA-approved drugs were used. These libraries were 
chosen for their chemical and pharmacological diversity. Trisomic SVZ NSC 
(P3-P12) pooled from at least 3-5 pups were dissociated in a single cell 
suspension and plated onto NunclonTM Delta Surface 96-well plate 
(Thermo Fisher Scientific) at a density of 4×103 cells per well in DMEM/F-
12 medium supplemented with B27, GlutamaxTM (2 mM, Life 
Technologies), heparin sodium salt (4 μg/ml; ACROS Organics), bFGF (10 
ng/ml, Peprotech) and 100 U/100 μg/ml Penicillin/Streptomycin (Life 
Technologies) for 30 min, at 37 °C. Compounds were added to each well in 
quadruplicates (1 µM final concentration, in 0.05% DMSO). In parallel, EGF 
(20 ng/ml, Peprotech) and LiCl (2 mM, Sigma-Aldrich), that have been 
shown to restore proliferation of NSC of Ts65Dn mice in vivo (Bianchi et al., 
2010a, Contestabile et al., 2013) and in vitro (Trazzi et al., 2014), were 
added to each plate in quadruplicates as pro-proliferative controls. Lithium 
concentration was chosen based on previous evidence (Trazzi et al., 2014). 
Cell proliferation was quantified after 96 h incubation in a humidity 
chamber (to minimize evaporation) and quantified as relative luminescence 
units (RLU) values using a CellTiter-Glo ATP-based assay kit (Promega) on a 
Victor3-V plate reader (PerkinElmer) (Stagni et al., 2017). Drug activity was 
calculated as percentage of change compared to basal conditions (cells 
grown in presence of 10 ng/ml FGF and 0.05 % DMSO). The same 
proliferation assay was performed to assess hit concentration response 
curves (0.1-1000 nM). 
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NSC Proliferation and Differentiation. In order to evaluate cell proliferation 
in secondary assays, EdU (5-ethynyl-2-deoxyuridine) incorporation was 
performed using the Click-iT® EdU Alexa Fluor® 488 HCS Assay Kit (Thermo 
Fisher Scientific). Briefly, neurospheres (P3-P12) were dissociated in a single 
cell suspension and plated onto laminin-coated 96-well plate (Falcon) at a 
density of 4×103 cells per well in DMEM/F-12 medium supplemented with 
B27, GlutamaxTM, heparin sodium salt (4 μg/ml; ACROS Organics), bFGF (10 
ng/ml) and 100 U/100 μg/ml Penicillin/Streptomycin (Life Technologies) in 
presence of CSA (1000 nM; MedChem Express) or its vehicle (DMSO 0.05%) 
for 72 h. In the last 12 h period, EdU was added to each well at a final 
concentration of 10 μM. After that, cells were fixed for 20 min at room 
temperature using 4% paraformaldehyde in phosphate-buffered saline 
(PBS, pH 7.4). EdU detection was performed according to manufacturer’s 
instructions. In each experiment, 37 fields/well (corresponding to about 50 
% of the total well surface) were counted using an InCell Analyzer 2200 (GE). 
Cell death was evaluated using the CytoTox-Glo™ Cytotoxicity Assay 
(Promega) according to the manufacturer’s instructions. Cells were 
exposed to CSA (30-1000 nM, MedChem Express) or its vehicle (DMSO 
0.05%) for 96 h. Cytotoxicity was quantified as relative luminescence unit 
(RLU) on a Victor3-V plate reader (PerkinElmer) and expressed as 
percentage over the total number of cells. For differentiation experiments 
neurospheres from the SVZ were dissociated into single cells and plated 
onto laminin-coated Lab-Tek 8-well permanox chamber slides (Thermo 
Fisher Scientific) at a density of 35×103 per well in differentiation medium 
(DMEM-F12 supplemented with B27, 2 mM Glutamax and 100 U/100 
mg/ml penicillin/streptomycin). NSC were treated in presence of CSA (3–
1000 nM) or vehicle (DMSO 0.05 %) for 96 h. After that, cells were fixed for 
20 min at room temperature using 4% paraformaldehyde. Phenotypic 
characterization of NSC-derived cells was carried out by immunolocalization 
for MAP2 (rabbit polyclonal, 1:50000; Abcam) and Nestin (chicken 
monoclonal, 1:2500; Neuromics). Secondary antibodies were as follows: 
AlexaFluor555-conjugated goat anti rabbit (1:1400; MolecularProbes), and 
AlexaFluor488-conjugated goat anti chicken (1:1400; Molecular Probes). In 
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additional experiments, in which NSC were exposed to selected 
concentrations of CSA (100–1000 nM) or vehicle for 96 h, in parallel to 
MAP2/nestin, GFAP immunoreactivity was evaluated using a mouse anti-
GFAP monoclonal antibody (1:600, Millipore), and a secondary 
AlexaFluor555-conjugated goat anti mouse antibody (1:1600; Molecular 
Probes). Nuclei were counterstained with 0.8 ng/ml Hoechst (Thermo 
Fisher Scientific) diluted in PBS. In each experiment, five fields/well 
(corresponding to about 150–200 cells/well) were counted with a 60X 
objective by a Leica DMIRB inverted fluorescence microscope. 
Immunoreactive cells were counted and their percentage over total viable 
cells was calculated. In differentiating cultures exposed to CSA (3-1000 nM) 
for 96 h, the number of MAP2+ cells exhibiting neuritic processes was 
counted at random locations in three fields/well and their number was 
expressed as the percentage over total cell number in each sampled 
location. All experiments were run in triplicate.  
 
IN VIVO EXPERIMENTS 
 
Experimental protocol. According to recent work, a dose of 15 mg/kg/day of 
CSA has a pro-neurogenic effect in the dentate gyrus of adult wild type mice 
(Chow and Morshead, 2016). Based on this evidence, we treated euploid 
and Ts65Dn mice with CSA (MedChem Express, 15 mg/kg/day in vehicle; 
subcutaneos injection) or vehicle (PBS with 2.5% DMSO) from postnatal day 
3 (P3) to P15. Mice that received CSA will hereafter be called “treated mice” 
(treated euploid mice: n=15; treated Ts65Dn mice: n=14). Mice that 
received the vehicle will be called “untreated mice” (untreated euploid 
mice: n=21; untreated Ts65Dn mice: n=21). Each experimental group was 
composed of a similar number of males and females (treated euploid mice: 
8 males, 7 females; treated Ts65Dn mice: 8 males, 6 females; untreated 
euploid mice: 10 males, 11 females; untreated Ts65Dn mice: 11 males, 10 
females). On P15, mice received a subcutaneous injection (150 g/g body 
weight) of BrdU in TrisHCl 50 mM 2h before being sacrified. The brains were 
excised and cut along the midline. The left hemispheres of a group of mice 
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were fixed by immersion in PFA 4% and frozen, and the right hemispheres 
were used for Golgi staining. The right hemispheres of other mice were kept 
at –80°C and used for western blotting. The body weight of mice of all 
groups was recorded prior to sacrifice and the brain weight was recorded 
immediately after brain removal. The number of animals used for each 
experimental procedure is specified in the figure legends. In order to 
establish whether lower doses of CSA have a pro-neurogenic effect in 
Ts65Dn mice similar to that elicited by the 15.0 mg/kg dose (see Results), 
we also tested the effects of 1.5 mg/kg (n=6 mice: 3 males, 3 females) or 
7.5 mg/kg (n=4 mice: 3 males, 1 female) of CSA (same protocol as above).  
 
Histological procedures.The frozen brains were cut with a freezing 
microtome into 30-m-thick coronal sections that were serially collected in 
anti-freezing solution (30% glycerol; 30% ethylen-glycol; 10% PBS 10X; 
sodium azide 0.02%; MilliQ to volume). 
 
Hoechst-staining. One out of six free-floating sections taken from the 
beginning to the end of the hippocampal formation (n=15-19 sections) 
were incubated for 2 min in Hoechst nuclear dye (2 mg/ml in PBS) and 
mounted on slides. 
 
BrdU immunohistochemistry. Immunohistochemistry was carried out as 
previously described (Contestabile et al., 2007, Bianchi et al., 2010b, Guidi 
et al., 2013, Giacomini et al., 2015). One out of six free-floating sections 
(n=15-19 sections) from the hippocampal formation was incubated with rat 
anti-BrdU antibody (diluted 1:200; Biorad) and detection was performed 
with a Cy3-conjugated anti rat-secondary antibody (diluted 1:200; Jackson 




Golgi staining. Brains were Golgi stained using the FD Rapid Golgi Stain TM 
Kit (FD Neuro Technologies, Inc.). Brains were immersed in the 
impregnation solution containing mercuric chloride, potassium dichromate 
and potassium chromate (the impregnation solution was prepared by 
mixing equal volumes of Solutions A and B of the FD Rapid Golgi Stain TM 
Kit) and stored at room temperature in the dark for 2 weeks. Then, brains 
were transferred into Solution C (FD Rapid Golgi Stain TM Kit) and stored at 
room temperature in the dark for at least 72 h. After these steps, 
hemispheres were cut with a microtome into 90-μm-thick coronal sections 
that were mounted on gelatin-coated slides, and were air dried at room 
temperature in the dark for at least one day. After drying, sections were 
rinsed with distilled water and subsequently stained in a developing 
solution (FD Rapid Golgi Stain Kit).  
 
Image acquisition. Immunofluorescence images were taken with a Nikon 
Eclipse TE 2000-S inverted microscope (Nikon Corp., Kawasaki, Japan), 
equipped with a Nikon digital camera DS-Qi2. Bright field images were taken 
on a light microscope (Leitz) equipped with a motorized stage and focus 
control system and a Coolsnap-Pro color digital camera (Media Cybernetics, 
Silver Spring, MD, USA). Measurements were carried out using the software 
Image Pro Plus (Media Cybernetics, Silver Spring, MD 20910, USA). 
 
Number of BrdU-positive cells. BrdU-positive cells in the dentate gyrus and 
the region of the SVZ that spans along the whole rostro-caudal extent of the 
hippocampal formation were detected using a fluorescence microscope 
(Eclipse; objective: x 20, 0.5 NA). Quantification of BrdU-labeled nuclei was 
conducted in every 6th section using a modified unbiased stereology 
protocol that has previously been reported to successfully quantify BrdU 
labeling (Malberg et al., 2000, Kempermann and Gage, 2002, Tozuka et al., 
2005). All BrdU-labeled cells located in the granule cell layer and 
subgranular zone and in the SVZ were counted in their entire z axis (1 µm 
steps) in each section. To avoid oversampling errors, nuclei intersecting the 
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uppermost focal plane were excluded. The total number of BrdU-labeled 
cells per animal was determined and multiplied by six to obtain the total 
estimated number of cells per dentate gyrus and per SVZ. 
 
Stereology of the dentate gyrus. Unbiased stereology was performed on 
Hoechst-stained sections. The optical disector method was used to obtain 
density, and the Cavalieri principle was used to estimate volume, as 
previously described (Stagni et al., 2017). 
 
Spine density. In Golgi-stained sections from the dentate gyrus, spines of 
granule cells were counted using a 100x oil immersion objective lens (1.4 
NA). Spine density values were evaluated in dendritic segments located in 
the inner (proximal dendrites) and outer (distal dendrites) half of the 
molecular layer. For each neuron, 3-4 proximal and 3-4 distal segments 
were analyzed. For each animal, spines were counted in at least 4 neurons. 
The length of each sampled dendritic segment was determined by tracing 
its profile and the number of spines was counted manually. The linear spine 
density was calculated by dividing the total number of spines by the length 
of the dendritic segment. Spine density was expressed as number of spines 
per 100m dendrite. 
 
Western blotting. In homogenates of the hippocampal formation, total 
proteins were obtained as previously described (Trazzi et al., 2011) and the 
levels of p21 (1:200, Santa Cruz Biotechnology; catalog number: sc-271532) 
were evaluated. Densitometric analysis of digitized images with ChemiDoc 
XRS+ was performed with Image Lab software (Bio-Rad Laboratories, 
Hercules, CA, USA) and intensity for each band was normalized to the 
intensity of the Ponceau S staining. This evaluation has the advantage that 
it does not rely on a single protein for normalization, thereby circumventing 
the possibility that the chosen ‘‘housekeeping” proteins may vary in some 




Statistical analysis. Results are presented as mean ± standard error of the 
mean (SE). Data were analyzed with the IBM SPSS 22.0 software. Before 
running statistical analyses, we checked data distribution and homogeneity 
of variances for each variable using the Shapiro-Wilk test and Levene’s test 
respectively. Data were normally distributed with the exception of granule 
cell density. In this case, statistical analysis was carried out using the 
Kruskal-Wallis test followed by the Mann–Whitney U test. For all other 
examined variables statistical analysis was carried out using either a one-
way ANOVA or a two-way ANOVA with genotype (euploid, Ts65Dn) and 
treatment (vehicle, CSA), as factors. Post hoc multiple comparisons were 
carried out using Fisher’s least significant difference (LSD) test. Based on 
the “Box plot” tool available in SPSS Descriptive Statistics, in each analysis 
we excluded the extremes, i.e., values that were larger than 3 times the IQ 
range [x ≥ Q3 + 3 * (IQ); x ≤ Q1 – 3 * (IQ)]. The number of mice included in 
(and excluded from, if any) individual analyses is reported in the legends of 






Identification and characterization of CSA effects in trisomic NSC phenotypic 
assays 
NSC from the SVZ of neonate Ts65Dn mice exhibit impairment of 
proliferation rate, similarly to the in vivo condition (Trazzi et al., 2011, Trazzi 
et al., 2013, Stagni et al., 2017). As result of a screening effort, among 1,887 
tested FDA-EMA drugs the immunosuppressant CSA was identified as a 
drug promoting proliferation of trisomic NSC (% increase of proliferation: 
+53% at 1000 nM vs. basal conditions) [F(2,15) = 56.10, p < 0.001] (Fig. 1A). 
We used as a positive control lithium chloride, a well-established in vivo 
neurogenesis enhancer in DS (Bianchi et al., 2010a, Contestabile et al., 
2013, Trazzi et al., 2014, Stagni et al., 2017), and found that lithium chloride 
at 2 mM enhanced proliferation by +39% vs. basal conditions [F(2,15) = 
56.10, p < 0.001] (Fig. 1A).  
CSA was then tested under a wide range of concentrations (0.1-1000 nM). 
A one-way ANOVA showed a significant effect of treatment [F(5,42) = 
10.855, p < 0.001]. A post hoc Fisher’s LSD test showed that CSA 
concentrations of 0.1-100 nM had no significant effect on proliferation, 
while a concentration of 1000 nM increased the number of trisomic NSC 
(Fig. 1B). By using a cytotoxicity assay, we could exclude that CSA-mediated 
effect on the number of NSC was due to increased cell viability. Indeed, 
none of the tested CSA concentrations affected cell death rate (Fig. 1C). In 
order to obtain more direct evidence on the pro-proliferative effect of CSA, 
we evaluated the proliferation rate based on incorporation of the thymidine 
analogue EdU (5-ethynyl-2-deoxyuridine) in trisomic and euploid cultures 
exposed to CSA (1000 nM) or vehicle. A two-way ANOVA showed a 
genotype X treatment interaction [F(1,8) = 72.531, p < 0.001], a main effect 
of genotype [F(1,8) = 277.386, p < 0.001] and a main treatment [F(1,8) = 
262.037, p < 0.001]. A post hoc Fisher’s LSD test showed that trisomic and 
euploid cells exposed to CSA 1000 nM underwent a proliferation increase 
in comparison with their untreated counterparts (Fig. 1D). Importantly, in 
response to CSA treatment, trisomic NSC displayed a proliferation rate 
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similar to untreated euploid NSC.  
In addition to proliferation impairment, trisomic NSC exhibit impairment in 
the acquisition of a neuronal phenotype and in neuronal maturation, i.e., 
development of neuritic processes (Trazzi et al., 2011, Trazzi et al., 2013, 
Stagni et al., 2017). In cultures of NSC under differentiating conditions we 
evaluated the percentage of cells that were i) immunopositive to MAP2 (a 
marker of cells with a neuronal phenotype) and immunonegative to Nestin 
(a marker of undifferentiated NSC); ii) double immunopositive to MAP2 and 
Nestin, i.e., neuroblasts; iii) immunonegative to MAP2 and to Nestin 
(putative glial cells). A one-way ANOVA on the percentage of cells that were 
MAP2-positive and Nestin-negative (MAP2+/Nestin-) showed a significant 
effect of treatment [F(6,14) = 7.735, p < 0.001]. Fisher’s LSD test, carried 
out post hoc, showed that drug concentrations of 100-1000 nM caused a 
significant increase in the percentage of MAP2+/Nestin- cells in comparison 
with cultures treated with vehicle (Fig. 1E), suggesting that CSA favors the 
acquisition of a neuronal phenotype. A one-way ANOVA on the percentage 
of cells that were MAP2-positive and Nestin-positive (MAP2+/Nestin+) 
showed no effect of treatment [F(6,14) = 2.182, p < 0.108] (Fig. 1F) 
suggesting that treatment does not affect the population of neuroblasts. An 
evaluation of the percentage of cells that were negative to both MAP2 and 
Nestin (MAP2-/Nestin-) showed a significant effect of treatment [F(6,14) = 
5.389, p < 0.004]. A post hoc Fisher’s LSD test showed that concentrations 
of 100-1000 nM caused a reduction in the percentage of MAP2-/Nestin- 
cells (Fig. 1G). Since cells that are immunonegative to both MAP2 and 
Nestin mainly represent cells committed to glia (Cvijetic et al., 2017), these 
results suggest that CSA treatment promotes neuronal differentiation of 
trisomic NSC and that this effect takes place at the expense of their 
commitment toward non-neuronal lineages (glia).  
In order to obtain a more direct evidence of the glial nature of MAP2-
/Nestin- cells, we carried out additional experiments in which we evaluated, 
in parallel to the percentage of cells that were MAP2+/Nestin- or 
MAP2+/Nestin+, the percentage of cells expressing the astrocytic marker 
GFAP. A one-way ANOVA on the percentage of MAP2+/Nestin- cells 
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confirmed a significant effect of drug treatment [F(3,11) = 14.94, p = 0.001]. 
Fisher’s LSD test, carried out post hoc, confirmed that CSA 100-1000 nM 
caused a significant increase in the percentage of MAP2+/Nestin- cells in 
comparison with vehicle-treated trisomic cells (Fig. 1H). A one-way ANOVA 
on the percentage of MAP2+/Nestin+ cells showed again no effect of 
treatment (Fig. 1I). An evaluation of the percentage of GFAP+ cells showed 
a significant effect of treatment [F(3,23) = 8.860, p = 0.001]. A post hoc 
Fisher’s LSD test showed that CSA concentrations 100-1000 nM reduced 
the percentage of GFAP+ (Fig, 1J). These results confirm our hypothesis that 
CSA promotes neuronal differentiation of trisomic NSC at the expense of 
their commitment toward an astrocytic phenotype.  
In order to establish the effect of CSA on neuron maturation we evaluated 
the percentage of cells exhibiting neuritic processes in differentiating 
cultures of trisomic NSC exposed to different concentrations of CSA. A one-
way ANOVA on the percentage of NSC that exhibited neuritic processes 
showed a significant effect of treatment [F(5,12) = 8.025, p = 0.002]. 
Fisher’s LSD test, carried out post hoc, showed that all tested drug 
concentrations increased the percentage of cells with neuritic processes in 
comparison with cultures in presence of vehicle (Fig. 1L). Taken together 
these data show that CSA increases the proliferation rate and fosters the 




Fig. 1. Effect of CSA on proliferation, differentiation and maturation of NSC derived from the 
SVZ. A,B: Effect of CSA 1000 nM or LiCl 2.0 mM (A) and of different concentrations of CSA 
(B) on the proliferation rate (evaluated as relative luminescence units, RLU; see Methods) 
of NSC of Ts65Dn mice at 96 h in culture. Data are expressed as fold change in comparison 
with NSC exposed to vehicle alone (DMSO 0.05%). C: Percentage of dead cells in trisomic 
cultures exposed to different concentrations of CSA for 96 h. D: EdU-positive cells in 
cultures of euploid and trisomic NSC exposed to vehicle or to CSA 1000 nM for 72 h. Data 
MAP2+/nestin- MAP2+/nestin+ MAP2-/nestin- 
MAP2+/nestin- MAP2+/nestin+ GFAP+ 
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are expressed as fold change in comparison with euploid NSC exposed to vehicle alone. E-
J: Percentage of MAP2+/Nestin- cells (E,H), MAP2+/Nestin+ cells (F,I), MAP2-/Nestin- cells 
(G), and GFAP+ cells (J) in cultures of trisomic NSC under differentiating conditions and 
exposed to the indicated concentrations of CSA for 96 h. K,L: Representative confocal 
microscope image (K) and percentage (L) of MAP2+ cells (red) exhibiting neuritic processes 
in cultures of NSC from the SVZ of Ts65Dn mice grown under differentiating conditions and 
exposed to the indicated concentrations of CSA for 96 h. Images in (K) show MAP2+ cells 
that were exposed to either vehicle (DMSO 0.05%) or CSA 300 nM. Nuclei were 
counterstained with Hoechst (blue). Scale bar=50 m. Data derive from pooled (3-5) mice. 
The asterisks in A, B, E, G, H, J, and L indicate a difference in comparison with vehicle-
treated cultures: * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001 (Fisher’s LSD test after ANOVA). 
Abbreviations: CSA, cyclosporine A; EdU, 5-ethynyl-2-deoxyuridine; Eu, euploid; GFAP, glial 
fibrillary acidic protein; LiCl, Lithium chloride; MAP2, microtubule associated protein 2; 
Veh, vehicle. 
 
Effect of neonatal treatment with CSA on neural precursor proliferation in 
the dentate gyrus and SVZ and of Ts65Dn mice 
The early postnatal period is a critical time window for neurogenesis in the 
SGZ of the hippocampal dentate gyrus. In addition, in neonate mice a 
prominent proliferation rate is present in the SVZ of the lateral ventricle. 
This is a neurogenic niche that gives origin to the neurons of the forebrain, 
prenatally, and thereafter produces granule cells destined to the olfactory 
bulb, glial cells and, possibly, generates neurons destined to the neocortex 
(Brazel et al., 2003). In view of the relevance of these two neurogenic 
niches, in the current study we examined the impact of CSA on the 
proliferation rate of NSC both in the dentate gyrus and SVZ of euploid and 
Ts65Dn mice. To this purpose, we treated mice with 15 mg/kg/day of CSA, 
because this dose has a pro-neurogenic effect in the dentate gyrus of adult 
wild type mice (Chow and Morshead, 2016).  
A two-way ANOVA on the total number of BrdU-positive cells in the dentate 
gyrus showed a genotype x treatment interaction [F(1,16) = 8.995, p = 
0.008], but no main effect of either genotype or treatment. A post hoc 
Fisher’s LSD test showed that, in agreement with previous evidence (Bianchi 
et al., 2010b, Giacomini et al., 2015, Stagni et al., 2016, Stagni et al., 2017), 
untreated Ts65Dn mice had notably fewer proliferating cells in comparison 
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with untreated euploid mice. The number of proliferating cells in treated 
Ts65Dn mice underwent a large increase (+26%) and became similar to that 
of untreated euploid mice (Fig. 2A,B). Treatment had no effect on the 
number of NSC in the dentate gyrus of euploid mice (Fig. 2A,B). In order to 
establish whether doses of CSA lower than 15 mg/kg positively affect cell 
proliferation, we treated Ts65Dn pups with 1.5 mg/kg or 7.5 mg/kg of CSA 
in the period P3-P15 and examined the effects of treatment in the dentate 
gyrus. A one-way ANOVA on the number of BrdU-positive cells in the 
dentate gyrus of Ts65Dn mice that had received vehicle or 1.5 mg/kg, 7.5 
mg/kg, and 15.0 mg/kg of CSA showed a significant effect of treatment 
[F(3,17) = 6.374, p = 0.004]. Post hoc LSD test showed that, unlike the dose 
of 15.0 mg/kg, the doses of 1.5 mg/kg and 7.5 mg/kg did not increase the 
number of BrdU-positive cells (Fig. 2C).  
A two-way ANOVA on the total number of BrdU-positive cells in the SVZ 
showed no genotype x treatment interaction, whereas a main effect of 
genotype [F(1,16) = 21.764, p < 0.001] and a main effect of treatment 
[F(1,16) = 38.978, p < 0.001] appeared. A post hoc Fisher’s LSD test showed 
that Ts65Dn mice had fewer cells in comparison with untreated euploid 
mice. After treatment with CSA, Ts65Dn mice underwent an increase in the 
number of proliferating cells (+25%) that became similar to that of 
untreated euploid mice (Fig. 3B). In the SVZ of euploid mice, treatment 
caused an increase in the number of proliferating cells that became larger 
(+21%) in comparison with that of their untreated counterparts (Fig. 3B). 
These results show that neonatal treatment with CSA is able to restore the 
proliferation rate of NSC in both the dentate gyrus and SVZ of Ts65Dn mice.  
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Fig. 2. Effects of neonatal treatment with CSA on the size of the population of cells in the S-
phase of the cell cycle in the dentate gyrus of Ts65Dn and euploid mice. A: Representative 
images of sections immunostained for BrdU from the dentate gyrus of untreated euploid 
and Ts65Dn mice, and of euploid and Ts65Dn mice that were treated daily with 15 mg/kg 
of CSA in the period P3-P15. Calibration bar=200m. B: Total number of BrdU-positive 
cells in the dentate gyrus of untreated euploid (n=5) and Ts65Dn (n=6) mice, and of treated 
euploid (n=4) and Ts65Dn (n=5) mice. C: Number of BrdU-positive cells in the dentate gyrus 
of Ts65Dn mice that received a daily injection of vehicle (n=6; same mice as in B) or 1.5 
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mg/kg (n= 6), 7.5 mg/kg (n=4), and 15.0 mg/kg (n=5; same mice as in B) of CSA in the period 
P3-P15. The number of BrdU-positive cells in euploid mice that received the vehicle 
reported in (B) is shown for comparison. Values (mean  SE) refer to one hemisphere. * p 
≤ 0.05; *** p ≤ 0.001 (Fisher’s LSD test after two-way ANOVA). Black asterisks in the gray 
bar indicate a difference between untreated Ts65Dn mice and treated euploid mice. 
Abbreviation: CSA, cyclosporine A; Eu, euploid; GR, granule cell layer; H, hilus; SGZ, 
subgranular zone; Veh, vehicle. 
Fig. 3. Effects of neonatal treatment with CSA on the size of the population of cells in the S-
phase of the cell cycle in the SVZ zone of Ts65Dn and euploid mice. A: Representative images 
of sections immunostained for BrdU from the SVZ of untreated euploid and Ts65Dn mice, 
and of euploid and Ts65Dn mice that were treated daily with CSA in the period P3-P15. 
Calibration bar=500 m. B: Total number of BrdU-positive cells in the SVZ of untreated 
euploid (n=5) and Ts65Dn (n=6) mice, and of euploid (n=4) and Ts65Dn (n=5) mice treated 
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with CSA. Values (mean  SE) refer to one hemisphere. ** p≤0.01; *** p ≤ 0.001 (Fisher’s 
LSD test after two-way ANOVA). Black asterisks in the gray bar indicate a difference 
between untreated Ts65Dn mice and treated euploid mice. White asterisks in the black bar 
indicate a difference between treated Ts65Dn mice and treated euploid mice. 
Abbreviations: CSA, cyclosporine A; d, dorsal; Eu, euploid; DG, dentate gyrus; FI, fimbria; l, 
lateral; m, medial; SVZ, subventricular zone; v, ventral; Veh, vehicle. 
 
 
Effect of CSA on the stereology of the dentate gyrus of Ts65Dn mice 
In the hippocampal dentate gyrus the production of granule cells mainly 
takes place in the first two postnatal weeks (Altman and Bayer, 1975). Thus, 
in view of the treatment-induced increase in the proliferation potency of 
NSC of the SGZ, we expected this effect to lead to improvement/restoration 
of the defective cellularity that characterizes the dentate gyrus of trisomic 
mice. To clarify this issue, we stereologically evaluated the total number of 
granule cells in treated and untreated mice. A two-way ANOVA on the 
volume of the dentate gyrus showed no genotype x treatment interaction, 
but a main effect of genotype [F(1,15) = 8.705, p = 0.010], and of treatment 
[F(1,15) = 8.887, p = 0.009]. Fisher’s LSD test, carried out post hoc, showed 
that the volume of the granule cell layer of untreated Ts65Dn mice was 
reduced (Fig. 4B) in comparison with that of euploid mice and that 
treatment restored the volume of the granule cell layer. The Kruskal-Wallis 
test showed a significant effect of treatment on granule cell density [χ2 (3) 
= 12.149, p < 0.007]. The Mann-Whitney test showed a reduced granule cell 
density in Ts65Dn mice compared to euploid mice (U = 0.001, p = 0.004) 
and demonstrated that treatment caused an increase in granule cell density 
(U = 0.001, p = 0.006) (Fig. 4C). A two-way ANOVA on total number of 
granule cells showed no genotype x treatment interaction, but did 
demonstrate a main effect of genotype [F(1,17) = 19.301, p = 0.001], and of 
treatment [F(1,17) = 15.844, p = 0.0.001]. A post hoc Fisher’s LSD test 
showed that untreated Ts65Dn mice had a reduced number of granule cells 
in comparison with euploid mice and that treatment restored granule cell 
number (Fig. 4D). A two-way ANOVA on the thickness of the granule cell 
layer showed no genotype x treatment interaction, whereas a main effect 
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of genotype [F(1,16) = 4.742, p = 0.045] was present, as was a main effect 
of treatment [F(1,16) = 6.039, p = 0.026]. A post hoc Fisher’s LSD test 
showed that the granule cell layer of untreated Ts65Dn mice had a reduced 
thickness in comparison with that of euploid mice and that this reduction 
was restored by treatment (Fig. 4E).  
At variance with the neocortex, the granule cell layer develops according to 
an outside-inside pattern. Therefore, the older neurons occupy the 
superficial part of the granule cell layer and the younger neurons occupy its 
lower portion. In Hoechst-stained sections, younger neurons are 
recognizable due to their smaller size and a more translucent pattern in 
comparison with older neurons (Fig. 4A). We deemed it of interest to 
evaluate the thickness of the region of the granule cell layer that was 
occupied by younger neurons (see the double-headed black arrow in Fig. 
4A). A two-way ANOVA on the thickness of the inner granule cell layer 
showed a genotype x treatment interaction [F(1,17) = 7.477, p = 0.014] and 
a main effect of genotype [F(1,17) =.5.791, p = 0.028], but no main effect of 
treatment. Fisher’s LSD test, carried out post hoc, showed that the inner 
part of the granule cell layer of untreated Ts65Dn mice was reduced in 
thickness compared to that of euploid mice and that this reduction was 
restored by treatment (Fig. 4F). The expansion of the inner part of the 
granule cell layer in treated Ts65Dn mice indicates that the treatment-
induced increase in the proliferation rate of granule cells precursors in the 
SGZ of Ts65Dn mice (see above) translates into an increase in the number 
of new granule neurons that are added to the inner part of the granule cell 
layer and, hence, in total granule cell number. Unlike in Ts65Dn mice, in 
euploid mice drug treatment had no effect on the stereology of the granule 
cell layer (Fig. 4B-F), which is consistent with the absence of effects on the 




Fig. 4. Effects of neonatal treatment with CSA on the stereology of the granule cell layer of 
Ts65Dn and euploid mice. A: Representative images of Hoechst-stained sections showing 
the granule cell layer of an animal from each experimental group. The double-headed 
white arrow indicates the thickness of the granule cell layer, while the double-headed black 
arrow indicates the thickness of the innermost part of the granule cell layer. Calibration 
bar=50 m. B-F: Volume of the granule cell layer (B), granule cell density (C), total number 
of granule cells (D), thickness of the granule cell layer (E), and thickness of the innermost 
part of the granule cell layer (F) of untreated euploid (n=6) and Ts65Dn (n=6) mice, and of 










dentate gyrus. * p≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001 (Fisher’s LSD test after two-way ANOVA 
for data reported in B and D-F; Mann-Whitney test after Kruskal-Wallis test for data 
reported in C). Black asterisks in the gray bar indicate a difference between untreated 
Ts65Dn mice and treated euploid mice. Abbreviations: CSA, cyclosporine A; Eu, euploid; 
GR, granule cell layer; MOL, molecular layer; SGZ, subgranular zone; Veh, vehicle. 
 
 
Effect of CSA on dendritic spine density in the dentate gyrus of Ts65Dn mice 
Spine density reduction is a typical feature of the trisomic brain (Benavides-
Piccione et al., 2004, Guidi et al., 2013) that, in conjunction with 
hypocellularity, is thought to be a critical determinant of intellectual 
disability. In order to establish whether CSA improves spine density, in 
Golgi-stained brains we evaluated spine density in the dendritic arbor of the 
granule neurons. Since the inputs to the dendritic tree of granule cells are 
organized in a laminar manner, we deemed it of interest to separately 
evaluate spine density in dendritic branches harbored in the outer half and 
inner half of the molecular layer. The examples of Golgi-stained dendritic 
branches reported in Fig. 5A clearly show that treatment causes a patent 
increase in spine density both in euploid and Ts65Dn mice. A two-way 
ANOVA on spine density in the proximal dendrites showed a genotype x 
treatment interaction [F(1,17) = 20.174, p = 0.001], a main effect of 
genotype [F(1,17) = 6.803, p = 0.018], and a main effect of treatment 
[F(1,17) = 180.800, p < 0.001]. A post hoc Fisher’s LSD test showed that the 
spine density of untreated Ts65Dn mice was significantly reduced (-24%) in 
comparison with that of untreated euploid mice (Fig. 5B,C). After treatment 
with CSA the number of spines of Ts65Dn mice underwent a notable 
increment (+78% vs. untreated Ts65Dn mice) and became larger (+36%) 
than that of untreated euploid mice (Fig. 5B,C). A large increase in spine 
density (+30%) also took place in treated euploid mice (Fig. 5B,C). A two-
way ANOVA on spine density in the distal dendrites showed a genotype x 
treatment interaction [F(1,17) = 18.574, p = 0.001], a main effect of 
genotype [F(1,17) = 4.748, p = 0.044], and a main effect of treatment 
[F(1,17) = 136.054, p < 0.001]. A post hoc Fisher’s LSD test showed a 
significantly reduced spine density (-21%) in untreated Ts65Dn mice 
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compared to untreated euploid mice (Fig. 5B,C). After treatment with CSA 
the number of spines of Ts65Dn mice underwent a notable increment 
(+64% vs. untreated Ts65Dn mice) and became larger (+30%) than that of 
euploid mice (Fig. 5B,C). A large increase in spine density (+23%) also took 
place in treated euploid mice (Fig. 5B,C). 
 
Fig. 5. Effects of neonatal treatment with CSA on dendritic spine density in the dentate gyrus 
of Ts65Dn and euploid mice. A: Photomicrographs of Golgi-stained granule cell dendrites 
showing spines on distal dendritic branches in an animal from each experimental group. 
Calibration bar=5 m. B,C: Spine density on dendritic branches in the inner (B) and outer 
(C) half of the dendritic tree of the granule cells of untreated euploid (n=6) and Ts65Dn 
mice (n=6) and euploid (n=4) and Ts65Dn (n=5) mice treated with CSA. Values in (B,C) are 







gray bar indicate a difference between untreated Ts65Dn mice and treated euploid mice. 
Abbreviations: CSA, cyclosporine A; Eu, euploid; Veh, Vehicle. 
 
Effect of CSA on p21 levels in the hippocampal formation of Ts65Dn mice 
Elongation of the cell cycle and a precocious exit from the cell cycle appear 
to be key mechanisms underlying the typical impairment of neurogenesis 
that characterizes DS. Overexpression of p21 in the trisomic brain appears 
to be an important determinant involved in cell cycle alteration and, hence, 
in the reduction in proliferation rate (see (Stagni et al., 2018)). A two-way 
ANOVA on the p21 levels in the hippocampal formation showed no 
genotype x treatment interaction, and no main effect of genotype or of 
treatment. A post hoc Fisher’s LSD test showed that untreated Ts65Dn mice 
had higher levels of p21 in comparison with euploid mice and that 
treatment with CSA reduced p21 levels to an extent that they became 
similar to those of euploid mice (Fig. 6B). In euploid mice, treatment had no 
effect on p21 levels (Fig. 6B). 
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Fig. 6. Effects of neonatal treatment with CSA on p21 protein levels in the hippocampal 
formation of Ts65Dn and euploid mice. A: Representative western blot showing 
immunoreactivity for p21 and Ponceau S-stained gel. Protein levels of p21 were normalized 
to all proteins with molecular weight between 10 and 50 kDa, as indicated by the dashed 
rectangle. B: Levels of p21 were examined in untreated euploid mice (n=11), untreated 
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Ts65Dn mice (n=12), treated euploid mice (n=10), and treated Ts65Dn mice (n=8). One 
untreated euploid mouse (yielding 10) and one untreated Ts65Dn mouse (yielding 11) 
were excluded from p21 analysis. Protein levels (mean  SE) are expressed as fold 
difference in comparison with untreated euploid mice. * p ≤ 0.05 (Fisher’s LSD test after 
two-way ANOVA). Black asterisks in the gray bar indicate a difference between untreated 




General effects of CSA  
The Ts65Dn strain is characterized by a high mortality rate during gestation 
and before weaning (Roper et al., 2006). The total number of mice used in 
the in vivo study was 81 (vehicle-treated mice: n=42; CSA-treated mice 
n=39). Three vehicle-treated (7.1%) and three CSA-treated (7.7%) mice died 
in the P3-P15 period. The similarity in the mortality rate across groups 
suggests that treatment has no adverse effects on the health of mice. We 
evaluated the body and brain weight of P15 mice that received vehicle or 
CSA (15.0 mg/kg) in order to establish the outcome of treatment on growth. 
A two-way ANOVA on body weight showed a genotype x treatment 
interaction [F(1,64) = 6.826, p = 0.011] and a main effect of genotype 
[F(1,64) = 29.560, p < 0.001], but no main effect of treatment. A post hoc 
Fisher’s LSD test showed that untreated and treated Ts65Dn mice had a 
lower body weight compared to their euploid counterparts (Table 1). A 
comparison of the body weight of treated and untreated mice showed that 
treated Ts65Dn mice had a similar body weight in comparison with their 
untreated counterparts and that treated euploid mice had a larger body 
weight in comparison with their untreated counterparts (Table 1). These 
findings indicate that treatment has no adverse effects on somatic growth. 
A two-way ANOVA on brain weight showed no genotype x treatment 
interaction, while a main effect of genotype [F(1,64) = 14.117, p < 0.001] 
and a main effect of treatment [F(1,64) = 7.899, p = 0.007] were present. A 
post hoc Fisher’s LSD test showed that untreated and treated Ts65Dn mice 
had a lower brain weight compared to their euploid counterparts (Table 1). 
A comparison of the brain weight of treated and untreated mice showed 
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that treated euploid and Ts65Dn mice had a reduced brain weight in 
comparison with their untreated counterparts (Table 1). Observation of the 
values reported in Table 1 shows that the brain weight reduction was 4% in 
treated vs. untreated euploid mice and 5% in treated vs. untreated Ts65Dn 
mice. This evidence shows that treatment exerts a moderately negative 
effect on brain growth. 
 
 
Table 1.Effect of treatment with CSA on body and brain weight. Body weight and brain 
weight (mean  SE), in grams, of euploid and Ts65Dn mice that received either vehicle 
(Veh) or cyclosporine A (CSA; 15.0 mg/kg) in the period P3-P15, measured on P15. The p 
value in the row below each variable refers to the comparison between untreated euploid 
(Euploid+Veh) and Ts65Dn (Ts65Dn+Veh) mice, and treated euploid (Euploid+CSA) and 
Ts65Dn (Ts65Dn+CSA) mice. The column “n.” reports the number of animals included in 
the statistical analysis. For the brain weight analysis, we excluded one untreated euploid 
mouse, one untreated Ts65Dn mouse, and one treated euploid mouse, based on the 
criteria explained in the Statistics section. The p value in the column on the right refers to 
the comparison between untreated and treated mice of the same genotype (Fisher’s LSD 






CSA positively impacts on proliferation, differentiation and maturation of 
trisomic NSC 
By exploiting cultures of NSC from the SVZ, we found that CSA i) restores 
the reduced proliferation rate that characterizes trisomic NSC; ii) rescues 
the aberrant differentiation program of trisomic NSC, because it increases 
the number of cells that differentiate into neurons and, concomitantly, 
reduces the number of cells that differentiate into astrocytes; iii) increases 
the development of neuritic processes. The pro-proliferative and pro-
neurogenic effects of CSA in trisomic NSC are consistent with evidence 
obtained in neurospheres from the dentate gyrus of wild type mice, 
showing that CSA increases both the number of neurospheres and the 
frequency of neuron-containing neurospheres relative to those containing 
glia (Chow and Morshead, 2016) at the same concentrations as those used 
here. It has been shown that CSA increases neurite outgrowth of cultured 
dorsal root ganglion cells with an EC50 of 50 nM (see (Hamilton and Steiner, 
1998)). This is in line with the current findings that CSA fosters neurite 
outgrowth of trisomic NSC and that concentrations as low as 3 nM are 
sufficient to elicit this effect.  
 
Neonatal treatment with CSA restores neurogenesis and spinogenesis in the 
Ts65Dn mouse 
In view of potential pharmacotherapies for DS, it is of obvious importance 
to demonstrate that the effects observed in vitro also take place in the 
greater complexity of the in vivo condition. Our results show that in Ts65Dn 
pups treated with CSA for 13 days there was full restoration of the number 
of BrdU-positive cells in the dentate gyrus and SVZ, indicating that 
treatment positively impacts on the two major forebrain neurogenic niches. 
An evaluation of the pro-neurogenic effects of three different doses of CSA 
showed that a dose of 15 mg/kg/day (but not lower doses) was able to fully 
rescue cell proliferation in Ts65Dn mice. It is worthy to note, that the 15 
mg/kg dose translates into approximately 1.2 mg/kg/day in the human 
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setting (Reagan-Shaw et al., 2008). The finding that the lower doses tested 
here did not increase NSC proliferation suggests a threshold for the pro-
neurogenic effects of CSA. 
The NSC of the SGZ give origin to granule neurons and astrocytes destined 
to the dentate gyrus. In agreement with the pro-neurogenic effect observed 
in vitro, in treated Ts65Dn mice there was an increase in the size of the 
innermost part of the granule cell layer, which harbors the newly-generated 
granule cells. This effect was accompanied by a large increase in the volume 
and thickness of the granule cell layer and total number of granule cells. 
The NSC of the SVZ give origin to granule cells destined to the olfactory bulb 
and to astrocytes and oligodendrocytes destined to the cortex (Brazel et al., 
2003). This suggests that the CSA-induced increase in the proliferation 
potency of NSC in the SVZ may positively impact on postnatal development 
of the olfactory bulb and neocortex.  
In the current study, we were interested in establishing whether treatment 
with CSA can ameliorate the severe spine density reduction that 
characterizes the granule cells of the dentate gyrus of Ts65Dn mice. We 
found that CSA largely enhanced the process of spinogenesis and that 
Ts65Dn mice treated with CSA underwent a large increase in spine density 
that even surpassed that of euploid mice. The effect took place along the 
whole extent of the dendritic tree of the granule cells. The major extrinsic 
input to the hippocampal formation is constituted by the perforant 
pathway, which takes its origin from the medial and lateral divisions of the 
entorhinal cortex (Amaral and Witter, 1995). Both inputs are fundamental 
for the participation of the hippocampal formation in long-term memory 
functions. The medial perforant pathway terminates on the middle third of 
the dendritic tree of the granule cells, while the lateral perforant pathway 
terminates on the outer third. The treatment-induced increase in spine 
density on proximal and distal dendrites suggests that this effect may lead 
to restoration of the memory functions mediated by both divisions of the 
entorhinal cortex.  
There are several candidates for the molecular mechanisms underlying NSC 
proliferation impairment in DS, among which p21 may be a particularly 
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critical one. The protein p21, also known as cyclin-dependent kinase 
inhibitor 1 or CDK-interacting protein 1, is overexpressed in the brain of 
fetuses with DS and in the Ts65Dn model (Engidawork et al., 2001, Stagni 
et al., 2015). Since p21 inhibits the transition from the G1 to the S-phase of 
the cell cycle, its overexpression may be a key determinant of proliferation 
impairment in DS. We found here that treatment with CSA normalized the 
levels of p21 in the hippocampal formation of Ts65Dn mice, suggesting that 
this effect may underlie restoration of proliferation. CSA is classically known 
to inhibit in T-lymphocytes the activity of the calcineurin-NFAT pathway and 
this effect is mediated by its binding to cyclophilin A. For this reason, it is 
used in a clinical setting in order to prevent graft rejection in organ 
transplantation. CSA, however, has a high affinity for other cyclophilins (B, 
C, D) (Hamilton and Steiner, 1998) and can therefore modulate various 
signaling pathways and exert calcineurin-independent effects (Sachewsky 
et al., 2014). It is worth noting that CSA appears to block the activity of the 
p38 signaling pathway (Matsuda and Koyasu, 2000), one of the three 
subgroups of the mitogen-activated protein kinase superfamily. Activation 
of p38 increases the mRNA and protein levels of the transcription factor 
p53 which, in turn, promotes the transcription of various genes, including 
p21 (Saha et al., 2014). In the brain of individuals with DS there is an 
increased activation of p38 and p53 (Swatton et al., 2004, Tramutola et al., 
2016), and increased activation of p53 has also been detected in Ts65Dn 
mouse brain (Tramutola et al., 2016). Thus, the inhibitory effect exerted by 
CSA on the p38 pathway may account for the normalization of p21 levels 
found here in treated Ts65Dn mice and, hence, restoration of proliferation.  
Several protein kinases, including p38, are essential factors in spine growth 
(Tada and Sheng, 2006). It has been shown that inhibition of p38 activity 
increases the size and number of dendritic spines (Fernandez et al., 2012) 
and that in p38 heterozygous knockdown mice there is an increase in 
dendritic spine density (Dai et al., 2016). In view of the inhibitory role of p38 
in spine morphogenesis, it seems reasonable to hypothesize that the spine 
density increase observed here in CSA-treated mice may be attributable to 
a CSA-mediated inhibition of p38.  
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CONCLUSIONS AND FUTURE PERSPERCTIVES 
 
DS is characterized by impairment of NSC proliferation, acquisition of a 
neuronal phenotype, and dendritic development. An obvious question 
regards the possibility of pharmacologically restoring this whole triad of 
deficits. While the gene burden is the primum movens of overall brain and 
somatic alterations in DS, it is likely that the triad of DS neurodevelopmental 
deficit is attributable to the alteration of specific pathways. Based on the 
complexity of these alterations, it may be necessary to use drug 
combinations to fully correct brain development. Importantly, the current 
study shows that treatment with a single drug, CSA, administered for a short 
but critical time window, can restore the entire triad of deficits of the 
trisomic brain.  
In view of its extensive effects in the murine model, CSA may be potentially 
effective in DS patients. However, caution must be exercised because CSA 
is an immunosuppressant drug and its clinical use is limited by side effects 
that include nephrotoxicity, neurotoxicity and hepatotoxicity (Matsuda and 
Koyasu, 2000, Bartynski et al., 2001). A recent study shows that three 
children with DS treated with CSA (approximately 6 mg/kg/day) as therapy 
for idiopathic aplastic anemia did not experience severe or unexpected 
adverse events during treatment (Suzuki et al., 2016). Another report 
describes the case of a girl with DS treated with prednisone and CSA (about 
4 mg/kg twice a day) for the treatment of alopecia. This report does not 
describe adverse effects of treatment either (Gensure, 2013). In both 
studies, the treatment lasted for months. Although these studies show that 
CSA is a tolerated treatment in individuals with DS, the possibility of side 
effects must be considered. To this regard, it is noteworthy that we did not 
observed apparent effects in 13 day-long CSA treatment on mice health 
status, as evidenced by no change in body weight of both genotypes. 
Conversely, in treated mice we found a small (4-5%) reduction in overall 
brain weight, which is in line with similar evidences obtained in rats 
(Setkowicz and Kadulski, 2007). The causes of this brain weight reduction 
remain to be elucidated. Recent evidences show that brain protein turnover 
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is much higher than previously assumed (3-4% day) which makes the brain 
prone to undergo considerable remodeling (Smeets et al., 2018). It has 
been shown that CSA inhibits protein synthesis in rat liver (Backman et al., 
1988). If a similar effect takes place in the brain, this may explain the brain 
weight reduction found here in CSA-treated mice. There is evidence that 
while CSA does not change the overall density of Nissl-stained neurons in 
rats, it reduces the number of calretinin-and parvalbumin-positive neurons 
(Setkowicz and Kadulski, 2007), the number of glioma-infiltrating microglial 
cells (Gabrusiewicz et al., 2011), and the survival of reactive astrocytes in 
culture (Pyrzynska et al., 2001). It cannot be ruled out that the brain weight 
reduction observed here after treatment with CSA may be due to a 
reduction in the number of some cells populating the brain. An important 
issue that needs to be addressed in further studies will be to establish 
whether a shorter treatment schedule can restore the neurodevelopmental 
defects of DS without affecting overall brain weight.  
The toxicity of CSA appears to be largely tied to its calcineurin-mediated 
mechanism of action. It must be remarked that various studies have shown 
that the immunosuppressive and neurotrophic actions of 
immunosuppressants can be dissociated and that the neurotrophic 
properties of immunosuppressant drugs are not mechanistically linked to 
their immunosuppressive actions but operate by separate pathways (see 
(Hamilton and Steiner, 1998, Nigro et al., 2013)). Non-immunosuppressant 
analogues of CSA (and of other immunosuppressant drugs such as FK506) 
have been shown to bind to their respective immunophilins and inhibit their 
activity, but they lack the ability to interact with calcineurin. For instance, a 
non-immunosuppressive analogue of CSA (MeAla-6-CsA) stimulates neurite 
outgrowth of PC12 cells, similarly to the action of CSA (Steiner et al., 1997), 
and the non-immunosuppressive analogue of CSA NIM811 mimics the pro-
survival effects of CSA on NSC in vitro (Sachewsky et al., 2014). The 
immunosuppressive effect of CSA may represent a serious liability in the 
context of treatment for DS. However, by exploiting non-
immunosuppressive analogues of CSA it may be possible to obtain positive 
effects on brain development as those elicited by CSA, in absence of 
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unwanted effects due to immunosuppression. We hope that our study may 
prompt further work to clarify this important issue. If CSA analogues prove 
to have the same positive impact as CSA on neurogenesis and spinogenesis 
they may be considered as practicable tools for ameliorating brain 
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DISCUSSION AND CONCLUSIONS 
 
Neurogenesis, the process by which new neurons are formed, occurs during 
brain development, contributing to the formation of the main neuronal 
circuitries. Neurogenesis is guaranteed by the presence of Neural Stem 
Cells (NSC) that, in addition to proliferation and maintenance of the pool of 
stem cells, are able to generate new functional neurons. 
Alterations in brain development period could lead to the formation of an 
abnormal brain with altered anatomical structures, loss of physiological 
cellular functions and consequent deficit in cognitive abilities. A typical 
example is the Down Syndrome (DS), a pathology characterized by brain 
reduced size and volume, hypocellularity (in particular in the hippocampus), 
altered neurotransmission functions, and decreased synaptic density 
associated to reduced learning and memory capacity (Bartesaghi et al., 
2011). 
 
NSC also persist in the adult brain in specific regions, such as in 
subventricular zone and in the subgranular zone of hippocampus where 
they continue to produce new neurons (Eriksson et al., 1998, Spalding et 
al., 2013). The hippocampal newborn neurons contribute to neural 
plasticity and it was demonstrated that in the murine and human 
hippocampus, they are involved in the acquisition of behavioural abilities 
(Kempermann, 2002; Shohayeb et al., 2018). Alterations in this process, 
could lead to deficits in hippocampus-mediated learning and memory 
(Garthe et al., 2016). 
 
In the several brain-related diseases, such as Alzheimer’s and Parkinson’s 
diseases, epilepsy, stroke, chronic pain, multiple sclerosis and in 
neuropsychiatric diseases (such as major depression), a reduced 
neurogenesis was shown. Besides pathologies, also many behavioural 
factors can positively and negatively modulate neurogenesis such as stress, 
diet, physical activities, enriched environment (Van Praag et al, 1999; Lee 
et al., 2002; Kempermann, 2015; Czéh et al., 2002; Westenbroek et al., 
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2004; Bortolotto and Grilli, 2017a). Surprisingly, depressed patients treated 
with antidepressants show a neurogenesis improvement that contributes 
to cognitive recovery (Santarelli et al., 2003; Boldrini et al., 2009). These 
data suggest that a pharmacological recovery is possible, not only in 
depressed patients, but also in other diseases where neurogenesis is 
impaired (Bortolotto and Grilli, 2017b; Bortolotto et al., 2014). 
In our laboratory, we previously demonstrated that some anticonvulsants, 
anxiolytics and analgesics are able to promote neurogenesis (Valente et al., 
2012; Cuccurazzu et al., 2013; Chiechio et al., 2017; Meneghini et al., 2013). 
Therefore, given the vastness of existing treatments in clinic, the chance 
that other drugs, in addition to their clinical effect, could solve an additional 
function as modulators of neurogenesis is incredibly high and still 
uninvestigated. This research approach is called drug-repurposing strategy. 
 
In such respect, during the three years of my PhD program, I contributed to 
enrich this knowledge in this field in two ways: 
 
1)  Investigation of trazodone (TZD) pharmacological profile to elucidate its 
role in neurogenesis. 
 
We demonstrated that TZD has a pro-neurogenic effect on murine adult 
hippocampal and human IPSC-derived NSC. This effect is mediated by 
antagonism of receptors 5-HT2a and 5-HT2c, as shown in vitro experiments. 
Since we found that TZD produces its proneurogenic effect by antagonizing 
5-HT2a and 5-HT2c receptors, we proposed that there is an endogenous 
serotoninergic tone, that acts on the 5-HT receptors, leading to an 
autocrine anti-neurogenic effect. In fact, we detected the presence of 5-HT 
in murine NSC culture, indicating that not only neurons, but also NSC are 
able to synthetize and release 5HT in the extracellular environment.  
Since serotonin are able to activate all serotoninergic receptors it is very 
interesting that both serotonin and TZD have a resulting proneurogenic 
effect on murine NSC despite their contradictory action on 5-HT2a and 5-
HT2c receptors. Experimental evidence show that NSC express different 
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serotonin receptors and their activation is able to modulate positively 
neurogenesis (Banars et al., 2004; Nandam et al., 2007; Kondo et al., 2015; 
Samuels et al., 2016). Lucas et al. demonstrated in vivo that activation of 
receptors 5-HT4 was able to increase the number of newborn neurons in 
the dentate gyrus (Lucas et al., 2007). Kondo et al., shown that 5-HT3 
receptors activation was essential in exercise-induced hippocampal 
neurogenesis and antidepressant effects (Kondo et al., 2015). In vivo studies 
in rodents demonstrated even that activation of 5-HT1b and 5-HT6 had 
antidepressant effects and the potential role in neurogenesis induction 
(Yohn et al., 2017). We suggest that, the effect of serotonin was due to the 
synergic effect obtained by all serotonin receptor activation. Furthermore, 
by blocking SERT, TZD increase extracellular level of serotonin that 
contributing in the same way to increase neurogenesis. 
 
We shown that the proneurogenic effect of TZD was not mediated by 
receptors 5-HT1a, 1 and2 as demonstrated by the non-effects of 
selective agonists/antagonists. We suggested that the serotonin receptors 
5-HT1a was involved in the proliferation mechanism of adult hippocampal 
NSC, in accordance with previously publications where selective agonists 
were able to increase their proliferation rate both in vivo and in vitro 
(Klempin et al., 2010; Benninghoff et al., 2010; Radley and Jacobs, 2002).  
Regarding the adrenergic receptors, we demonstrated that they were 
involved in the neurogenesis process since inhibition of receptors 1 and 
activation of receptors 2 were both able to induce neuronal 
differentiation of adult hippocampal NSC (Meneghini et al., 2014). As 
expected, the proneurogenic effect of TZD was not mediated by 1 and 2 
receptors since the 1 agonist was not able to counteract the 
proneurogenic effect of TZD and the 2 antagonist was not able to increase 
the percentage of MAP2 positive cells. 
 
From these studies, serotonin receptors contribute in different way to the 
proneurogenic effect once activated. However, to fully understand the 
complex system of serotonin signalling in our in vitro model of NSC, it will 
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be essential to study also the expression of other 5-HT receptors and their 
singular contribution in the neurogenesis mechanisms. 
 
To further investigate TZD dependent downstream signalling, we evaluated 
the involvement of NF-B. Our group previously demonstrated that NF-B 
subunit p50 is implicated in drug induced neurogenesis (Valente et al., 
2012; Cuccurazzu et al., 2013) Interestingly inhibition of p50 translocation 
in the nucleus, prevented TZD-mediated proneurogenic effect. However, in 
presence of exogenous serotonin, cells responded to TDZ. These data need 
to be further clarified, especially regarding signalling pathways, since NF-B 
seems to be involved, but in the presence of exogenous serotonin, other 
mechanisms appears to be activated. 
 
Through this project, we contributed to reveal novel potential mechanisms 
underlying the proneurogenic effect of antidepressants such as TZD. In 
particular, many neurogenesis studies have been carried out on rodents 
and in our laboratory, we studied murine adult hippocampal NSC since 
many years. However, there are few data concerning the human 
counterpart. During my PhD, I validated an in vitro method to study NSC 
derived from human IPSC. These cells, unlike murine one, need an enriched 
condition to maintain their proliferative state and a very long time to 
differentiate into progeny. Consequently, I investigated the effect of TZD 
and the involved receptors in the neurogenesis on human cells. As obtained 
in murine model, TZD had the same proneurogenic effect mediated at least 
by 5-HT2a in human IPSC-derived NSC, confirming further our hypothesis. 
Furthermore, Daniele et al. shown that trazodone has a neuroprotective 
effect in human NSC and this effect was mediated by the antagonism of the 
5-HT2a receptors. These data further suggested the involvement of the 
receptors 5-HT2a antagonism in the NSC regulatory mechanisms (Daniele 





2) Identification of a new drug that could recover DS deficit at anatomical 
and cellular levels in neonatal Ts65Dn mice. 
 
By our screening, we demonstrated that cyclosporine (CSA) has a pro-
proliferative and a pro-neurogenic effect in neonatal trisomic mice both in 
vitro and in vivo. In fact, we found that CSA in vitro restores cell 
proliferation, with no effect on cell survival, and increases neuronal 
differentiation at the expenses of astroglial differentiation. In vivo, in 
collaboration with Bartesaghi’s groups, we demonstrated that CSA restored 
the number and the volume of newborn granule cells in SVZ and DG, 
increased spine density and reduced the overexpression of the cyclin-
dependent kinase inhibitor p21 in trisomic mice.  
 
With this study, we contributed to identify CSA, a known 
immunosuppressant, as a treatment able to correct some neural deficits in 
trisomic mice in vivo. Experimental evidences are in agreement with our 
hypothesis since in vitro and in vivo CSA could improve neurogenesis (Chow 
and Morshead, 2016) and it seems trough calcineurin-independent 
pathways (Sachewsky et al., 2014). Moreover, since we have previously 
shown that some treatments could contribute to restore cognitive 
impairment in trisomic mice (Stagni et al., 2017; Giacomini et al., 2018), it 
will be important to study the effect of CSA also on cognitive functions and 
understand whether this effect will be maintained after cessation of 
treatment. This would be a very relevant result since, given the potentiality 
of CSA, we could think of a possible transferability of this therapy in DS 
patients. 
 
However, since TS65Dn mice show triplication of only a subset of DS 
associated genes, studies in human cells are highly needed. It was 
demonstrated that the neuronal differentiation and the proliferation 
capacity were severally altered in human IPSC-derived NSC of DS patients 
to confirm that the pathological aspect was maintained in vitro (Hibaoui et 
al., 2014). Lu et al. suggested that human IPSC-derived NSC expressed high 
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level of amyloid precursor protein in vitro to indicate even the correlation 
of Alzheimer disease (Lu et al., 2013). Furthermore, Hibaoui et al. shown 
that neurogenesis impairment of IPSC-derived NSC could be 
pharmacologically rescued using DYRK1A inhibition (Hibaoui et al., 2014). 
These data proposed that drugs could restore neural defects even in human 
model. In such respect, in our laboratory we have available human IPSC 
derived from DS patients (Weick et al., 2013). During my PhD, I tried to add 
more information besides the murine data. In particular, I was trying to 
differentiate human IPSC to obtain an expandable and pure population of 
NSC from healthy and DS affected patients. This resource could be relevant 
to validate further the proneurogenic hits discovered in murine cells, such 
as cyclosporine A, and investigate the downstream signalling involved. 
 
In conclusion, these studies demonstrated that drug repurposing could be 
an effective strategy for translational research aimed at treating brain 
diseases. In fact, both TZD e CSA have been discovered to have an “off-
labelled” action: the modulation of neurogenesis of neonatal and adult 
murine NSC. The finding of these drugs could be proposed in the future to 
treating diseases where neurogenesis is compromised, such as in 
neurodegenerative (depression, ect.) or neurodevelopmental disease 
(Down syndrome, ect.), and to greatly increase the therapeutic potential 
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